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ABSTRACT 
Background 
There is a delay between obstetric injury and the onset of faecal incontinence 
(FI) for most females, yet traditional surgical management has focussed on the 
obstetric injury when treating FI. Recently, electrical stimulation has been used 
in a number of treatments however the modes of action and efficacies are 
unknown. This study aimed to assess the aetiology of FI, while exploring the 
efficacy of the three main modalities of electrical stimulation for FI, namely 
sacral nerve stimulation (SNS), percutaneous tibial nerve stimulation (PTNS) 
and electrically stimulated gracilis neosphincter (ESGN).  
 
Methods 
Data was analysed for 999 females, who had undergone anorectal physiology 
testing (ARP) excluding confounding factors other than aging and childbirth. 
Patients treated for FI with PTNS or SNS were investigated with ARP to assess 
their efficacy and any potential indicators of success. Patients with ESGN were 
evaluated to assess efficacy in the short, mid and long term. 
 
Results 
The function of the external anal sphincter is affected by childbirth, while the 
internal anal sphincter deteriorates with age. SNS can be effective in the 
treatment of FI, but only 26% of patients experience a resolution of symptoms 
with 74% remaining incontinent. PTNS performs slightly better with 32% of 
patients experiencing apparent continence; however this is significantly cheaper 
and less invasive than SNS. Outcome for ESGN also revealed a high failure 
rate, yet in the long term, this outperforms SNS and PTNS with 43% of patients 
being successfully treated.  
 
Discussion 
Both aging and childbirth contribute via different mechanisms to produce 
decreased anal sphincteric function. Symptomatic patients can be treated with 
electrical stimulation therapies however, a high failure rate is noted for all 
modalities. A treatment “ladder” is emerging, starting with minimally invasive 
PTNS, through SNS and finally the costly and demanding ESGN for highly 
motivated patients. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Clinical and Epidemiological Aspects of Faecal Incontinence 
 
1.1.1 Clinical Presentation of Faecal Incontinence  
Faecal incontinence (FI) is the involuntary loss of faecal contents through the 
anal canal. It is a common, non fatal condition with marked social, psychological 
and economic sequelae. Patients can experience shame, embarrassment, 
social isolation and depression as they plan their life around this condition to 
ensure rapid access to toileting facilities at all times1. The reported community 
prevalence of FI varies between 0.4 and 18%, however, in those studies that 
minimise significant sources of bias, the estimate is 11-15%2. This represents a 
major public health problem3, which is likely to intensify with a proportionally 
older population4,5. The economic burden of FI on society is difficult to quantify 
as the condition is frequently under reported6, however the personal costs to the 
individual through hygiene and employment, as well as the cost to society from 
benefit payments, health resources and the provision of care are likely to be 
considerable. Over 20 years ago, it was shown that over $400million was spent 
annually on incontinence products in the United States7.  
 
Maintenance of continence is complex and multifactorial. Simplistically, formed 
stool progresses along a healthy, compliant colon at a controlled rate until it 
reaches a rectum with capacity for storage. The rectum distends and the 
internal anal sphincter relaxes to allow sampling, stool is detected and a desire 
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to defecate is perceived8. If this is convenient, the external anal sphincter (EAS) 
relaxes along with puborectalis and the bowel is evacuated. However, if this 
occurs at an inconvenient time, both the EAS and puborectalis contract 
resulting in deferment, rectal and colonic accommodation of the stool and 
continence is maintained8.  If this process is disrupted at any stage, 
incontinence can occur, e.g.; if the stool is liquid, the colon or rectum inflamed, 
the perception of intra rectal stool is lost, the sphincter complex structurally 
damaged, the innervation of the sphincter inadequate or the bowel unable to 
empty fully, then the patient is at risk of an episode of incontinence. FI can be 
subdivided depending on symptoms surrounding an episode, urge faecal 
incontinence (UFI – the appreciation of impending defecation with an inability to 
defer), passive faecal incontinence (PFI – an awareness of having soiled, only 
after it has actually occurred) and post defecatory leakage (PDL – the ongoing 
seepage of stool which only occurs following defecation). It may also be 
quantified depending on the amount of stool lost; incontinence to full motions or 
smearing on underwear or pads. In practice however, it is frequently an 
amalgam of some or all of the above.   
 
1.1.2 Assessment of Faecal Incontinence  
Various scoring systems have been deployed to assess the severity of 
symptoms and also the response to treatment as well as their own 
reproducibility9-13. The most commonly used scoring system is the Cleveland 
Clinic Faecal Incontinence (CCFI) score11. This assess the frequency of 
incontinence of flatus, liquid and solid stool as well as the need for pads and 
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lifestyle restrictions, producing a score between zero (completely asymptomatic) 
to 20 (daily incontinence together with daily pad use and lifestyle alteration 
secondary to the condition. Prior to the development of this system, more 
rudimentary systems were used including the Williams score14. This more 
simplistic system allocated patient symptom profiles between 1 and 6 with 1 - 
perfect continence; 2 - occasional incontinence to flatus; 3 - occasional 
incontinence to liquid stool; 4 - occasional incontinence to solid stool; 5 - 
complete incontinence to liquid and solid stool; 6 -stoma. Although this scoring 
system has been applied less frequently since the description of the CCFI, it 
remains applicable when comparing outcomes in patients seen and assessed 
prior to the development and widespread use of the CCFI.        
 
1.1.3 Aetiology of Faecal Incontinence 
The aetiology of incontinence can be divided into four categories (adapted 
from1):  
1) Anatomical:  Obstetric injury, anal surgery, anal trauma, colorectal 
neoplasia, rectal surgery, rectal intussusception and prolapse, 
rectocoele, history of perianal sepsis and fistulation. 
2) Functional: Inflammatory bowel disease, hyper/hypothyroidism, 
malabsorption states, enteric infection, radiation proctitis, faecal 
impaction, physical disability, psychiatric disorder, psychosocial 
behaviour. 
3) Neurological: Diabetes, stroke, dementia, multiple sclerosis. 
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4) Congenital: imperforate anus, rectal agenesis, cloacal defects 
myelomeningocele, meningocele. 
 
The most common aetiology of FI in females is thought to be anal sphinter 
damage secondary to obstetric trauma however, there is usually a significant 
time delay between the original obstetric insult and the onset of symptoms, 
averaging at almost 18 years, suggesting that the obstetric injury alone is 
usually insufficient to result in FI15-21. It has also been shown that advancing age 
is detrimental to the function of the sphincter complex, but that alone is rarely 
sufficient to cause symptoms21-25. Therefore, if neither alone are adequate to 
explain the onset of symptoms, then there is likely to be either a further insult, or 
a relationship between the two that combine to produce FI in later life.      
 
1.1.4 Investigation and Assessment of Faecal Incontinence 
In practice, once an organic source of such symptoms has been excluded, 
(colorectal neoplasia, inflammatory bowel disease, hyperthyroidism, coeliac 
disease, enteric infection etc.), and any potentially reversible causes have been 
eliminated or optimised, patients with ongoing symptoms would be suitable for 
further physiologic assessment15. Given the diversity of causes of FI, it is 
important that patients being considered for management of their symptoms are 
fully evaluated. Anorectal physiologic assessment (ARP) is now generally 
considered an important adjunct to history taking and clinical examination in the 
management of patients with functional colorectal disorders4. Several studies 
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attest to the clinical impact of such investigations in patients with faecal 
incontinence, demonstrating that information provided improves diagnostic 
yield, quantifies the magnitude of any defect26,27 and can directly influence or 
alter the management plan in a significant proportion of cases4,26. The most 
widely accepted tools for investigation of anorectal function and structure are 
anal manometry, endo-anal ultrasonography, rectal sensory threshold volumes 
and compliance, the defaecating proctogram and, perhaps more controversially, 
determination of pudendal nerve conduction16. Normative physiologic data 
discussed describing rectal sensation and anal manometry pressures are from 
historic values in age and sex-matched healthy controls derived by this 
colorectal tertiary referral centre. Normal values for sphincteric function and 
rectal sensory toleration have been obtained in 91 volunteers (median age 38 
[IQR 30–58] years; 50 female). None of the control subjects had symptoms or 
signs of colorectal disease; all were continent and had a normal pattern of 
defecation. 
 
1.2 Management of Faecal Incontinence 
1.2.1 Traditional Management of Faecal Incontinence 
First line treatment of FI is a course of conservative management4. Under the 
expert guidance of a specialist practitioner in this area, patients can be 
assessed and treated with a spectrum of measures depending on the likely 
aetiology incorporating; counselling, advice, stool softeners, anti-diarrhoeal 
medications, enemas, suppositories, rectal irrigation and biofeedback. Patients 
with intractable symptoms and impaired quality of life, who have failed 
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conservative management, may be offered a surgical treatment4. As the primary 
aetiological factor in FI is most commonly believed to be compromised anal 
sphincter function26, surgery has traditionally been directed to restoration of 
anatomy. However, direct repair of isolated sphincter defects is reported to have 
a less than 50% success rate over the long term28-30. While other techniques to 
restore or augment the pelvic floor such as post-anal repair, anterior 
levatorplasty and a combination of the two termed total pelvic floor repair have 
poor results even in the short term31. The long term outcome from recent novel 
treatments such as the Secca procedure, injectable bulking agents (e.g. 
Durasphere FI) and the Fenix Continence Restoration System are as yet 
unknown and will not be considered further. 
 
1.2.2 Electrically Stimulated Gracilis Neosphincter 
Electrical stimulation to improve faecal continence was first deployed as a 
modification of the gracilis neosphincter32. The electrically stimulated gracilis 
neosphincter (ESGN) was developed to avoid the need for permanent stoma 
construction in patients with end stage FI, and since the 1980s, it has been 
used to treat patients with a variety of aetiologies33,34. The technique involves 
wrapping the gracilis muscle around the anal canal, which is chronically 
stimulated by an implanted electrical device to convert the gracilis muscle fibres 
from fatigable fast twitch to fatigue resistant slow twitch muscle fibers, allowing 
sustained chronic contraction33. This creates a functioning neosphincter that 
can be switched on and off at will to allow control of continence. However, this 
is an expensive, highly invasive procedure with significant rates of morbidity 
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reserved for only the most highly motivated patients with end stage FI as an 
alternative to end colostomy. Furthermore, as with anterior sphincter repair, 
ESGN is associated with the development of rectal evacuatory dysfunction in 
approximately 6-26% of patients (depending upon definition)29,35-37. Usually this 
responds to conservative measures but in severe refractory cases, further 
surgery may be necessary38. Thus far, published data suggest that the medium-
term continence and GI quality of life scores improve in the majority of patients 
following ESGN39, although the long-term functional outcomes of this procedure 
remain unclear. It is also unknown whether indication for surgery or baseline 
physiological parameters can successfully predict postoperative functional 
outcome.    
 
1.2.3 Sacral Nerve Stimulation 
More recently, minimally invasive techniques using direct neural electrical 
stimulation have been developed, without the need for the major surgical 
dissection as in ESGN, have been shown to be effective in the treatment of FI. 
Both percutaneous tibial nerve stimulation (PTNS) and sacral nerve stimulation 
(SNS) were developed by urologists to treat detrusor overactivity40-43, yet both 
have subsequently been shown to also be effective in the treatment of FI44-57. 
Data on the efficacy of PTNS for FI is limited, but SNS has been shown 
repeatedly to be successful since the mid 1990s44.  
 
SNS involves inserting an electrode into the third sacral foramen and attached 
to a stimulator which is either external (for temporary evaluation – [PNE] 
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peripheral nerve evaluation) or buried in a subcutaneous pocket (for permanent 
stimulation). Both provide continuous subsensory electrical stimulation of the 
nerves of the S3 foramen. The mechanism of action is unclear, however it has 
been postulated and that stimulation at the S3 level was augmenting the 
contractile ability of the EAS and improving continence by enhancing sphincter 
function, however papers reporting manometry pressures following stimulation 
are conflicting45,50,58-59. Due to this initial hypothesised mechanism of action, the 
SNS implant was initially limited to patients with an intact sphincter complex as 
it was believed that this was a requirement for efficacy of the treatment60. Given 
that the most likely aetiology of FI is obstetric injury in females and anal surgery 
in men, the application of SNS for FI would be severely limited. The early 
reports described the success rate of SNS to be between 67-100%, with a 
definition of “success” set at a 50% (or more) reduction in symptoms44-53. This 
threshold was from taken from the urologists where SNS was deployed for the 
treatment of patients with detrusor overactivity and urinary frequency.40-42 While 
a 50% reduction in symptoms may represent a significant improvement for 
urinary incontinence, it is unclear whether such a reduction applies also to FI. 
Indeed, the majority of the published literature for FI has previously used 
continence to solids +/- continence to flatus as a measure of successful 
treatment29-31. Furthermore, studies published to date have not expressed data 
using intention to treat analysis. Thereby, any patient who failed the temporary 
PNE stage or were dissatisfied with the result were excluded from analysis 
when calculating success rates. It therefore remains to be seen what the true 
efficacy of SNS is in treating FI and also to which patients it should be 
deployed. This will be explored in chapter 3 in this thesis. 
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1.2.4 Percutaneous Tibial Nerve Stimulation 
If SNS is considered minimally invasive compared to other forms of surgery for 
FI, then percutaneous tibial nerve stimulation (PTNS) is even more so. It is 
administered in an outpatient setting, no operative procedure is needed and no 
implant is required61. An electrode is inserted through the skin posterior to the 
medial malleolus and advanced towards the tibial nerve. Stimulation is gradually 
increased until sensation is perceived in the foot or a motor flexor response was 
seen at the great toe. Stimulation is maintained at a tolerable sensory level for 
30 minutes. This process is repeated weekly for 12 weeks, fortnightly for 1 
month then repeated again 1 month later. This regime has been taken from 
studies for urinary dysfunction because of the efficacy in that field43. Studies for 
FI have severe limitations due to patient selection, poor methodology, small 
sample size or organic bowel pathology55-57. Once again, the true efficacy of 
this procedure for FI remains elusive while no guidance is available as to which 
patients would receive the most benefit. Finally, as both SNS and PTNS are 
considered minimally invasive, it is unclear which treatment modality is superior 
in treating FI, the relative costs involved for each and which patients should be 
considered for which treatment. 
 
 
 
 
 
28 
 
1.3 Objective of Thesis 
The aims of this thesis are: 
1) To examine the relative effects of age and parity on the anorectum, to 
the strict exclusion of other potential factors, and explore the interaction 
between the two which may result in delayed onset of symptoms of FI. 
2)  To examine the true efficacy of SNS in the treatment for FI with analysis 
performed with intention to treat. 
3) To identify any potential physiological parameters which may be 
predictive of success for SNS. 
4) To study the role SNS has to play in patients with FI with a sphincter 
defect and assess if outcome is related to the severity of defect. 
5) To explore the potential efficacy of PTNS in the treatment of patients with 
UFI via a small pilot study and to identify any potential physiological 
parameters which may be predictive of success for PTNS. 
6) To compare the outcomes, cost and morbidity of SNS and PTNS in two 
matched groups of patients with FI. 
7) To assess the short / mid and long-term functional outcome of patients 
with a variety of aetiologies, undergoing EGSN construction. 
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CHAPTER 2: THE RELATIVE EFFECTS OF AGE, PARITY AND MODE OF 
DELIVERY ON THE ANORECTUM, TO THE STRICT EXCLUSION OF 
OTHER POTENTIAL FACTORS. 
 
2.1 Introduction 
2.1.1 Anorectal Physiology 
ARP has been become an established adjunct to history, clinical examination 
and endoscopy in the investigation of hindgut dysfunction. Armed with the 
results of these investigations the clinician has insight into the structure and 
function of the anorectum4,26,27. The major caveat is that there is no uniform 
standardization of tests, and thus results between centres are often difficult to 
compare. In addition, there is lack of normative data for all measures of 
function, particularly with regard to age and gender stratification. 
 
2.1.2 Anorectal Physiology in the Literature 
In females, it is acknowledged that vaginal childbirth may be associated with 
compromise in anorectal function and morphology, irrespective of presence or 
absence of symptoms17. In addition, several studies assessing cohorts of 
predominantly asymptomatic women have shown that measures of anorectal 
function may change with age. However, results have been conflicting. In some 
studies, for example, it has been demonstrated that anal resting tone reduces 
with age, increasing parity and with obstetric related factors17-21, yet in others, 
such relationships have not been established19,21,25. 
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Similarly, although age, parity and obstetric factors have been shown to be 
associated with decreased anal squeeze increment pressures18-21,62, other 
studies have failed to show these associations19,21,22,24,25,63. Ageing has also 
been shown to both increase and decrease rectal sensory thresholds19,25,64, 
while both age and parity have been implicated in prolongation of pudendal 
nerve terminal motor latencies17,65,66. Interpretation of the results of tests of 
anorectal function and morphology is confounded by the interdependent effects 
of ageing and obstetric history. The aim of this study was to examine the 
relative contributions of these factors in a large cohort of patients with hindgut 
dysfunction (faecal incontinence and constipation) of sufficient severity to 
warrant referral for specialist physiologic investigation. 
 
2.2 Methods 
2.2.1 Patient Selection 
Three thousand six hundred and eighty six (3686) consecutive female patients 
referred to a single surgical tertiary referral centre underwent anorectal 
physiologic assessment. In order to reduce confounding factors, only those 
complaining of chronic constipation, faecal incontinence or both were 
considered; further rigorous exclusion criteria were applied, including: a history 
of any form of gastrointestinal, pelvic or anal surgery; anorectal pathology; 
metabolic and neurologic conditions (e.g. diabetes, hypo / hyperthyroidism, 
multiple sclerosis); ongoing medication with known effects on anorectal 
function; a history of psychotic illness or eating disorders; and finally, where the 
full complement of physiologic investigations had not been performed. 
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2.2.2 Anorectal Physiology 
Standard anorectal physiologic assessment (ARP) included measurement of 
anal sphincter resting and squeeze increment pressures performed using a 
single-channel side-hole catheter linked to an Arndorfer-type pneumohydraulic 
water perfusion system using a pull-back technique that assessed functional 
anal canal length, maximum resting tone and maximum voluntary squeeze 
increment67, determination of rectal sensory thresholds to air filled balloon 
distension (by inflating a latex balloon with air at 1 ml/sec and determining the 
threshold volumes for first constant sensation (FCS), defecatory desire (DDV) 
and maximum toleration (MTV)68), pudendal nerve terminal motor latency 
(PNTML) measurements using the St Mark’s electrode (Dantec Ltd, Bristol, 
UK), and structural sphincter assessment by endoanal ultrasound (7 or 10 MHz, 
B-K Medical, Berkshire UK). All patients also underwent evacuation 
proctography, and in some, a test of colonic transit (where indicated - results 
pertaining to these investigations are not included in this study). Detailed 
methods have been described previously69,70. 
 
2.2.3 Statistical Analysis 
Prospective collection of clinical and physiologic data was standardised 
between different investigators within the department using questionnaires and 
reporting forms and entered onto a bespoke database. Explanatory variables 
were systematically recorded including age, parity, and obstetric factors (mode 
of delivery). Main presenting symptoms were treated as individual binary 
covariates (constipation and faecal incontinence). Parity was stratified as 
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nulliparous (0), 1, 2, 3 and 4 or more deliveries, this being analysed as a 
continuous variable taking values of 0-4. In parous females, the influence of 
delivery type was initially analysed on the basis of binary covariates (= 1 vaginal 
delivery, = 1 Caesarean sections and = 1 instrumental delivery). A summary 
variable (analyzed as an indicator variable) was also derived for mode of 
delivery: 0 = no delivery (nulliparous), 1 = Caesarean section only, 2 = any 
vaginal delivery, 3 = instrumented vaginal delivery. 
 
Both univariate and multivariate regression analyses were performed to 
examine the effects of age, presenting symptom, parity and obstetric factors on 
anorectal physiologic measures. Linear regression models were used in the 
case of continuous variables such as anal resting and squeeze incremental 
pressures, while logistic regression models were used in the case of the binary 
outcomes of internal and external anal sphincter defects. All analyses were 
performed using proprietary software (Stata v10.0, Texas, USA). Main results 
are presented with linear regression coefficients or odds ratios and confidence 
intervals; P<0.05 was taken to indicate statistical significance. 
 
2.3 Results 
2.3.1 Patient Demographics 
Two thousand six hundred and eighty-seven patients were excluded. Of these: 
598 had undergone gynaecologic surgery; 560 had anal surgery / pathology; 61 
had undergone colonic surgery; 85 had undergone other abdominal surgery; 
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and 18 had undergone pelvic radiotherapy. Medical criteria for exclusion 
included: diabetes (n=123); neurological causes (n=55); metabolic causes 
(n=18); inflammatory bowel disease (n=26); and psychiatric disorders (n=76). 
Many patients had more than one exclusion criteria, and the remainder were 
excluded on the basis of incomplete results of physiologic tests. 
 
Nine hundred and ninety nine females satisfied the inclusion criteria. Median 
age was 46 (range 16 –88 years), and median parity 2 (0 –11). One hundred 
and sixty females were nulliparous, with a median age of 31 (16 –87). Overall, 
360 patients (median age 52, range 19 –87; parity 2, range 0 –11) complained 
of symptoms of faecal incontinence, 352 (age 41, range 16 –84; parity 2, range 
0 –10) presented with symptoms of intractable constipation, and 287 (age 46, 
range 17 –88; parity 2, range 0 –10) had combined symptoms. Age at 
presentation was associated with incremental parity, with patients predicted to 
be 4.6 years older with each birth, (P<0.0001, r2= 0.137, coef: 4.6, CI= 3.89 –
5.32: Figure 2.1). 
 
2.3.2 Anorectal Physiology 
Summary data for the whole cohort are presented in Table 2.1. 
 Figure 2.1 Comparison o
between increasing parity and increasing age [n=999 i.e. including caesarean 
sections]. Medians marked with a 
 
 
 
Variable 
Anal resting tone (cmH
Anal squeeze increment (cmH
IAS defect (%) 
EAS defect (%) 
Combined defect (%)
Left PNTML (msec)
Right PNTML (msec)
FCS (mls) 
DDV 
MTV 
 
Table 2.1: Results of anorectal physiolog
 
f parity and age. A relatively linear relationship is seen 
bar and 5th and 95th percentiles shown.
Mean 
2O) 72 
2O) 56 
16 
47 
 13 
 2.37 
 2.34 
51 
118 
177 
y tests in 999 females studied.
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SD 
34 
37 
  
  
  
0.54 
0.43 
43 
71 
82 
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2.3.3 Effects of Age 
Anal resting tone decreased significantly with advancing age, equivalent to 0.66 
cmH2O / year (linear regression, P<0.0001, r2 =0.10, coef: -0.66, CI = -0.8 –
0.53), e.g. a 70 year-old patient would be expected to have a resting tone 26 
cmH2O lower than that of a 30 year-old (Figure 2.2). Anal squeeze increment 
pressures also decreased significantly, but by only 0.3 cmH2O per year (linear 
regression, P=0.001, r2 =0.01, coef: -0.30, CI = -0.4 –-0.11) (Figure 2.3). The 
relationship with resting pressure was maintained in the nulliparous cohort, with 
a 0.6 cmH2O / year reduction in resting tone (P<0.0001, r2 =0.09, coef: -0.60, CI 
= 0.8–-0.28), however, no statistical effect of age was observed for squeeze 
increment pressures in the nulliparous cohort (P=0.38, r2 =0.005, coef: -0.13, CI 
= -0.46 –+0.18). 
 
Age had no significant association with the finding of an internal anal sphincter 
defect and a small (albeit statistically significant) association with external anal 
sphincter defects (O.R 1.01, P = 0.002; CI 1.0 to 1.02). With regard to pudendal 
nerve function, left PNTML increased significantly with age (0.01 msec / year; 
P=0.0001, r2 =0.05, coef: 0.008, CI = 0.006 –0.010), e.g. a 70 year-old patient 
would be expected to have a left PNTML 0.4 msec longer than that of a 30 
year-old. Results were similar for right PNTML, although the magnitude of 
change was halved (0.005 msec / year). There was no relationship between 
age and rectal sensory threshold volumes. 
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Figure 2.2 Relationship between anal resting tone and age. Anal resting tone is 
seen to decrease significantly with advancing age [n = 999]. Linear regression 
and 95% CI lines are shown. 
 
0 20 40 60 80 100
0
25
50
75
100
125
150
age at presentation
sq
ue
ez
e 
(c
m
 H
20
)
 
Figure 2.3 Relationship between anal squeeze increment and age. Anal 
squeeze increment is seen to decrease with advancing age [n = 999]. Linear 
regression and 95% CI lines are shown. 
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2.3.4 Effects of Parity 
Anal resting tone decreased significantly with parity, and was associated with a 
reduction of 4.3 cmH2O per incremental birth (P=<0.0001, r2 =0.03, coef: -4.3, 
CI = -5.9–-2.7) (Figure 2.4). There was a similar significant decrease in squeeze 
increment pressures of 3.8 cmH2O per birth (P=<0.0001, r2 =0.02, coef: -3.8, CI 
= -5.5 –-1.9) (Figure 2.5). There was no relationship between increasing parity 
and rectal sensory thresholds. With each vaginal delivery, PNTMLs significantly 
increased by 0.06 msec on the left (P<0.0001, r2 =0.02, coef: 0.060, CI = 0.032 
–0.087), and by 0.04 msec on the right. Overall, increasing parity was also 
associated with the finding of both an internal (P=0.006, OR: 1.2, CI = 1.1 –1.4) 
and external anal sphincter defect (P<0.0001, OR: 1.4, CI = 1.3 –1.6). This 
relationship is borne out almost exclusively by the first delivery (external anal 
sphincter: P=0.0001, OR: 7.6, CI 4.3 –13.2 (Figure 2.6); internal anal sphincter: 
P=0.002, OR: 3.3, CI 1.5 –7.2) (Figure 2.7). Anal resting pressure was reduced 
in association with both an internal and external anal sphincter defect (intact 
IAS: median 77 cmH2O, range 6 –213 vs. defective IAS: 42 cmH2O, range 3 –
184, P<0.0001; intact EAS: median 80 cmH2O, range 6 –207 vs. defective EAS: 
60 cmH2O, range 3 –213, P<0.0001) (Figure 2.8). Anal squeeze increment 
pressures was also reduced in the presence of both IAS and EAS defects 
(intact EAS: median 59 cmH2O, range 0 –249 vs. defective EAS: 40 cmH2O, 
range 0 –205, P<0.0001; intact IAS: median 53 cmH2O, range 0 –249 vs. 
defective IAS: 39 cmH2O, range 0 –225, P<0.0001) (Figure 2.9). 
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Figure 2.4 Relationship between parity and anal resting pressures. Anal resting 
pressures are  seen to decrease with advancing parity [n = 999]. Medians 
marked with a bar and 5th and 95th percentiles shown (P=<0.0001, r2 =0.03, 
coef: -4.3, CI = -5.9–-2.7). 
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Figure 2.5 Relationship between parity and squeeze increment pressures. Anal 
squeeze pressures are seen to decrease with advancing parity [n = 999]. 
Medians marked with a bar and 5th and 95th percentiles shown (P=<0.0001, r2 
=0.02, coef: -3.8, CI = -5.5 –-1.9). 
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Figure 2.6 Histogram showing prevalence of internal anal sphincter defects with 
increasing parity. 
 
Figure 2.7 Histogram showing prevalence of external anal sphincter defects 
with increasing parity. 
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Figure 2.8 Relationship between resting pressures and anal sphincter defects 
a) internal anal sphincter defects and resting tone; b) external anal sphincter 
defects and resting tone. Medians marked with bar. 
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Figure 2.9 Relationship between squeeze pressures and anal sphincter defects 
a) internal anal sphincter defects and squeeze increment; b) external anal 
sphincter defects and squeeze increment. Medians marked with bar. 
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2.3.5 Obstetric Factors 
Of the 839 parous females, 354 (42%) had deliveries that were assisted with 
instrumentation (forceps, Ventouse or episiotomy) on at least 1 occasion. One 
hundred and twelve patients had undergone at least one Caesarean section 
(elective and / or emergency) with 45 females having only undergone 
Caesarean sections (range 1-4). Patients who had only had Caesarean 
sections had higher anal resting tone compared to those who had delivered 
vaginally, with or without instrumentation (Caesarean:median 95 cmH2O, range 
10 –160, vs. normal vaginal delivery: 67 cmH2O, range 3 – 213, vs. instrumental 
vaginal delivery: 68 cmH2O, range 10 – 185; P=0.0013) (Figure 2.10). Anal 
squeeze increment pressures were greater in both the Caesarean group 
(median 70 cmH2O, range 40 – 225) and non-assisted vaginal deliveries 
(median 50 cmH2O, range 0 – 249) than those having instrumental deliveries 
(median 40 cmH2O, range 0 – 160, P<0.0001: (Figure 2.11). Univariate analysis 
using the single derived mode of delivery indicator variable for resting pressure 
revealed no significant effect of Caesarean section but roughly equal effects of 
vaginal (P<000.1, coef: -13.5, CI = -19.5 to –15.4) and instrumental (P<0.0001, 
coef: -11.6, CI = -17.7 to –5.4) delivery. For the external sphincter, instrumental 
delivery was associated with a greater fall in squeeze pressure than vaginal 
delivery (P<0.0001, coef: -18.4, CI = -25.1 to –11.7) vs. (P<0.0001, coef: 8.1, CI 
= -14.6 to –1.6). 
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Figure 2.10 Relationship between mode of delivery and resting tone; 
(P=0.0013: one-way ANOVA). Medians marked with a bar and 5th and 95th 
percentiles shown. 
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Figure 2.11 Relationship between mode of delivery and squeeze increment 
pressures (P<0.0001: one-way ANOVA). Medians marked with a bar and 5th 
and 95th percentiles shown. 
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In keeping with these observations (using the same indicator variable), the risk 
of an internal anal sphincter defect was significantly higher but roughly equal 
following both unassisted (P=0.0001, OR: 4.0, CI 0.9 –7.6), and instrumental 
(P=0.0001, OR: 3.6, CI 1.7 –7.4) deliveries but not with Caesarean section (no 
difference from nulliparous). 
 
However, all 3 methods of delivery were associated with increased risk of 
external anal sphincter injury (Caesarean: P<0.0001, OR: 5.7, CI 2.7 –12.3; 
unassisted: P<0.0001, OR: 8.6, CI 5.1 –14.5; instrumental: P<0.0001, OR: 10.2, 
CI 6.0 –17.4) with the additive risk of instrumental delivery clearly 
demonstrated. 
 
2.3.6 Effect of Presenting Symptom 
Patients presenting with constipation had higher mean resting and squeeze 
pressures than those with incontinence: resting pressures, constipation mean = 
77 cmH2O (CI 75-80) vs. incontinent mean = 65 cmH2O (CI 62-68), difference 
12 cmH2O, P<0.0001; squeeze pressures, constipation mean = 63 cmH2O (CI 
60-66) vs. incontinent mean =49 cmH2O (CI 46-52), difference 12 cmH2O, 
P<0.0001. One hundred of 360 (28%) patients with FI only had IAS defects 
compared to 12 / 352 (3%; P<0.0001) patients with constipation only and 51 / 
287 (18%) with both faecal incontinence and constipation. Two hundred and 
twenty four of 360 (62%) patients with FI only had EAS defects compared to 
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103 / 352 (29%; P<0.0001) patients with constipation only and 141 / 287 / 
(49%) with both faecal incontinence and constipation. 
 
2.3.7 Multivariate Analysis 
Multivariate models were developed for anal pressures (Table 2.2) and anal 
sphincter defects (Table 2.3). These models took an iterative approach from 
information derived from univariate analyses using stepwise omission of 
covariates to improve the models. Table 2.2 shows that for anal resting 
pressure, the main determinants were age, presence of sphincter defects 
(particularly IAS defects) and a presentation with faecal incontinence. Of these, 
the strongest association was with IAS defects which on average conferred a 21 
cmH2O reduction in sphincter pressure. Reduced incremental squeeze 
pressures were also associated with presentation (faecal incontinence), but the 
other main independent determinants were a defective EAS and instrumental 
delivery. Table 2.3 shows that IAS defects are only associated with a presenting 
complaint of faecal incontinence, this being roughly reciprocal (as would be 
expected) with that of constipation. In contrast, EAS defects are also 
independently associated with parity and type of delivery. 
 
2.4 Summary of Results 
Increasing age is associated with decreased resting tone and prolongation of 
PNTML but squeeze increment is relatively unaffected. Resting and squeeze 
pressures are both (seen to be) reduced by both IAS and EAS defects. 
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Caesarean section is protective of the structure and function of the sphincter 
complex while vaginal delivery (and especially instrumentation) has a 
detrimental effect on both. In addition, multivariant anaylsis has shown that the 
main determinants of decreased resting tone are increasing age and the 
presence of an IAS defect while the main determinants of decreased squeeze 
pressures were an EAS defect and a delivery involving instrumentation.  
 
Resting Coef. P > |t| 95% Conf. 
Interval 
Faecal incontinence -10.9 <0.0001 -14.9 to -6.9 
Age* -0.5 <0.0001 -0.6 to -0.4 
IAS defect -21.4 <0.0001 -26.8 to -16.1 
EAS defect -4.7 0.021 -8.7 to -0.7 
Constant 105.8 <0.0001 99.8 to 111.8 
 
Model: Prob > F = 0.0000, adjusted r2 = 0.20 * based on 1 year of advancing 
age  
Squeeze Coef. P > |t| 95% Conf. 
Interval 
Faecal incontinence -16.1 <0.0001 -20.5 to -11.7 
Instrumental delivery -9.4 <0.0001 -13.9 to -4.9 
EAS defect -12.9 <0.0001 -17.3 to -8.5 
Constant 72.8 <0.0001 64.8 to 80.8 
 
Model: Prob > F = 0.0000, adjusted r2 = 0.13 
 
Table 2.2 Multivariate models of anal resting tone and squeeze increment 
pressures (cm H2O). 
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IAS Defect OR P > |t| 95% Conf. 
Interval 
Age 0.99 0.218 0.98 to 1.00 
Parity 1.14 0.083 0.98 to 1.33 
Type of delivery* 1.10 0.259 0.93 to 1.31 
Constipation 0.38 <0.0001 0.25 to -0.57 
Faecal incontinence 2.90 <0.0001 1.86 to 4.51 
 
Model: Prob >  X 2 = 0.0000, pseudo r2 = 0.10. * all types of delivery vs. 
Caesarean only.  
EAS Defect OR P > |t| 95% Conf. 
Interval 
Age 0.99 0.642 0.99 to 1.00 
Parity 1.16 0.022 1.02 to 1.33 
Type of delivery* 1.63 <0.0001 1.37 to 1.93 
Constipation 0.415 <0.0001 0.31 to 0.55 
Faecal incontinence 1.51 0.007 1.12 to 2.02 
 
Model: Prob > X 2 = 0.0000, pseudo r2 = 0.09. * all types of delivery vs. 
caesarean only. 
 
Table 2.3 Multivariate models for prediction of anal sphincter defects  
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CHAPTER 3: EFFICACY OF SACRAL NERVE STIMULATION FOR THE 
TREATMENT OF FAECAL INCONTINENCE 
 
3.1 Introduction 
3.1.1 Sacral Nerve Stimulation 
The management of FI has evolved with the advent of sacral nerve stimulation 
(SNS).  SNS was initially developed for the treatment of patients with detrusor 
overactivity, urinary frequency and urge urinary incontinence with 59-83% of 
patients experiencing a 50% or greater reduction in symptoms.5,41 More 
recently, this technique has been applied to patients with FI, with early reports 
revealing the success rate to be between 67-100%.44-53  
 
Since 2003, patients referred to Barts and The London NHS Trust with FI who 
had failed conservative management were considered for SNS as first line 
surgical therapy. During the study period, it became apparent that the level of 
success reported elsewhere,44-53 was not being replicated within this tertiary 
referral centre. The aim of this study was to establish the true efficacy of SNS 
within a single centre and compare this with previous studies. 
 
3.2 Methods 
3.2.1 Patient Selection 
The study protocol was approved by the East London and City Health Authority 
Research Ethics Committee (P1/04/025), and all patients provided written 
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informed consent. Where appropriate for a cohort study, this trial adhered to the 
CONSORT guidelines.71 Fifty consecutive patients (47 female) undergoing SNS 
for faecal incontinence unresponsive to conservative management were 
recruited over a five year period. The overall median age was 55 (range 30-84) 
years, with a median parity of two (range 0-5) deliveries for female patients. All 
patients had symptoms that were refractory to maximal conservative treatment 
(including biofeedback), and had undergone a detailed clinical history and 
investigation to exclude any obvious organic cause for their incontinence; 
clinical history included assessment of the Cleveland Clinic Faecal Incontinence 
(CCFI) score.11 Prior to commencing the study four primary outcome measures 
were identified: 1) percentage of patients who were free of FI throughout a two 
week monitoring period following permanent implantation; 2) reduction in 
episodes of FI; 3) change in CCFI scores; and, 4) perceived increase in ability 
to defer defecation in minutes. Two secondary outcome measures were also 
identified: 1) percentage of patients achieving a 50% reduction in episodes of FI 
during peripheral nerve evaluation (PNE); and, 2) percentage of patients 
achieving a 50% reduction in episodes of FI during permanent implantation. 
Clinical outcome measures were assessed at all time points by requesting 
patients to prospectively record the above data points in a two week non-
validated bowel diary. Quality of life data were not recorded for study 
participants, as this was not identified as a primary or secondary outcome 
measure during the design of this study.  
 
 
49 
 
3.2.2 Anorectal Physiology 
Standard anorectal physiology testing was performed before treatment and 
consisted of anorectal manometry assessment of anal sphincter function by a 
pull-back technique, rectal sensation to volumetric distension, endoanal 
ultrasonography, evaluation of pudendal nerve terminal motor latency and 
defaecating proctography.72 This was repeated to assess any changes in twenty 
subjects with permanent implants at 3 months and again at a median of 21.5 
months following permanent implantation (range: 6-53 months).  
 
3.2.3 Peripheral Nerve Evaluation 
Patients underwent unilateral PNE with the percutaneous insertion of a 
stimulating electrode (3065USC; Medtronic, Minneapolis, Minnesota, USA) into 
the sacral foramen under general (N=41) or local (N=9) anaesthesia. Optimal 
positioning of the electrode was confirmed by fluoroscopy and observation of 
the appropriate motor contraction responses, which consisted of a bellowing of 
the pelvic floor and plantar flexion of the ipsilateral great toe. Testing was 
undertaken in the S3 foramina and performed bilaterally. The side that 
demonstrated the best motor response was chosen. The stimulating wire was 
secured with dressings and connected to an external pulse generator (3625; 
Medtronic). Patients were advised against driving, bathing, energetic activities 
and lifting heavy objects during the test period to avoid wire displacement.   
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Stimulation parameters were set at 210 µs pulse width, 15 Hz frequency and at 
subsensory amplitude ranging between 0.5 and 10V continued for 14 days. The 
amplitude was patient controlled and perineal sensation was documented 
throughout the test period. A clinical result was deemed “successful” when, on 
review of the bowel diary, patients demonstrated a 50% decrease in episodes of 
FI.47 A permanent implant was offered if continence improved in combination 
with a patient's desire to pursue permanent stimulation. Ten patients were non-
responders to PNE and three patients achieved a 50% reduction in episodes of 
faecal incontinence but chose not to proceed to permanent implant secondary 
to dissatisfaction with the response to stimulation. At the end of the test phase, 
the electrode was removed with the patient conscious, in an outpatient setting. 
 
3.2.4 Permanent Stimulation 
Thirty seven patients (74% of total patients; median age 48 (range 31-84) years; 
35F) who experienced significantly reduced FI with temporary SNS 
subsequently underwent permanent stimulation with a unilateral tined lead 
(3093-28; Medtronic) and pulse generator (3023; Medtronic), implanted under 
general (N=34) or local (N=3) anaesthesia. The electrode was sited in the same 
sacral foramen as that used for temporary stimulation, except in two patients in 
whom the original foramen could not be accessed hence the contralateral 
foramen was used. The pulse generator was placed in a subcutaneous pocket 
in the ipsilateral buttock of the implanted electrode. Stimulation commenced the 
following day using similar stimulation parameters to those detailed above, 
again at a subsensory threshold. 
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3.2.5 Clinical Assessment 
Patients completed a CCFI assessment and a two week bowel diary before and 
during temporary stimulation. Diaries recorded both controlled and uncontrolled 
(urge and passive-related) bowel movements. In the responders, a further CCFI 
assessment and bowel diary were completed by day 90 and at a median of 17 
months (range 2-55) after permanent stimulation. 
 
3.2.6 Analysis of Previous Studies 
Given the success rates following SNS for FI reported elsewhere were not 
replicated within our centre, 44-53 a systematic review was conducted to establish 
the published efficacy of this treatment. A literature search was performed using 
PubMed and the Cochrane Databases for cohort studies between January 1995 
(first description of use of SNS for FI) and March 2010 reporting patients 
undergoing this treatment for FI. The literature was reviewed and data 
extraction performed. Data were formally tabulated by preset data criteria 
(Table 3.1). Only studies in English were considered. Search terms used, either 
in isolation or various combinations, were: SNS; sacral nerve stimulation; sacral 
neuromodulation; faecal (and faecal) incontinence. Hand-searching of all 
references in reviewed literature was performed to complete the search.  
 
Papers were included when patients awaiting permanent implant were specified 
and could be subtracted from the data at PNE stage.  Where multiple time 
points were reported by individual studies, the follow up period with the greatest 
number of patients was used and the others excluded. Papers were excluded if 
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analysing physiological data, cost, technique but not functional outcome; and, if 
patient outcomes were reported as a cohort without specification of absolute 
patient numbers at each phase of treatment. Studies were not included if from 
the same institution, unless data were clearly mutually exclusive; otherwise, the 
study containing the greatest number of recruited patients was used, and the 
others excluded. When intention to treat (ITT) outcome measure analyses were 
not presented by studies, these were calculated by the author. 
 
This literature review is adherent to the Quality of Reporting of Meta-Analyses 
protocol. Despite these recommendations being initially designed for meta-
analyses, where appropriate for a systematic review, its guidelines have been 
implemented. In keeping with this, the validity of each included study was 
determined. Assessment of methodology, as described by the Delphi criteria for 
quality assessment of randomized controlled trials where appropriate for cohort 
studies, was performed and a 1-to-9 rating assigned to each study.73 
 
3.2.7 Statistical Analysis 
Data are expressed as the median and range. Statistical analysis was 
performed for non-parametric data (episodes of FI, deferment of defecation, 
Cleveland Clinic continence scores) by the Friedman test and Dunn's Multiple 
Comparison Test using a commercially available statistical software package 
(Prism 4.0; GraphPad Software, San Diego, California, USA). P values 
represent the statistical difference between preoperative and postoperative 
values, with a value of 0.05 considered to show statistical significance. 
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3.3 Results   
3.3.1 Preoperative Assessment 
Primary risk factors for FI were identified for individual patients4: obstetric injury-
26, anal surgery-eight, idiopathic-six, mixed anal surgery/obstetric trauma-eight, 
and pelvic surgery-two. Patients reported a median of 14 (0-53) episodes of FI 
per fortnight, with a median maximal deferment of one (0-15) minute(s). Median 
pre procedure Cleveland Clinic continence scores were 15 (3-20). Thirty six 
patients were found to have a disrupted external anal sphincter. Twenty two 
patients also had a concomitant abnormality of the internal anal sphincter, with 
one patient found to have an isolated internal anal sphincter defect. For all 
patients preoperatively, median maximum anal resting pressure was 54 mmH20 
(16-132), with a median maximum anal squeeze increment of 27 (0-90). Median 
first constant sensory threshold volume during rectal balloon distension was 45 
ml (10-285), median defecatory desire volume 98 ml (20-300), while median 
maximal tolerable volume was 145 ml (35-380). Eleven patients demonstrated 
rectal hypersensitivity, defined as a maximum tolerated volume (MTV) of less 
than 90 ml and five were hyposensate defined as a maximal tolerated volume of 
over 300 ml. Preoperative evacuation proctography identified a functional 
rectocoele >4cm in nine patients. Volume of neostool instilled was 200 ml (80-
600) with an expulsion value of 75% (0-100) over 70 seconds (10-300).   
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3.3.2 Peripheral Nerve Evaluation Outcomes 
At the end of the test period, 13 (26%) patients reported no episodes of 
incontinence with median episodes of incontinence reduced to two (0-21) per 
fortnight (P<0.001). Overall median continence score reduced to nine (0-18; 
[P<0.001]) during PNE. Ability to defer increased to five minutes (0-20; 
[P<0.001]). At the end of the test period, the lead was found to be radiologically 
displaced in five patients, two of whom underwent repeat evaluation before 
progressing to permanent implantation. The remaining three patients did not 
wish to undergo repeat PNE. Forty patients (80%) met the criteria to progress to 
permanent implantation, however only thirty seven (74%) elected to do so with 
three further patients dissatisfied with the effect of the treatment. 
 
3.3.3 Short-Term Follow Up: Three Months after Permanent Implantation 
At 90 days following permanent implantation median episodes of incontinence 
were two (0-19) per fortnight (P<0.001). Ability to defer defecation increased to 
five minutes (0-15; [P<0.001]). Overall median continence score reduced to 
nine (0-18; [P<0.001]). One patient required a further period of PNE at the S3 
level since permanent implantation at S4 did not improve symptoms. Twenty 
seven patients (54%) reported a significant decrease in episodes of 
incontinence (50% or greater) following permanent implantation, however, 10 
patients failed to obtain a satisfactory outcome at 90 day follow up. One patient 
received oral antibiotics for a superficial wound infection. 
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3.3.4 Mid-Term Follow Up: Seventeen Months after Permanent Implantation 
At a median follow up of 17 months (3-55), 33 of the 37 patients who 
progressed to permanent implantation could be assessed, with four unavailable 
for the following reasons: lost to follow up; treatment failure - electrically 
stimulated gracilis neosphincter; treatment failure - end ileostomy; death-
unrelated to treatment. Overall, the 33 assessed patients reported a median of 
two (0-20) (P<0.001) (Figure 3.1) episodes of FI per fortnight with a maximum 
deferment of five minutes (0-20) (P<0.001) (Figure 3.2). Median CCFI score 
was eight (0-17) at this time point (P<0.001). When assessing the 10 patients 
who had disappointing 90 day outcomes, two patients reported a significant 
improvement in continence following adjustment of stimulation parameters. Of 
the 27 patients who had reported a successful 90 day outcome, two patients 
suffered deterioration in symptoms at mid-term follow up. Therefore, at the mid-
term assessment period, 27 patients (54% of total subjects) reported greater 
than 50% reduction in episodes of FI when assessed in accordance with an 
intention to treat basis, with 13 (26%) reporting no episodes of FI during the two 
week monitoring period (Figure 3.3). Tined lead migration occurred in four 
cases with reimplantation on the contralateral side required in one case. Two 
patients experienced discomfort from superficial implantation of the stimulator 
which required repositioning in both cases. 
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Figure 3.1: Episodes of FI during a two week evaluation period. Presented data 
are median and range. *Friedman (Dunn’s post analysis) test: P<0.0001. 
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Figure 3.2: Alteration in Cleveland Clinic scores following treatment with SNS. 
Presented data are median and range. *Friedman (Dunn’s post analysis) test: 
P<0.0001. 
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Figure 3.3: Flowchart of patient outcomes from SNS 
 
 
50 patients (3 male) with 
faecal incontinence  
underwent PNE  
27 (54%) “success“ with 
permanent SNS 
 
3 achieved 50% 
reduction in symptoms, 
but were dissatisfied 
10 failed to achieve a 
50% reduction in 
symptoms 
37 (74%) proceeded to 
permanent SNS 
 
14 (28%) with ongoing 
FI but 50% better or 
more 
10 (20%) failed to regain 
benefit of PNE, (1 lost to 
follow up) 
13 (26%) with no 
symptoms of FI 
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3.3.5 Outcome Versus Physiological Parameters 
There were 27 patients with at least a 50% reduction in symptoms and 23 which 
failed to achieve this threshold. The following describes the physiological 
parameter, medians and range for the 27 successful patients followed by 
medians and range for 23 failures and the P value respectively. Age: 57 (36-
84),  45 (30-75) (P=0.0731); RP: 42cmH2O (20-121), 55cmH2O (16-132) 
(P=NS); SP: 24cmH2O (0-90), 31.5cmH2O (0-88) (P=NS); Preoperative 
episodes of FI: 15 (2-53), 7 (0-25) (P=0.0026); Preoperative ability to defer in 
minutes: 1 (0-15), 1 (0-15) (P=NS); Preoperative CCFI scores: 14 (6-20), 15 (3-
20) (P=NS); and pre operative PNTML: 2.5 (1.9-3.9), 2.5 (1.5-3.5) (P=NS). 
Fourteen of the 27 success and 13 of the 23 failures had an intact IAS (P=NS) 
while 9 of the 27 success and 5 of the 23 failures had an intact EAS (P=NS). 
 
3.3.6 Effect of SNS on Physiological Parameters 
ARP was performed in twenty patients before SNS, 3 months following 
permanent implantation and again at a median of 21.5 months (range: 6-53). 
The following pre and postoperative (median 21.5 months) respective medians 
and range were obtained: resting pressures 55cmH20 (range: 20-121) to 
39cmH20 (range: 20-121); squeeze pressures were 26cmH20 (range: 7-74) to 
28cmH20 (range: 0-85); FCS 37mls (range: 10-105) and 35mls (range: 10-100); 
DDV 95mls (range: 35-150) and 95mls (range: 30-160); MTV 130mls (range: 
45-240) and 150mls (range: 75-300) and PNTMLs 2.5 (range: 1.8-3.3) and 
2.3mls (range: 1.5-3.9).  No statistical change was noted in any of these 
parameters (Figure 3.4). 
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Figure 3.4: Change in physiological parameters between baseline and midterm 
follow up (MT) after SNS. No statistical difference was seen in any parameters 
measured.  Data shown as medians with range. 
 
3.3.7 Comparison with Previous Studies 
Nineteen studies were identified which satisfied the eligibility criteria52,74-91 
(Table 3.1). Two randomised controlled trials were excluded from the 
systematic review as they reported outcomes from patient cohorts that had 
already been described in the published literature by other authors from the 
same institutions.92,93 All studies included in the analysis reported patient 
cohorts with heterogeneous aetiologies of FI. Seven of the 19 studies presented 
ITT analyses with the remaining 12 (63%) calculated by the author. Fourteen of 
the studies analysed involved more than 20 patients and had provided data 
which showed ITT success between 19-78%. Of these 14 studies, only eight 
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highlighted patients free from FI during the monitoring period following 
permanent implantation. These eight studies reported continence rates of 
between 0-37% during a two week monitoring period following treatment with 
SNS. The results from our own study demonstrate an ITT success of 54% and 
ITT continence of 26%, comparing favourably with the published literature.  
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3.4 Summary of Results 
SNS can be an effective treatment for FI in some patients and this improvement 
is sustained in the midterm assessment. There is an improvement in the 
perceived ability to defer defecation, however this falls short of a return to 
normality. The majority of patients continue to experience symptoms of FI albeit 
at a reduced level. The CCFI scores decrease, but the reduction is modest. 
There is a high failure rate both at the PNE stage and at permanent 
implantation. The ability to select patients who will receive the most benefit 
remains elusive however those with more frequent episodes of incontinence are 
more likely to gain benefit and there is a (not statistically significant) trend that 
an older subgroup of patients may be more likely to experience successful 
outcome. There is no significant change in the ARP assessments following SNS 
suggesting there is no “augmentation” of sphincteric function. The results from 
this cohort of patients would appear to compare favourably with the majority of 
published studies producing transparent data or deploying ITT analysis, 
suggesting that patient selection or surgical technique were not responsible for 
disappointing outcomes. 
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CHAPTER 4: EFFICACY OF SACRAL NERVE STIMULATION FOR FAECAL 
INCONTINENCE IN PATIENTS WITH ANAL SPHINCTER DEFECTS 
 
4.1 Introduction 
4.1.1 Conventional Surgery for Faecal Incontinence 
As the primary aetiological factor in FI is most commonly considered to involve 
anatomical sphincter disruption26, surgery has traditionally been directed to 
restoration of anatomy. However, direct repair of isolated sphincter defects is 
reported to have a less than 50% success rate over the long term28.   
 
4.1.2 SNS and Sphincter Integrity 
SNS provides an alternative surgical therapeutic option and has been shown to 
effectively improve symptoms of FI and quality of life over the medium term, in 
patients with weak but structurally intact sphincters.51,94 Indeed, this was the 
principal indication for SNS when the first UK National Institute of Clinical 
Excellence (NICE) guidelines were published in 200460. Recently however, it 
has been reported that SNS may also be effective in patients with limited 
internal (IAS) or external anal sphincter (EAS) defects51,75,95. Consequently, we 
sought to determine, by prospective study, the efficacy of SNS in patients with 
FI and sphincter defects, and to assess the relationship between extent of 
sphincter disruption and clinical outcome. 
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4.2 Methods 
4.2.1 Patient Selection 
Between 2003 and 2007, 32 consecutive patients with faecal incontinence were 
treated with SNS at the Royal London Hospital. In 15 (all female, median age 
53 years; range 26-82), anal sphincter defects were demonstrated on endoanal 
ultrasound (EAUS). The aetiology of sphincter disruption was obstetric injury in 
12 and anal surgery in 2. The remaining patient had a history of imperforate 
anus and vestibular fistula and had undergone rectoplasty at 3 weeks of age but 
failed to achieve continence. At three years of age, the colon was defunctioned 
with the anal canal dilated on 26 separate occasions (Hegar 8-22) due to 
stricturing followed by reversal of the colostomy a year later with an immediate 
resumption of daily FI. No patient had undergone previous sphincter repair.  
 
4.2.2 Preoperative Evaluation 
Pre-operative evaluation also included detailed history, examination, records of 
standardized continence diaries over a two week period96, Cleveland clinic 
continence scores11, and comprehensive anorectal physiological assessment as 
described previously. Clinical symptoms were derived from the bowel diary and 
patient history, and classified according to severities of FI, soiling and urgency, 
with soiling defined as the number of days with stained underwear during the 14 
day evaluation period without frank incontinence. Faecal urgency was defined 
as the ability to defer defecation, and classified into categories: < 1 minute; 1 to 
5 minutes; and over 5 minutes. Patients were considered for SNS if they failed 
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maximal conservative management, had a frequency of incontinent episodes of 
≥ 1 per 2 weeks, and following counselling, wished to proceed. 
 
4.2.3 Structural Assessment of Anal Sphincters 
Sphincter integrity was assessed by EAUS (type 1846 probe with 10MHz 
transducer, B-K Medical, Berkshire, UK) and graded using a previously 
published scoring system97 in which both the IAS and EAS are independently 
assessed. Hard copy 2D axial images were acquired at 5 levels from 
puborectalis to the anal verge. Defects were graded from these images 
according to length, depth and circumference to produce a score of 0-8 for both 
the IAS and EAS and a combined sphincter complex score of between 0-16 
(Table 4.1). Sphincter defects were scored using the criteria outlined on Table 
4.1 by two independent observers to calculate inter-observer variation. This was 
repeated by one of the observers (blinded) after three months to assess intra-
observer variation. 
 
4.2.4 Sacral Nerve Stimulation 
Temporary and permanent stimulation were performed as described earlier and 
in detail previously98. Stimulation parameters were set at 210 µs pulse width, 15 
Hz frequency and at a subsensory amplitude ranging between 0.5 and 10V. The 
latter was patient controlled. Patients were reviewed after 2 weeks of temporary 
stimulation and permanent implantation was offered if temporary stimulation 
resulted in a greater than 50% improvement in symptoms, as evidenced by 
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patient bowel diary records. Patient enthusiasm to progression to permanent 
stimulation was also required.  
 
Score 
 0 1 2 3 
IAS     
     Length         None <Half >Half Whole 
     Depth         None Partial Total  
     Size         None <900 91-1800 >1800 
EAS     
     Length         None <Half >Half Whole 
     Depth         None Partial Total  
     Size         None <900 91-1800 >1800 
 
Table 4.1: Sphincter defect scoring chart. Defects were graded according to 
length, depth and circumference for both the IAS and the EAS producing a 
score between 0 (completely intact) to 16 (severely disrupted). Adapted from 
Stark et al97.   
 
4.2.5 Outcome Variables and Analysis 
Bowel diaries were collated prospectively to determine changes in symptoms. 
For this study, 4 outcome variables were defined a priori: 1) episodes of FI per 
week; 2) episodes of soiling per week; 3) Cleveland clinic continence scores (all 
ordinal continuous); and 4) ability to defer defecation (categorical). Differences 
before and after stimulation were compared using paired t-tests (ordinal) on the 
basis of normality testing of data (Shapiro-Wilk) or chi2 tests (categorical). The 
relationship between EAUS severity scores and FI episodes was examined 
using linear regression. Intra- and inter- observer agreement were determined 
and expressed using Wilcoxon rank sum test. A P value <0.05 was taken to 
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indicate significance. Analyses were undertaken using a commercially available 
statistical software package (Prism 4.02; GraphPad Software, San Diego, 
California, USA). 
 
4.3 Results 
4.3.1 Structural Assessment 
Severity scores for sphincter defects as determined on EAUS are shown in 
Table 4.2 (median 10, range 3-16). Overall 6 patients had an isolated sphincter 
defect (4 EAS, 2 IAS) with the remaining 9 having combined defects. There was 
minimal intra-observer error (difference = +1 [range:-1 to +5, P=0.0001; 
Spearman rs = 0.85]) and inter-observer error (difference = + 1 [range: -4 to +6, 
P=0.0002; Spearman rs = 0.80]). At baseline, there were no correlations 
between defect scores and clinical measures of FI severity. 
 
4.3.2 Sacral Nerve Stimulation: Clinical Outcome 
There was no operative morbidity relating to the placement of either temporary 
or permanent electrodes. One patient had a poor response to temporary 
stimulation and was dissatisfied with the treatment while another achieved a 
greater than 50% reduction in symptoms, yet declined permanent implantation 
for personal reasons. Two patients who had very few episodes of FI pre-
treatment failed to gain a 50% reduction in episodes of FI at temporary 
stimulation, but their overall symptom improvement and enthusiasm was such 
that they proceeded to permanent stimulation.  
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        Episodes of FI 
Patient  
number 
EAS 
defect 
score 
IAS 
defect 
score 
Total 
score 
Baseline After 
PNE 
After 
perm 
1 3 0 3 8 1 declined 
2 3 0 3 9 3 3 
3 0 3 3 53 26 5 
4 4 0 4 28 10 10 
5 0 4 4 1 2 0 
6 6 0 6 21 10 13 
7 4 4 8 21 10 6 
8 7 3 10 21 1 0 
9 6 4 10 25 20 Failed 
10 5 7 12 15 2 16 
11 7 5 12 7 0 0 
12 6 7 13 1 1 0 
13 6 7 13 6 1 9 
14 5 8 13 35 1 0 
15 8 8 16 4 0 0 
 
Table 4.2: Sphincter defect scores and the outcome after sacral nerve 
stimulation.   
 
4.3.3 Episodes of Faecal Incontinence 
Thirteen of the fifteen patients (87%) progressed to permanent stimulation, with 
episodes of incontinence decreasing from a median of 15 per fortnight (range 1-
53) before stimulation to 3 per fortnight (0-16) after stimulation (P=0.01) (Table 
4.2, Figure 4.1). Ten of the thirteen patients (77%) derived >50% reduction in 
episodes of FI with permanent implantation, including 2 with isolated EAS 
defects, 2 with isolated IAS defects and 6 with combined defects (Table 4.2). 
Three patients (1 EAS and 2 combined defects) had a reduced response to 
permanent stimulation compared to temporary stimulation. The presence of a 
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pudendal neuropathy was unrelated to success or failure of the procedure in 
this study. 
 
4.3.4 Episodes of Soiling 
All 15 patients described symptoms of soiling before SNS. Of the thirteen who 
progressed to permanent stimulation, seven described a greater than 50% 
improvement in soiling with a median frequency of soiling of 6 days per fortnight 
(range 0-14) compared to a median of 10 (range 1-14) at baseline (P=0.009). 
 
4.3.5 Cleveland Clinic Incontinence Score 
Scores improved in eleven of the thirteen patients who had permanent SNS 
implanted (baseline: median 12, range 9-18; permanent: median 9, range 4-14, 
P=0.0005) (Figure 4.2). The median reduction in incontinence scores was, 
however, only 3 (range 0-10). 
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Figure 4.1: Change in episodes of FI before and after sacral nerve stimulation. 
Data shown as medians with range. Baseline to PNE (P<0.001); baseline to 
permanent (P=0.012); PNE to permanent (P=NS). 
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Figure 4.2: Change in CCFI scores before and after sacral nerve stimulation in 
the 13 patients who progressed to permanent stimulation. Data shown as 
medians with range. Baseline to permanent (P<0.001). 
 
 
 
 
71 
 
4.3.6 Ability to Defer Defecation 
Urgency was improved following temporary stimulation in 12 patients, and this 
was sustained in 10 of the 13 who progressed to permanent stimulation. 
Overall, for the 15 patients, contingencies of different degrees of urgency were 
significantly improved (P=0.05: Figure 4.3). 
 
4.3.7 Outcome Versus Sphincter Defect Severity Score 
There was no correlation between the sphincter defect score and the reduction 
in the number of FI episodes or soiling following permanent stimulation (r2 = 
0.10, P=0.29 [Figure 4.4]; r2 = 0.001, P=0.94 respectively). Similarly, the 
reduction in incontinence scores following permanent stimulation were 
unrelated to defect scores (r2 = 0.10, P=0.28). 
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Figure 4.3: Alteration in perceived ability to defer defecation at baseline, PNE 
and permanent stimulation.  
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Figure 4.4: Correlation between severity of sphincter defect and change in 
episodes of FI from baseline. 
 
 
 4.3.8 Effect of SNS 
The single patient with a background of ano
continence to stool in childhood, nor adult life, yet had a significant benefit 
following SNS. Endoanal ultrasound revealed
significant anterior and posterior defects and although s
was identified posteriorly, 
(Figure 4.5). Anal manometry validated the ultrasound findings with significantly 
attenuated resting and squeeze pressures (Table 4.3
marked reduction in urgency and FI, and an ability to defer defecation. This 
produced a call to stool and a normal defecation habit. Permanent SNS was 
thus performed with persistence of symptoma
increase in the abil
physiology showed no increase in resting or squeeze pressures on anal 
manometry, but a further reduction in maximum tolerated volume and also an 
improvement in the ability to expel barium neostool on proctography.
Figure 4.5: Normal sphincter complex and following surgery for ano
malformation. a) showing a normal 2D EAUS with complete IAS and EAS as 
marked. b) patients grossly disrupted 
bilaterally and a small segement of EAS posteriorly.
with Ano-Rectal Malformation  
-rectal malformation never achieved 
 the internal anal sphin
ome striated muscle 
the external anal sphincter was grossly deficient
). 
tic improvement and a further 
ity to delay defecation (Table 4.4). Post SNS, anorectal 
complex with some IAS identified 
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ARP Baseline Permanent SNS  
RP (cmH20) 54 30 
SP (cmH20) 20 11 
FCS (mls) 100 45 
DDV (mls) 180 130 
MTV (mls) 300 180 
Neostool expelled (1min) 30% 90% 
 
Table 4.3: ARP pre and post SNS. Neostool expelled corresponds to the 
percentage of barium contrast expelled during proctography. 
 Baseline PNE Permanent 
SNS 
Deferment (mins) 0 1 15 
Episodes urgency 28 3 5 
Controlled BM 0 20 26 
Episodes of UFI 3 0 0 
Total episodes FI 4 0 0 
 
Table 4.4: Alteration in symptoms of urgency and FI as recorded per week at 
baseline and following PNE and Permanent SNS. Relatively low levels of 
symptoms at baseline were due to severe lifestyle restrictions which were not 
required following SNS. (BM-bowel movements). 
 
 
4.4 Summary of Results 
SNS can be suitable for patients with sphincteric defects. The severity of the 
defect appears unrelated to the outcome. There is no correlation between 
success and an isolated IAS defect, isolated EAS defect or a combined defect. 
The presence or absence of a pudendal neuropathy was unrelated to outcome.  
In the presence of a severe structurally and functionally deficient sphincter 
complex, SNS resulted in significantly less urgency, less episodes of FI and an 
improvement in the perceived ability to defer defecation without any objective 
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evidence of functional improvement in the sphincter complex. Permanent SNS 
in this single patient was also associated with an apparent improvement in the 
efficiency of defecation as shown by defecation proctography (Table 4.3). 
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CHAPTER 5: PERCUTANEOUS TIBIAL NERVE STIMULATION FOR THE 
TREATMENT OF URGE FAECAL INCONTINENCE 
 
5.1 Introduction 
5.1.1 Neuromodulation of the Sacral Plexus 
It is well recognised that extra-sphincteric mechanisms also play an important 
role in the control of continence26,99,100. The mechanism of action of SNS in FI is 
however unclear, but may involve neuromodulation via the S3 level with the 
effect of increasing the ability to defer defecation and reduce episodes of FI 
regardless of sphincteric integrity. SNS is however, expensive, with limited 
adaptability once in situ and has well described associated morbidity101.   
 
Neuromodulation of the sacral nerve plexus is possible via percutaneous tibial 
nerve stimulation (PTNS)102. This is a remote, minimally invasive technique, 
with reported similar efficacy to SNS in patients with urinary dysfunction42,43. 
Despite limited data, PTNS has been approved as an acceptable potential 
treatment for urge FI54-57. The aim of this study was therefore to prospectively 
study the efficacy of PTNS in the treatment of patients with UFI. 
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5.2 Methods 
5.2.1 Patient Selection 
Intractable symptoms (failure of conservative management) remain a 
prerequisite prior to invasive surgery for FI within our unit. Between January 
2008 and January 2009, conservative management was requested for 39 
potential surgical candidates with symptoms of UFI. Inclusion criteria for this 
study were all patients referred for conservative management of UFI. Exclusion 
criteria included pregnancy or intended pregnancy, implanted pacemaker or 
defibrillator, a history of ischaemic heart disease, peripheral neuropathy or any 
medication affecting coagulation. Patients with mixed symptoms (e.g. 
concomitant passive incontinence, constipation and rectal evacuatory disorder) 
were excluded from this preliminary study. Urinary symptoms were not 
considered for this present study. Patients were counselled for PTNS and those 
who wished to proceed were offered this as first line therapy after obtaining 
informed consent. The procedure was performed by clinical nurse specialists 
within a specialist colorectal surgery unit. No patient involved received any other 
conservative management techniques alongside PTNS.  
 
During the study period, 31 patients (1 male) satisfied the study criteria and 
received PTNS for symptoms of UFI (median age 58 years, range 34 to 77). 
Pre-treatment evaluation included detailed history, examination, and 
comprehensive ano-rectal physiological assessment as described previously. 
The aetiology of FI in the females was obstetric trauma in 24 (77%), pelvic 
surgery in 2 (6%) and unknown (labelled idiopathic) in 4 (13%). Parity ranged 
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from 0 to 5 (median 2). The single male patient had undergone a 
haemorrhoidectomy 6 years previously with iatrogenic internal sphincter injury.  
 
All patients were reassessed regarding outcome in March 2009 at a median 
follow up of 9 months (range 3-14) from the end of treatment. All patients who 
embarked on treatment with PTNS are included in the analysis, regardless of 
length of treatment and outcome, with results expressed as intention to treat. 
Success of the procedure was considered a 50% or more reduction in episodes 
of UFI as measured by bowel diary combined with patient enthusiasm to 
continue. 
 
5.2.2 Percutaneous Tibial Nerve Stimulation 
PTNS was performed using the Urgent® PC neuromodulation system (Uroplasty 
Ltd, Manchester, UK) on an outpatient basis as described in detail previously61. 
This system is licensed in the UK for treatment of urinary and faecal 
incontinence54. A needle is inserted through the skin posterior to the medial 
malleolus and advanced towards the tibial nerve. Stimulation was gradually 
increased until sensation was perceived in the foot or motor flexor response 
were seen at the great toe. Stimulation parameters were set at 200 µs pulse 
width, 20 Hz frequency and at an amplitude ranging between 0.5-9mA. The 
amplitude was then maintained at a tolerable, sensory level. To assess efficacy 
for individual patients, an initial course of treatment involved 12 weekly sessions 
of 30 minute duration, followed by two at two weekly intervals and one a month 
later as has been described previously61,103. Patient commitment to the whole 
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course of treatment was essential.  Patients were encouraged to self refer back 
for further treatment if/when symptoms deteriorated, at which point they were 
offered a further three weekly sessions as a “top up” 61,103. 
 
5.2.3 Outcome Variables and Analysis 
Incontinence records and scores were collated prospectively to determine 
changes in symptoms. For this study, three outcome measures were defined a 
priori: 1) episodes of FI per week; 2) Cleveland clinic continence scores11; and 
3) degree of faecal urgency. Faecal urgency was defined as the patient’s 
perceived ability to defer defecation, and classified as maximal deferment of 
defaecation in minutes following the call to stool. Differences before and after 
stimulation were compared using a paired t-tests or Wilcoxon signed rank test 
depending on normality testing of data (D'Agostino & Pearson omnibus 
normality test). Analysis of variance was performed on non parametric data 
using Mann Whitney tests. A P value < 0.05 was taken to indicate significance. 
Analyses were undertaken using a commercially available statistical software 
package (Prism 4.02; GraphPad Software, San Diego, California, USA). 
 
5.3 Results 
5.3.1 Anorectal Physiological Assessment 
The internal anal sphincter was disrupted in 10 patients and the external 17. 
Nine patients had a combined EAS/IAS defect and 13 patients had an intact 
sphincter complex. The resting manometry pressures were attenuated in 14, 
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(range 10 to 105, median 50 cmH20). Maximal squeeze increment was 
attenuated in 25 patients, (range 4-150, median 40 cmH20). Rectal sensory 
thresholds to balloon inflation revealed 8 patients to have relative rectal 
hypersensitivity (maximal tolerated volume < 90ml ), none were hyposensate 
(maximal tolerated volume >300 ml). Normal ranges were calculated from 92 
healthy volunteers examined in this unit.  
 
5.3.2 PTNS: Clinical Outcome 
The procedure was very well tolerated by all patients with no morbidity 
observed in the placement of the electrode and during or after stimulation.  Two 
patients withdrew from the study after only the second treatment session, one 
citing lack of commitment to continue the treatment and the other became 
pregnant. A further two patients withdrew following the 6th session, two following 
the 7th, and three following the 12th session having failed to show improvement 
when assessed by the outcome measures above. One patient who 
demonstrated a marked improvement in all outcome measures and had 
achieved apparent continence, decided to embark on alternative treatment. 
Thus, from the initial 31 patients, 21 were satisfied with the response and 
continued within the treatment protocol. This conferred an overall treatment 
response rate (50% reduction in episodes of UFI combined with patient 
satisfaction) of 68% when analysed with intention to treat (Figure 5.1).   
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5.3.3 Episodes of Faecal Incontinence 
Twenty two of the thirty one patients (71%) improved by 50% or more, with 
episodes of incontinence decreasing from a median of 4 per week (range 0 to 
30) pre-stimulation to 0 per week (range 0 to 27) post-stimulation (P<.0001) 
(Figure 5.2). Twelve patients (32%) were “continent” (complete cessation of 
episodes of UFI) following treatment. The median reduction in incontinence 
episodes was 3 per week (range +2 to -24). The nine patients who failed to 
record a 50% improvement included four who did not experience weekly 
episodes in incontinence. Of these four, three had incontinence on a monthly 
basis while one had episodes, on average, every 2 months. 
Figure 5.1: Flowchart of patient outcomes following PTNS for UFI.  
 
31 patients (1 male) with 
urge faecal incontinence 
started PTNS  
21 (68%) with sustained 
improvement continue 
with PTNS 
4 (1 male) failed to 
improve and left mid way 
through the study 
2 left protocol after only 
the second treatment 
 
1 became continent, yet 
decided to explore other 
treatment options 
3 failed to improve by the 
end of the treatment 
protocol 
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Figure 5.2: Weekly episodes of faecal incontinence pre-stimuation and post 
stimulation. Medians marked by bar (P<.0001).  
 
5.3.4 Incontinence Scores 
Cleveland Clinic Score improved in twenty of the thirty one patients (65%) and 
deteriorated in one following PTNS (baseline: median 13, range 5 to 20; post-
stimulation: median 7, range 0 to 20, P<.0001) (Figure 5.3). The median 
reduction in incontinence scores was, however, only 2 (range -1 to 13).  
 
5.3.5 Ability to Defer Defecation 
Urgency was improved following PTNS in twenty patients (65%) (baseline: 
median 1 minute, range 0 to 15; post treatment: median 5 minutes, range 0 to 
25, P<.0001) (Figure 5.4). The median increase in ability to defer was 3 minutes 
(range 0 to 25). 
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Figure 5.3: Cleveland Clinic incontinence scores prestimulation and post 
stimulation. (Presented as medians and range, P<.0001).  
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Figure 5.4: The ability to defer in minutes pre and post stimulation (medians 
marked with bar, P<0.001). 
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5.3.6 Duration of Effect 
Currently, 4 patients have requested “top up” therapy, 2 with a return of 
symptoms and 2 for prophylaxis. Of the 2 patients who had recurrent 
incontinence, one received 2 blocks of three weekly 30 minute sessions of “top 
up” therapy after symptom free periods of 4 and 3 months, while the other has 
received a single block after 7 symptom free months. The other 2 patients 
requested and received a single block of treatment after 3 and 7 months without 
the resumption of incontinence. 
 
5.3.7 Outcome Versus Physiological Parameters 
There was no correlation between improvement (or deterioration) in outcome 
measures and any physiological parameters assessed: age, resting anal tone, 
squeeze increment, internal or external sphincter defects, rectal sensation 
thresholds (desire to defecate, maximal tolerated volume). An intact anal 
sphincter complex appeared to confer a increased probability of improvement 
when this group was compared with patients with any anal sphincter defect, 
however, the result was not statistically significant (P=0.077) (Figure 5.5). 
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Figure 5.5: Effect of sphincter defect on outcome in PTNS. ASD, anal sphincter 
defect (IAS and /or EAS); CSD combined sphincter defect (IAS and EAS); IAS, 
internal anal sphincter defect; EAS, external anal sphincter defect. 
 
5.4 Summary of Results 
Within this limited study group, PTNS appeared well tolerated with no 
associated morbidity. The majority of patients undergoing this technique 
experienced a significant reduction in episodes of incontinence and an 
improvement in their perceived ability to defer defecation. Efficacy does not 
appear related to any of the physiological parameters assessed however, an 
increased sample size may reveal that an intact sphincter complex to be 
associated with an increased probability of benefit. The duration of effect is as 
yet unknown and the “washout” period of this technique is unknown and could 
be the subject of further study.  
31 Patients 
8 failed: 
3CSD,  1IAS 
4EAS. 
11 improved 
with PTNS 
10 improved: 
6CSD, 4EAS 
13 with intact 
sphincter complex 
18 with ASD: 9 CSD, 
1 IAS , 8 EAS   
 
2 failed to 
improve. 
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CHAPTER 6: COMPARISON OF PERCUTANEOUS TIBIAL NERVE 
STIMULATION AND SCARAL NERVE STIMULATION FOR THE 
TREATMENT OF URGE FAECAL INCONTINENCE 
 
6.1 Introduction 
6.1.1 Effect of Neuromodulation 
 
Neuromodulation of the sacral nerve plexus is possible via PTNS and SNS but 
there are no published comparative studies to date comparing these treatments. 
Earlier, it has been shown that SNS appears more likely to produce a 50% 
reduction in symptoms in patients with more frequent symptoms of 
incontinence.  Furthermore, there was a non statistically significant trend for 
SNS to be more effective in an older subgroup of patients. Internal anal 
sphincter defects, EAS defects, RP, SP, PNTMLs, ability to defer and 
preoperative CCFI scores appeared unrelated to outcome. When PTNS was 
examined in a similar fashion using the same parameters, no predictors of 
success were identified. However, both were analysed with a limited number of 
study participants (SNS 50, PTNS 31) and it is possible that as yet unidentified 
predictors may be elicited with larger study numbers.  
 
6.1.2 Comparison of Two Techniques 
PTNS has been reported to have a similar efficacy to SNS in patients with 
urinary dysfunction42,43, yet it is unknown which of these two treatments would 
have a better efficacy in the treatment of UFI or which patients would derive 
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most benefit from which modality.  SNS is expensive, requires a permanent 
implant, at least two operations and is dependent on a multidisciplinary team 
consisting of specialist nursing staff, theatre personnel and surgeons yet suffers 
from limited adaptability once in situ101.  PTNS can be administered in the 
outpatient setting by a specialist nurse, is more adaptable, less invasive and is 
likely to be considerably cheaper than SNS. The aim of this study was to 
compare the efficacy, cost and morbidity of both PTNS and SNS in the 
treatment of patients with UFI. 
 
6.2 Methods 
6.2.1 Patient Selection 
Between August 2006 and January 2009, 25 consecutive females were 
identified who had undergone SNS for symptoms UFI (median age 57 years 
old, range 31 to 84). Patients with symptoms of PFI, post defecatory leakage 
etc. were excluded from this present study. From January 2008, first line 
therapy within our tertiary referral colorectal department evolved to incorporate 
PTNS for UFI, which was subsequently administered prior to consideration of 
any surgical intervention. The first 25 patients receiving PTNS (median age 57 
years old, range 35 to 78, 1 male) with pure UFI were compared to the earlier 
SNS cohort. Pre-treatment evaluation for all patients included detailed history, 
examination, and comprehensive anorectal physiological assessment as 
described previously. No patient received both treatments.  
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6.2.2 Aetiology of Patients’ Urge Faecal Incontinence  
Within the SNS group, the aetiology of UFI was obstetric trauma in 20 (80%), 
anal surgery in 3 (12%) and unknown (labelled idiopathic) in 2 (8%). Parity 
ranged from 0 to 5 (median 2). Within the PTNS group, the aetiology of UFI was 
obstetric trauma in 20 (80%), anal surgery in 2 (8%; including the single male 
patient) and unknown (labelled idiopathic) in 3 (12%). Parity amongst the 
females in the PTNS group ranged from 0 to 5 (median 2).  
 
6.2.3 Treatment Selection 
The decision to use SNS or PTNS within the two groups reflected the change in 
first line management for UFI within our tertiary referral centre. Whereas prior to 
January 2008 SNS was offered to patients who had failed conservative 
management, after this date, patients were offered PTNS in place of 
conservative management. No selection criteria or randomisation applied to any 
patient to guide them into one arm or the other. Inclusion criteria for this study 
were all patients referred for management of pure UFI. Exclusion criteria 
included pregnancy or intended pregnancy, implanted pacemaker or 
defibrillator, a history of ischaemic heart disease, peripheral neuropathy, any 
medication affecting coagulation or previous exposure to the other treatment 
modality. Patients with mixed symptoms (e.g. concomitant passive 
incontinence, constipation and rectal evacuatory disorder) were excluded from 
this preliminary study. Urinary symptoms were not considered in this present 
study. Patients were counselled as described previously and the procedures 
performed as outlined earlier. Patients were not offered counselling on which 
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treatment to have: the SNS group were assessed for treatment prior to the 
availability of PTNS, while the PTNS group were treated instead of conservative 
management, prior to consideration for any potential surgical management 
including SNS. 
 
6.2.4 Patient Follow-up  
PTNS patients were reassessed 3 months after their last treatment session. 
The SNS group were assessed 3 months after permanent implantation unless 
they had failed the PNE stage, in which case, data and outcome at the end of 
the temporary evaluation stage were used to assess the efficacy of treatment. 
All patients who embarked on treatment with PTNS or SNS are included in the 
analysis, regardless of length of treatment and outcome, with results expressed 
as intention to treat. Success of the procedure was considered a 50% or more 
reduction in episodes of UFI as measured by bowel diary combined with patient 
enthusiasm to continue. 
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6.2.5 Outcome Variables and Analysis 
Incontinence records and scores were collated prospectively to determine 
changes in symptoms. For this study, six outcome measures were defined a 
priori:  
1) Success rates for PTNS and SNS in the treatment of UFI. 
2) The relative reductions in episodes of UFI following treatment. 
3) The perceived increase in ability to defer defecation.  
4) The comparative reductions in CCFI scores.  
5) The relative costs incurred in treatment. 
6) The rates of morbidity for each procedure.  
Comparisons between the two groups before and after stimulation were 
performed using unpaired t-test, Wilcoxon matched pairs test or Mann-Whitney 
U test depending on normality testing of data (D'Agostino & Pearson omnibus 
normality test). A P value < 0.05 was taken to indicate statistical significance. 
Analyses were undertaken using a commercially available statistical software 
package (Prism 4.02; GraphPad Software, San Diego, California, USA). 
 
6.3 Results 
6.3.1 Cohort Analysis: Physiological Parameters 
Comparison of physiological parameters for the two groups is shown by Table 
6.1. The median age of the PTNS group was 57 years (range: 35-78) and in the 
SNS patients this was also 57 years (31-84) (P=NS). Median parity for both 
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cohorts was 2 (0-5) (P=NS).  The internal anal sphincter was disrupted in 10 
patients in the PTNS group and 12 in the SNS group (P=NS). EAS disruption 
was seen in 17 and 19 patients respectively (P=NS). Nine PTNS patients had a 
combined EAS/IAS defect and 7 patients had an intact sphincter complex. 
Eleven SNS patients had combined IAS/EAS defects while 5 had an intact 
sphincter (P=NS). The pre-treatment median resting manometry pressures was 
44cmH20, (range: 10 to 105) for PTNS patients and 51 (range:16-93) for SNS, 
(P=NS). Maximal squeeze pressure was 35.5cmH20 (range: 4-80) for PTNS 
and 25 (range:0-90) for SNS, (P=NS). Rectal sensory thresholds 
(FCS,DDV,MTV) and PNTMLs were comparable between the two groups with 
no significant difference on statistical analysis. 
 
Parameter SNS PTNS P value 
Median Age (range) 57( 31-84) 57( 35-78) NS 
Median Parity (range)  2 (0-5) 2 (0-5) NS 
IAS Disrupted 12/25 10/25 NS 
EAS Disrupted 19/25 17/25 NS 
Combined Defects 11/25 9/25 NS 
Intact Sphincter 5/25 7/25 NS 
Median Resting  
Pressure {cmH20} (range) 
51 
(16-93) 
44 
(10-105) 
NS 
Median Squeeze  
Pressure {cmH20} (range) 
25 
(16-93) 
35 
(4-80) 
NS 
 
Table 6.1 Comparison of physiological parameters between the SNS and PTNS 
groups. Combined defects: patients with both an IAS AND an EAS defect.  
 
6.3.2 Cohort Analysis: Pre-treatment Symptom Profile 
Over a two week monitoring period prior to stimulation the PTNS group had a 
median of 7 (range:0-30) episodes of UFI while the SNS group had a median of 
92 
 
9 (range: 0-44) (P=NS). PTNS had a median CCFI score of 13 (range: 5-20) 
while SNS was 14 (range 3-20) (P=NS). The median ability to defer defecation 
was limited to 1 minute for PTNS (range: 0-15) and 2 minutes for SNS (range: 
0-15) (P=NS).  
 
6.3.3 Post Stimulation Success Rates 
Twenty one PTNS patients and 17 SNS patients experienced a reduction in 
episodes of UFI following stimulation (P=NS). Eighteen patients from the PTNS 
group achieved a 50% reduction in symptoms while only 13 from SNS obtained 
this level of benefit (P=0.089). Twelve PTNS patients experienced a complete 
resolution of symptoms of incontinence however this was only seen in 6 SNS 
patients (P=0.082). Five patients declined further PTNS prior to completing a 
full treatment protocol with a further 2 withdrawing after a full treatment protocol 
citing lack of efficacy. Eighteen patients achieved at least a 50% reduction in 
symptoms conferring a success rate of 72% when analysed with intention to 
treat. Five patients failed SNS at the PNE stage with a further 7 failing at 
permanent implantation with 13 achieving a 50% reduction in symptoms 
conferring an intention to treat success rate of 52% (P=0.089) (Figure 6.1).  
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Figure 6.1: Flowchart of outcome for PTNS and SNS comparison study. Forty 
eight percent of PTNS had a resolution of symptoms with 52% having ongoing 
episodes of FI. Sacral nerve stimulation achieved 24% continence with 76% 
having ongoing symptoms. (50% threshold: Patients that had a 50% or greater 
reduction in episodes of FI following stimulation. Apparent continence: patients 
with no episodes of FI during monitoring period.)  
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6.3.4 Episodes of Faecal Incontinence 
The median frequency of UFI post stimulation in the PTNS group had reduced 
from 7 (range:0-30) to 1 (range: 0-27) (P<0.001), while for SNS patients, the 
baseline median of 9 (range: 0-44) was reduced to a median of 2 (range: 0-19) 
(P=0.007). The two pre stimulated groups were similar (P=NS) however, the 
outcome from PTNS was significantly better than that of SNS (P=0.045) (Figure 
6.2).  
 
6.3.5 Ability to Defer Defecation 
Urgency was improved following PTNS in 16 patients (64%) (median 5 minutes, 
range 0 to 25) and in 12 (48%) SNS patients (median 3, range 0-15) (P=NS). 
The median change in ability to defer was 3 minutes (range 0 to 25) in the 
PTNS patients and zero minutes for SNS (range: -10 to 15) (P=NS). 
 
6.3.6 Incontinence Scores 
CCFI scores improved in 17 (68%) PTNS patients and 18 (72%) of SNS 
patients. PTNS improved the CCFI scores from a median of 13 (range: 5-20) to 
7 (range: 0-20) (P<0.001), while SNS was from a median of 14 (range 3-20) to 
10 (range: 1-18) (P<0.001) for SNS. There was no significant difference 
between the two groups CCFI scores pre or post stimulation (P=NS) (Figure 
6.3).    
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Figure 6.2: Weekly episodes of FI pre stimulation and post stimulation for 
PTNS and SNS.  (post PTNS and post SNS groups compared, P=0.0475). 
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Figure 6.3: Pre and post stimulation CCFI scores for PTNS and SNS groups.  
 
 
6.3.7 Outcome Versus Physiological Parameters 
None of the physiological parameters assessed: age, resting anal tone, 
squeeze increment, internal or external sphincter defects, rectal sensation 
thresholds (FCS,DDV,MTV) or parity were associated with a predictive ability of 
improvement for one arm of the study compared to the other. 
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6.3.8 Morbidity Encountered 
From the SNS group of 25 patients, tined lead migration occurred in two cases 
with reimplantation on the contralateral side required in one case. Two patients 
experienced discomfort from superficial implantation of the stimulator which 
required repositioning in both cases. In total, 48 operative procedures (PNE -25, 
permanent implantation -20, adjustment of permanent implantation -3) were 
required for the SNS cohort to date. PTNS was well tolerated by all patients with 
no morbidity observed in the placement of the electrode and during or after 
stimulation with no operative intervention required for any patient. 
 
6.3.9 Cost of Treatment 
In a centre with specialist nursing service, an additional set up cost of £835 for 
the PTNS programmer is required. This can be used for up to 70 individual 
patient sessions in a standard working week (fourteen X 30min sessions per 
working day) . Following this, the cost of PTNS is £385 per course of treatment 
per patient61. The resulting direct medical costs (excluding specialist nursing 
costs) are therefore £385 + £835/70 = £397 per patient, per course of 
treatment. The cost of SNS is significantly more and has been shown to be 
£20,000 for the direct medical costs alone (device, operations, anaesthesia, 
hospital stay- excluding specialist nursing costs) per patient, that goes on to 
permanent implantation.104  
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However, the “washout” period of PTNS is as yet unknown and repeat 
treatments are likely to be required, although the life of the implanted battery for 
SNS is limited to a median of 7 years for Interstim I and estimated at 5 years for 
the smaller more commonly used Interstim II.104 With replacement costing 
approximately an additional £10,000, the first 5 to 7 years of SNS may be 
expected to cost around £30,000 per successful patient depending on the 
implant used. For PTNS to be similarly as expensive as SNS (longer lasting 
Interstim I), each patient would require 75 twelve week courses of PTNS which 
would take 17.4 years of continuous unbroken administration.  
   
6.4 Summary of Results 
In two similar groups of patients with UFI, there was a trend, which did not 
reach statistical significance, for PTNS to produce more patients who achieved 
either a 50% reduction in symptoms or indeed a resolution of symptoms of UFI 
when compared to SNS. PTNS patients experienced significantly fewer 
episodes of UFI when compared to SNS patients after treatment. Alterations in 
CCFI scores and ability to defer were similar for both groups. SNS is associated 
with more morbidity than PTNS reflecting the invasive nature of SNS when 
compared to PTNS. PTNS is considerably cheaper than SNS and would 
appear, from this limited study, to be a more effective treatment. 
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CHAPTER 7: ELECTRICALLY STIMULATED GRACILIS NEOSPHINCTER 
CONSTRUCTION FOR END STAGE FAECAL INCONTINENCE: 
EVALUATION OF LONG-TERM FUNCTIONAL OUTCOME. 
 
7.1 Introduction 
7.1.1 Limitations of Surgical Therapies  
Patients with FI who fail conservative therapy are frequently considered for 
surgical management, with the majority of techniques concentrating upon 
restoration of normal anatomy. Anterior sphincter repair has been the first line 
surgical intervention for many years, since sphincteric disruption is thought to 
be causal for the majority of patients26, though the long-term results of this 
procedure are poor29. More recently, minimally invasive techniques such as 
sacral nerve stimulation (SNS) have shown long-term benefit in up to 75% of 
patients105, however as described earlier, the “success” rate of SNS is 
frequently overestimated and the majority of studies disregard those who fail the 
trial period of peripheral nerve evaluation yet include patients who remain 
symptomatic with the “success” group.88,105 
 
7.1.2 End Stage Faecal Incontinence 
Therefore, despite recent developments, a cohort of patients will continue to 
suffer from FI that is refractory to standard interventions, and may be classified 
as suffering from end-stage FI. In such patients electrically stimulated gracilis 
neosphincter (ESGN or dynamic graciloplasty) construction may be considered. 
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This is an expensive, highly invasive procedure with significant rates of 
morbidity reserved for only the most highly motivated patients with end stage FI 
as an alternative to end colostomy35-37. ESGN has been shown to be effective in 
the treatment of FI, yet the long term outcome of this procedure remains 
unknown. Furthermore, it is unclear if the efficacy of ESGN is dependent on, or 
related to, the aetiology of FI. This study was designed to address these two 
questions. 
 
7.2 Methods  
7.2.1 Patient Selection 
The study was approved by the East London and City Health Authority 
Research Ethics Committee. Written informed consent was obtained from all 
participants. Sixty patients who underwent ESGN construction between October 
1989 and October 2001 at a tertiary colorectal referral centre were available for 
long-term follow-up during 2009. All patients presented with symptoms of 
severe FI (as defined by a Williams’ Continence Score of ≥5: see 7.2.3 Clinical 
Evaluation), and had failed maximal conservative management (including 
dietary manipulation, enemas or suppositories, rectal irrigation, medications 
altering transit, and from 1998 onwards, bowel retraining incorporating 
‘biofeedback’). In addition, a proportion of patients had also failed standard 
surgical treatment (4 direct sphincter repair, 11 post anal repair) prior to ESGN 
construction.  
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Inclusion criteria for ESGN construction have been described previously72, 
namely FI with a William’s Continence Score ≥ 5 and at least one of:  
1) A significant (> 1/3 of circumference) external anal sphincter deficit as 
assessed by endoanal ultrasound;  
2) Prolonged bilateral pudendal nerve terminal motor latencies;   
3) Attenuated voluntary anal squeeze increment.  
Prior to commencing the study, 2 primary outcome measures were identified: 1) 
Percentage of patients achieving a Williams Continence Score of 3 or better 
and 2) Percentage of patients that avoided stoma formation. In addition, the 
study was designed to assess if level of response was related to aetiology of FI 
and the functional and surgical morbidity involved in ESGN construction. 
 
7.2.2 Aetiology of Symptoms 
ESGN construction was performed for the following indications: traumatic 
childbirth (n=22), surgical trauma (n=17), anorectal atresia (n=7), idiopathic 
faecal incontinence (n=6), anorectal excision (n=4), and ileoanal pouch 
incontinence (n=4). The median age at operation was 42 years (interquartile 
range [IQR] 33-50; 46 female). Obstetric “injuries” recognized at childbirth 
thought to have given rise to the symptoms of FI include: perineal tear 16/22 
cases, episiotomy 3/22, and forceps delivery 3/22. Secondary purported risk 
factors for FI included: pelvic surgery (hysterectomy 6; pelvic adhesiolysis 1; 
sterilization 2; rectopexy 3, colposuspension 1), decreased gut transit time 
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(chronic laxative abuse 2; thyroxine 1), and neurological impairment (Diabetes 
Mellitus 10; spinal surgery 1). 
 
7.2.3 Clinical Evaluation  
Patients were evaluated preoperatively, and postoperatively at a median of 4 
(IQR 3-8), 21 (IQR 10-43) and 155 months (IQR 122-213). Williams’ Continence 
Score14 was used to assess the severity of faecal incontinence:  
1) Perfect continence;  
2) Occasional incontinence to flatus;  
3) Occasional incontinence to liquid stool;  
4) Occasional incontinence to solid stool;  
5) Complete incontinence to liquid and solid stool;  
6) Stoma.  
A Williams’ Continence Score of 3 or less was considered an acceptable result 
as occasional loss of liquid stool could be manipulated by conservative 
measures.  
 
7.2.4 Anorectal Physiology 
Preoperatively all patients underwent standard anorectal physiological 
investigation in the left lateral position as described previously. 
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7.2.5 Surgical Procedure  
The ESGN procedure has been described in detail previously33,34. Briefly, the 
gracilis muscle is mobilized along its entire length, and with the distal vessels 
ligated, it is detached from its insertion into the medial aspect of the tibia, 
thereby preserving its proximal blood supply and innervation. Two incisions are 
made either side of the anus and a tunnel encircling the anal canal formed. The 
gracilis is then wrapped around the anal canal in a gamma configuration with 
the inserting tendon being sutured to the contra-lateral ischial spine. An 
electrode is fixed directly onto the obturator nerve proximal to its insertion into 
the muscle, and the stimulating wires tunnelled to the anterior abdominal wall, 
lying in a pocket created in the subcutaneous tissues. A defunctioning loop 
ileostomy is created to divert the faecal stream whilst muscle training takes 
place. A pulse generator is implanted at this operation if it is considered a 
sufficiently sterile procedure. Stimulation is then commenced at a low frequency 
and sequentially increased until continuous stimulation is initiated at around 8 
weeks. Following this, the ileostomy is reversed and an external radiotelemetry 
controller is provided to enable the stimulator to be turned off prior to 
defecation, and on following bowel evacuation33. 
 
Formation of a continent colonic conduit was undertaken for those patients who 
developed obstructed defecation following ESGN construction. This procedure 
was initially developed for the treatment of rectal evacuatory disorders and its 
formation is described in detail elsewhere106. It was subsequently used in the 
management of patients who underwent ESGN construction but developed 
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severe evacuatory dysfunction that did not respond to the use of laxatives, and 
required regular manual evacuation. 
 
7.2.6 Statistical Analysis  
Statistical analysis was performed for non-parametric data (confirmed by 
D’Agostino and Pearson omnibus normality test) using Mann-Whitney / 
Wilcoxon matched pairs / Kruskal-Walis / Friedman (Dunn’s post analysis) tests 
where appropriate. Analyses were undertaken using a commercially available 
statistical software package (Prism 4.02; GraphPad Software, San Diego, 
California, USA). P values represent the statistical difference between 
preoperative and individual postoperative groups, with a value of 0.050 
considered to show statistical significance. Due to the limited nature of the 
Williams’ Continence Score, data are presented with medians and inter-quartile 
range, as opposed to range, to highlight variations between groups. For 
consistency, this has been applied to all data in this chapter.  
 
7.3 Results   
7.3.1 Preoperative Assessment 
Median patient age was 42 (IQR 33-50) with median symptom duration of 5 
years (IQR 2-13). Median pre-ESGN Williams’ continence scores were 5 (IQR 
5), representing persistent incontinence to solid and/or liquid stool. Preoperative 
constipation was reported by 8 of the 60 patients. 
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For all patients preoperatively, median maximum anal resting pressure was 
34cmH20 (IQR 25-57), with a median maximum anal squeeze increment of 
20cmH20 (IQR 11-36). Median first constant sensory threshold volume during 
rectal balloon distension was 30 ml (IQR 17-71), median defecatory desire 
volume 60 ml (IQR 30-145), while median maximal tolerable volume was 110 ml 
(IQR 61-180). Preoperative evacuation proctography identified protracted rectal 
emptying without evidence of mechanical outlet obstruction in 1 patient, intra-
rectal intussusception with associated rectocele in 3 patients, isolated rectocele 
in 6, and recto-anal prolapse in 3. 
 
7.3.2 Short-Term Follow Up: Four Months Postoperatively   
Median time to the reversal of defunctioning ileostomy following muscle training 
was 4 months (IQR 3-8). Immediately following this, overall median continence 
score was 2 (IQR 2-5; P<0.0001; [Figure 7.1]). Continence scores varied by 
surgical indication but were not statistically assessed at this time point as 
optimal function had not been attained: traumatic childbirth – 2 [IQR 2-2]; 
surgical trauma – 2 [IQR 2-3]; anorectal atresia – 2 [IQR 2-5]; anorectal excision 
– 2 [IQR 2-3]; idiopathic fecal incontinence – 3 [IQR 2-5]; and ileoanal pouch 
incontinence – 5 [IQR 4-5].  
 
7.3.3 Mid-Term Follow Up: Two Years 
At a median follow up of 21 months (IQR 10-43) perfect continence or 
occasional loss of liquid stool was reported by 39/60 patients (65%; median 
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score 2[IQR 2-5]; P<0.0001 [Figure 7.1]). Postoperative continence scores 
varied by indication: traumatic childbirth – 2 ([IQR 2-2]; P<0.0001); surgical 
trauma – 2 ([IQR 2-3]; P<0.0001); anorectal atresia – 5 ([IQR 2-6]; P=NS); 
anorectal excision – 2 ([IQR 2-3]; P=0.0034); idiopathic fecal incontinence – 3 
([IQR 2-5]; P=NS); and ileoanal pouch incontinence – 5 ([IQR 4-5]; P=NS) 
(Figure 7.2). Overall, 18/60 patients (30%) described rectal evacuatory disorder 
necessitating regular laxatives, with 10 (17%) progressing to colonic conduit 
formation in order to facilitate antegrade colonic irrigation. Two of these patients 
went on to require the formation of a permanent end colostomy, with a further 
patient requiring formal revision of the conduit. End colostomy was avoided in 
57 (95%) of patients while 44 (73%) had a Williams score of 3 or less (Table 
7.1).   
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Figure 7.1: Outcome following ESGN construction for all patients as assessed 
by Williams score at 4, 21 and 155 months post surgery. Data presented as 
medians with IQR.  
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         Avoided stoma             Williams score ≤ 3 
Indication Number 21 155 21 155 
traumatic childbirth 22 22(100) 15 (68) 20 (91) 9(41) 
surgical trauma 17 16(94) 13(76) 13(76) 12(71) 
anorectal atresia 7 5(71) 3(43) 3(43) 1(14) 
Idiopathic 6 6(100) 3(50) 4(67) 3(50) 
anorectal excision 4 4(100) 3(75) 3(75) 1(25) 
ileoanal pouch 4 4(100) 0 1(25) 0 
Total 60 57(95) 37(62) 44(73) 26(43) 
 
Table 7.1: Indication and cohort analysis of mid and long term rates of stoma 
avoidance and successful outcome following ESGN construction.  
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Figure 7.2: Outcome following ESGN construction by indication for surgery. a) 
traumatic childbirth, b) surgical trauma, c) anorectal atresia, d) anorectal 
excision, e) idiopathic fecal incontinence and f) ileoanal pouch incontinence. 
Data presented as medians with IQR. 
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7.3.4 Long-Term Follow Up: Twelve Years 
At a median of 155 months following surgery, end colostomy was avoided in 37 
(62%) of patients while 26 (43%) had a Williams’ score of 3 or less (median 5[3-
6]; P=NS; Table 7.1, Figure 7.1). Seventeen patients had undergone 
replacement of the implanted stimulator. As with 4-month and 2-year follow-up, 
postoperative continence scores varied by indication at twelve-years: traumatic 
childbirth – 5 ([IQR 3-6]; P=0.0010); surgical trauma – 3 ([IQR 2-5]; P< 0.0001); 
anorectal atresia – 6 ([IQR 5-6]; P=NS); anorectal excision – 5 ([IQR 4-5]; 
P=NS); idiopathic fecal incontinence – 5 ([IQR 2-6]; P=NS); All patients with 
ileoanal pouch incontinence required stoma construction by twelve-year follow-
up. When assessing all patients, none of the following factors were found to 
adversely affect long-term functional outcome: increasing age, pre / 
postoperative constipation, rectal sensation, or septic / anal complications.  
 
7.3.5 Surgical Morbidity 
Early complications were seen in 15/60 patients (25%), with 5 patients (8%) 
developing more than one complication. Three patients suffered muscle loss 
following iatrogenic injury of the neurovascular bundle during gracilis muscle 
dissection. Overall, 2 patients developed a superficial leg wound infection that 
responded to antibiotic therapy. Seven patients required nerve exploration for a 
displaced electrode plate, while in one additional case a stimulator had to be 
resited. An ischemic ulcer was identified in 3 cases prior to covering ileostomy 
closure, all of which responded to temporarily discontinuing stimulation of the 
gracilis muscle. A further 4 patients developed neo-anal necrosis due to gracilis 
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tendon erosion. Late complications were seen in 4/60 patients (4%): anal 
stenosis – 4; hardware failure – 1. 
 
7.3.6 Functional Morbidity 
New onset postoperative rectal evacuatory disorder was reported by 18 patients 
(30%; P=0.0003), resulting in a total of 26/60 patients (43%) describing 
postoperative symptoms of obstructed defecation. Ten patients elected to 
undergo colonic conduit construction to improve symptoms of evacuatory 
disorder during this study. Twenty three patients (38%) required formation of a 
permanent stoma for the following indications: 14 patients reporting 
unsatisfactory long-term function, 8 evacuatory disorder, and 1 small bowel 
obstruction necessitating resection and permanent stoma. No late onset 
episodes of sepsis occurred. 
 
7.3.7 Predictors of Functional Outcome 
Variables and physiological parameters capable of determining postoperative 
outcomes were sought. Median continence scores at long-term follow up were 
not found to be significantly different for those patients enrolled within the first or 
last seven years of the study. Similarly, the following preoperative variables 
were not found to adversely affect functional outcome at twelve years after 
surgery: increasing age (distribution of ages within each continence score 
group), septic or anal morbidity. Preoperative constipation was associated with 
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better continence scores at long-term follow up (P= 0.0022) but was not found 
to be predictive for rectal evacuatory dysfunction. 
 
7.4 Summary of Results 
ESGN is associated with a significant morbidity in the short and medium term 
and RED is a common complication which frequently requires further surgical 
intervention. A high failure rate is seen in short, mid and long term analysis 
necessitating end colostomy formation. However, ESGN can be an effective 
long term treatment for “end stage” FI in some patients in order to avoid stoma 
formation with the outcome related to the indication for surgery. At a median of 
155 months following surgery for end stage FI, colostomy was avoided in 37 
(62%) of patients while 26 (43%) had a Williams’ score of 3 or less signifying 
long term acceptable outcome. 
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CHAPTER 8: DISCUSSION 
 
8.1 Faecal Incontinence 
8.1.1 Clinical Presentation and Aetiology  
Simplistically, faecal incontinence can be defined the involuntary loss of faecal 
contents through the anal canal, yet a panacea (other than an end colostomy) 
for FI remains elusive. Behind this definition of FI lies a diverse spectrum of 
symptoms caused by a complex array of interacting pathologies and social 
attitudes which complicate the management.1,2,3,6,26 Some patients describe 
episodes of FI multiple times per day, others much less frequently. Some may 
have UFI secondary to a severely disrupted sphincter complex, while others 
have PFI secondary to a functional rectocoele with an attenuated, but intact, 
sphincter. Some patients may be satisfied if the frequency of FI could be 
reduced to once per week, while others horrified at having minor seepage on a 
monthly basis. Given this, it would appear that any one intervention is unlikely to 
be suitable for all as this thesis has suggested.  
 
The most common aetiology for FI is thought to be anal sphincter trauma 
secondary to childbirth, with the EAS considered by many, to be the most 
important factor.15-21 Given the average 18 year delay before the onset of 
symptoms, this mechanism alone is likely to be too simplistic.16 Patients can 
therefore remain continent despite having a EAS defect for almost two decades 
yet many surgeons focus primarily on this injury as the source of symptoms. 
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From a “cause and effect” approach, repairing the damaged EAS with an 
overlapping repair should alleviate the symptoms, yet 10 years following this 
surgery the rate of complete continence has been shown to be as low as 
zero.29,30 Therefore, a disrupted EAS may be asymptomatic for up to 2 decades, 
and repairing it does not eradicate symptoms of FI, suggesting other factors are 
likely to  be involved.   
 
8.1.2 Age, Parity and Obstetric Trauma 
This thesis has addressed the impact of age, parity and obstetric factors on 
anorectal function in a large cohort of females, all investigated using 
contemporary  physiologic assessment, for significant symptoms of hindgut 
dysfunction (faecal incontinence and constipation), but in whom potentially 
confounding factors have been excluded. It is important to stress that since 
subjects were all symptomatic, results cannot be extrapolated to asymptomatic 
populations. Nevertheless, discussion of the results from this study group 
(n=999), a number unfeasible in a longitudinal prospective study with healthy 
volunteers, is justified.  
 
Previous studies have examined the effect of ageing, parity and mode of 
delivery in isolation and together,17,19-21,23-25,62-64 however these covariates (e.g. 
age and parity), are likely to be interdependent, and an attempt at modelling 
data together is required. This issue has been addressed with a series of 
univariate and multivariate models accepting that in statistical terms, some of 
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these models poorly explain the overall distribution and interdependence of 
data. 
 
With regard to anal sphincter function, univariate analysis revealed that 
nulliparous females showed an almost identical reduction in resting tone with 
advancing years to the parous group, with the decrease in resting pressure 
associated with successive vaginal deliveries to be equivalent to 6.5 years of 
ageing per birth. However, when childbirth resulted in an internal, external or 
combined sphincter defect (exclusion criteria allowing the assumption that any 
defect arose as a consequence of childbirth), the effect upon anal resting tone 
was much more profound. The effect of ageing upon squeeze increments, 
although statistically significant, was in functional terms minor, and similar to the 
effect of parity in the absence of sphincter defects. The impact of an external 
sphincter defect on squeeze increment pressures was far greater. This study 
demonstrates, as have others that the presence of sphincteric disruption is 
almost exclusively related to the first vaginal delivery, with the incidence of 
external sphincter defects (and thus impact on anal function) greatest in those 
who had undergone instrumentation-assisted delivery.17,20,108 Delivery by 
Caesarean section was protective against external sphincter defects and 
against reduction of resting and squeeze increment pressures (Figures 2.10 
and 2.11- page 42). Univariate analysis revealed rectal sensation to be 
unaltered by age, parity or mode of delivery. There was, however, correlation 
between age and parity with increasing PNTML, with a greater impact of each 
on the left pudendal nerve. 
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Multivariate analysis using models to investigate anal function (resting tone and 
squeeze increment) demonstrated that age and an internal anal sphincter 
defect  were the strongest determinants of reduced tone. As might be expected, 
an external sphincter defect was the greatest determinant of reduced squeeze, 
with parity per se an insignificant co-variate. However, the assumption that 
internal anal sphincter dysfunction alone is responsible for reduced resting tone 
and symptoms109,110 must be challenged, since external anal sphincter integrity 
is also significantly associated with anal resting pressure (Figure 2.8 –page 40). 
Equally, the data suggests that squeeze increment is adversely affected by a 
defect in the IAS (Figure 2.9 –page 40). Given the presence of such a defect in 
this cohort is caused by obstetric injury (secondary to the exclusion criteria), it is 
likely that this association is spurious and more realistically explained by a 
severe sphinteric injury which involved the EAS and IAS at the time of delivery. 
 
The innervation of the sphincter complex has also been shown to be affected by 
both age and parity which our data confirm.17,19,65 However, despite an apparent 
small increase in PNTML with age but a greater increase with successive births, 
multivariate analysis shows the effect to be almost entirely secondary to ageing, 
as a result of the colinearity between age and parity. The correlation between 
age and increasing PNTML must therefore be taken into account when 
interpreting results of this test in the context of defining a neuropathy. The 
greater impact of parity on the left pudendal nerve is in accord with the results 
of the prospective study by Sultan investigating pudendal nerve conduction in 
relation to childbirth.111 
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These data suggest that not only is Caesarean section protective of the 
sphincter complex, but that manometrically-recorded pressures are preserved, 
in accord with results from other studies.17,23 Furthermore these data confirm 
the results of several other studies,17,20,112 which show that a history of 
instrumentation results in increased frequency of sphincter defects. Although 
these data also confirm studies showing that instrumentation adversely affects 
anal pressures,20 this relationship is related to squeeze increment but not 
resting pressures. Some of the CS only group however, did have sphincter 
defects. Given the exclusion criteria and stratification of parity applied, this is 
likely to represent trauma occurring prior to emergency section or a history of 
anal injury, unreported by the patients at the time of assessment. 
 
This study does have several limitations, including its retrospective design, and 
although physiology testing was performed by multiple investigators, all were 
trained by a single physiologist, using the same technique, and all followed the 
Unit’s guidelines. Ultrasound evidence of degeneration, rather than true 
structural defects, was not sought, and it may be that degeneration may have a 
relation with age, perhaps through prolongation of pudendal motor nerve 
conduction. Of course half the cohort studied suffered from faecal incontinence 
which may have skewed the data in terms of prevalence of sphincter defects, 
although, interestingly, parity and age were similar between those with 
incontinence and those with constipation. Unfortunately, data relating to time of 
menopause were not sought; it is known that there are independent effects of 
changes in the hormonal milieu on certain aspects of pelvic and anorectal 
function.113,114 
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It must be remembered that this is not a study of asymptomatic subjects, and 
the concepts of normality and abnormality have been avoided. Defining 
normality, stratified according to age and parity thus remains a challenge. 
Despite some weaknesses in statistical modelling, this study possesses three 
main strengths which confirm some, but also contest results of previous studies. 
The vigorous exclusion criteria employed limit as far as possible the effect of 
any other confounding aetiological factors other than increasing age and parity 
on the female anorectum. Secondly, the statistical models presented reveal 
individual changes with each year and with each delivery to be small, but 
cumulatively significant. Finally, by highlighting a predictable association 
between increasing age and increasing parity, it is clear why other studies have 
attributed statistically significant associations that may now appear tenuous. 
Age affects resting pressures (presumably by effects on innervation of the 
sphincter complex, or myopathy) and the innervation of the sphincter complex 
while parity appears detrimental to the structure and function of the external 
(and more rarely the internal) sphincter. The effect of parity is exacerbated by a 
history of instrumentation, while caesarean section is protective. Neither age 
nor parity has any association with rectal sensory thresholds. These findings 
have clear clinical significance whenever any procedure is contemplated with 
may adversely affect the sphincter complex e.g. fistula, fissure surgery etc. The 
surgeon should bear in mind while performing an assessment of the sphincter 
that the unaffected or remaining part will deteriorate over time. In the older 
population this may be less relevant as the changes per annum are small, 
however, in a 20 year old nulliparous female, the findings at EUA are at 
significant risk of change over the years and consideration is required prior to 
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any sphincteric sacrifice. In such circumstances, it may be prudent to perform 
more conservative but less definitive surgery e.g. long term seton or botox 
injection as opposed to laying open an intersphincteric / trans-sphincteric fistula 
or performing a lateral sphincterotomy for fissure.     
 
8.2 Sacral and Percutaneous Tibial Nerve Stimulation 
8.2.1 Sacral Nerve Stimulation and Anorectal Physiology 
The age and parity data may provide a potential model to explain why obstetric 
injury has a significant delay before onset of symptoms. The sphincter complex 
must be capable of generating sufficient pressure through resting tone and 
squeeze increment, exceeding a minimum threshold, to prevent inappropriate 
expulsion of stool and maintain continence. For the majority of obstetric injuries, 
the damage incurred is initially insufficient to cause the pressure generated to 
fall below this threshold, and continence is maintained. As years pass and the 
effect of aging described above accumulates, this threshold is breached and 
symptoms appear.  If this is indeed the case, then augmention of the sphincter 
complex function by electrical stimulation could potentially increase pressures 
once again above the threshold and thereby re-establish continence. SNS was 
originally limited to patients with intact sphincters as this was believed to be a 
prerequisite for success in this “augmention” of sphincter function.60 Indeed 
previous studies have shown that the pressures generated as measured by 
manometry have increased following SNS.45,50,58 During the course of this 
study, ARP was performed repeatedly and such results were not reproducible, 
indeed, this study was unable to elicit any neither consistent nor significant 
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change in rectal sensory thresholds, resting pressures, squeeze increment or 
pudendal nerve terminal motor latencies. Furthermore, while this work was 
progressing, studies were published showing that there was no sphincter 
augmentation following stimulation confirming the findings of this thesis76,79.  
 
8.2.2 Efficacy of Sacral Nerve Stimulation 
While collating data on SNS efficacy, it became clinically apparent that the 
success rates of SNS widely reported in the literature, were not being 
reproduced within this department. Patient profiles, phsyiology data, functional 
outcomes, operative techniques and the published literature were therefore 
investigated for potential causes of this difference. This study reports the 
experience of a single tertiary colorectal referral centre over a five year period 
with results expressed as intention to treat. With 54% of patients describing an 
improvement in symptoms, the data described demonstrates that SNS can be 
an effective treatment for FI. However, these results appear at variance with 
early reports of SNS which suggest that the majority of individuals who undergo 
this procedure derive significant benefit.44-53  Therefore, although there have 
been multiple studies which have investigated SNS as a treatment for FI, the 
efficacy of this procedure remains contentious. 
 
Reports describing functional outcome following SNS for FI have previously 
specified success rates of between 67-100% following implantation of the 
permanent stimulator.44-53 If functional outcome data reported by this study were 
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presented in a similar fashion to the majority of the published literature, a 
response rate of 73% would have been achieved, since 27/37 patients who 
progressed to permanent stimulation experienced a 50% or greater reduction in 
episodes of FI. This is comparable with previous reports and confirms that these 
results are not secondary to surgical technique, or biased by experience or 
patient selection. However, when assessed with an intention to treat analysis, 
the overall ‘success’ rate for SNS was reduced to 54%, as 13 (26%) patients 
failed PNE, while 10 (20%) patients did not experience an improvement in 
symptoms compared with those during PNE. Furthermore, only 26% of patients 
experienced an apparent complete resolution of symptoms. Studies included in 
the systematic review which have included data on those not responding to 
PNE, have similar response rates to those described in this study (Table 3.1 –
page 61). 
 
Establishing the true efficacy of SNS is further compounded by the definition of 
what is deemed an acceptable outcome. While a 50% reduction in episodes of 
FI is widely held as the threshold of success, the significance of such a limited 
improvement should be explored. Seventy-four percent of the patients enrolled 
in this study continued to experience at least fortnightly episodes of FI while 
68% suffered weekly episodes. Consequently, although SNS may have resulted 
in a degree of improvement, the majority of patients would satisfy the criteria for 
considering further surgical intervention. SNS was originally used to treat 
detrusor overactivity and urinary frequency5,41 and while a 50% reduction in 
symptoms may be acceptable for these conditions, it is questionable whether 
the same arbitrary measure of success should be applied to FI. It is generally 
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accepted that for a medical treatment to be considered a “success”, patients 
would either have to experience a resolution in symptoms or the physiological 
parameter being assessed return to an acceptable level. Our results show that 
despite having a similar outcome to other units, 68% of patients who enter into 
treatment with SNS for FI continue to experience weekly episodes of faecal 
incontinence. Such a level of incontinence is unlikely to represent a satisfactory 
resolution of symptoms and this is highlighted by mid-term median CCFI score 
of eight. Similarly, the effect of SNS upon perceived ability to defer defecation is 
uncertain; while most study participants reported an improvement, the median 
deferment of five minutes falls short of a return to normality. Therefore, the 
lifestyle of the majority of patients is likely to remain affected by urgency and the 
need to be near toileting facilities, even in those who achieve apparent 
“continence”. However, although this study evaluated the effect of SNS on 
symptoms of FI, it does not address alterations in the quality of life (QOL) 
scores of these patients. Further studies will be required to assess 
improvements in QOL following SNS and specifically, the threshold reduction in 
symptoms required to consistently produce an improvement in QOL scores to 
deem the treatment a success. 
 
Irrespective of the definition of a successful outcome following SNS, a 
proportion of patients report resolution of FI symptoms following this 
intervention, but the preoperative identification of this subgroup remains 
problematic. PNE has been used as means to identify these individuals, 
however, in addition to the 26% of study participants who derived no 
improvement in symptoms following test stimulation, PNE failed to exclude a 
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further 20% for whom SNS was ultimately unsuccessful. The reason for this 
apparent failure to regain the effect of temporary stimulation is unclear. It is 
possible that lifestyle restrictions whilst undergoing temporary stimulation may 
contribute to fewer episodes of FI, or that patient concerns over being refused 
permanent treatment for their symptoms could influence the completion of 
bowel diaries at PNE. Nevertheless, the reported data do suggest that for most 
patients, short term benefits of permanent implantation are sustained at medium 
term follow up, in keeping with previous reports.  
 
The treatment of FI with SNS is expensive81 and this study suggests that the 
actual cost involved to achieve resolution of symptoms may be considerable. 
The efficacy of PNE to select patients appears uncertain despite the greater 
control afforded by the four electrodes on the tined lead. From our data 
following PNE, we are unable to predict who would achieve continence at 
permanent stimulation therefore the cost of deploying PNE and permanent 
implant as it is designed is questionable. From these data, one in four patients 
achieved “continence”, at a cost of four patients undergoing PNE and three 
having permanent implantation. Therefore if cost were analysed with an 
intention to achieve continence, SNS may be significantly more expensive than 
previously reported. As yet, we are unable to determine either preoperatively, or 
following PNE which patients will achieve maximal benefit. It would appear that 
SNS is an effective therapy for some patients with FI, however this study would 
suggest that careful counselling of patients regarding outcomes is required prior 
to embarking on this treatment. In particular, suggesting that SNS is effective in 
the treatment of FI for 67-100% of patients can only mislead and result in false 
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expectations. These data show that permanent SNS was “successful” in 73% of 
permanently implanted patients, however, they also show that SNS is effective 
in only 26% of patients treated. This is compounded by the fact that predictive 
criteria identifying those who will obtain most benefit from SNS remain elusive. 
These data show that SNS is likely to achieve a 50% reduction in symptoms in 
those who experience more frequent episodes of incontinence with a trend to 
be being more effective in an older population, nonetheless this neither helps 
guide patient selection.  An understanding of the mechanism of action of 
modalities such as SNS and PTNS is required to enable appropriate patient 
selection with patients requiring detailed evaluation to understand exactly what 
is the cause(s) of their symptoms to enable appropriate selection of treatment. 
There are limited data available regarding outcomes for different types of FI 
(UFI,PFI,PDL) following different forms of treatment. It may be subsequently 
shown that different treatments are more effective for different forms or 
aetiologies of FI.  Ultimately, further studies will be required to determine the 
extent of improvement required from the preoperative symptom level that 
constitutes an acceptable outcome, and whether the efficacy, cost and low rate 
of progression to permanent implantation associated with SNS will allow its use 
as a practical therapeutic intervention for the majority of patients in the long 
term.  
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8.2.3 Sphincter Defects and Sacral Nerve Stimulation  
Given the minimally invasive nature of SNS, and certainly the PNE stage, it was 
decided to examine what effect SNS would have on patients with a sphincter 
defect and also, whether or not the extent/severity of the defect was relevant to 
the efficacy of SNS. This study examined a small series of patients with faecal 
incontinence, who on pre-operative endo-anal ultrasound were found to have a 
range of sphincter defects. The outcome is that efficacy of SNS is not related to, 
or limited by, the extent of sphincter injury. Within this limited series, there was 
no correlation between the extent of sphincter disruption and episodes of FI, 
episodes of soiling, incontinence scores, or the ability to defer defecation.  
Defect score reproducibility, examined by both intra- and inter-observer 
evaluation, was excellent (4.3.1 Structural Assessment). 
 
Previous studies have shown that patients with limited IAS and EAS defects can 
benefit from SNS.51,75,95,115 In these studies, sphincter damage was described 
as either “limited” or by the percentage of the circumference involved, with 
maximum defects described from 25%115 to 33%95 with no mention or 
consideration of defect length or depth. The sphincter complex is a three 
dimensional structure and when assessing damage and grading damage with 
the intention of describing the severity of the injury, describing one dimension is 
clearly insufficient. A 33% circumferential defect affecting only 10% of the depth 
and 5% of the length of the anal canal is likely to behave very differently to a 5% 
circumferential defect affecting 100% of the depth and 100% of the length of the 
anal canal.  The scoring system used in this thesis considered circumference, 
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depth and length of defect97. The same scoring system has been applied in one 
previous study of SNS116, which suggested that patients with an intact sphincter 
may have a better outcome, however, the relationship between extent of defect 
and outcome following SNS has not been explored.  
 
The threshold for offering permanent stimulation has historically been based on 
a greater than 50% reduction in episodes of FI. In the present study however, 
patient satisfaction and a desire to proceed was also considered, and two 
patients within this trial went onto permanent stimulation despite not achieving 
the 50% improvement threshold. This was based on an improvement in the 
perceived ability to defer which had provided a sensation of greater control for 
these two patients. Such improvements are difficult to quantify and are not 
reflected in standard continence scoring systems. Indeed, the reduction in CCFI 
scores post permanent stimulation in the sphincter defect study (Chapter 4) 
were modest at best (median 3, range 0-10). These compare to mean 
improvements of 2 – 14 in previous studies following SNS117. In addition, 
although 85% of the patients who underwent permanent stimulation reported an 
increase in the ability to defer defecation, this was often only for 1 minute or 
more (with only 4 having an improvement to > 5 mins). Whether such an 
increase represents a significant clinical improvement is probably debatable 
depending on social context. Furthermore, this reported or perceived 
improvement in the ability to defer warrants further examination. The ability to 
defer defecation was estimated prior to surgery by the patients and many 
described a complete inability to defer, i.e. the first sensation of requiring to 
defecate is as the stool is in the anal canal and defecation is occurring. This 
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study has not examined whether this is an actual improvement or a perceived 
improvement. The data within this study has confirmed the findings of other 
groups that SNS has no effect on the functional ability of the anal sphincter 
which poses the question; how does SNS work? It is possible that the effects of 
SNS are not via efferent fibres to the sphincter complex but instead afferent 
fibres to the central nervous system. It is possible that the perception of 
improved ability to defer does not reflect any prolongation of deferment, but 
instead improved perception of intrarectal stool, enabling time to attend the 
lavatory to defecate prior to this occurring spontaneously. This shall require 
further study to examine this hypothesis. 
 
The anal sphincter complex represents the final continence barrier. The 
mechanism of SNS is unclear, but appears not to relate directly to augmentation 
of sphincteric function as assessed manometrically. In addition, the influence of 
neuropathy has not been fully explored. The results of this study indicate that 
SNS may result in positive outcomes irrespective of the degree of sphincter 
disruption and should not be denied on this basis. This study is necessarily 
limited by the small number of patients and by the absence of comparison 
group with a different or no intervention. It cannot be concluded whether the 
patients in this study would have benefited more from direct sphincter repair 
either alone or in combination with SNS. This remains an area of interest, not 
least because of the high cost of SNS in comparison with sphincter repair. 
However, it is one that can only adequately be addressed by a randomised 
control trial design and formal economic analysis. Such a study would answer 
the question of the appropriate (after optimal conservative therapy) second line 
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management in severe FI. Further study will be required to elucidate the 
components of the continence mechanism that are augmented or altered by 
SNS or indeed if the modulation is occurring via the efferent fibres in the nerve 
or perhaps the afferent fibres.  
 
Within the sphincter defect study, a trial of PNE in a single patient who had 
essentially no anal sphincter was performed. This patient had an extensive 
surgical history secondary to a neonatal malformation with imperforate anus 
and vestibular fistula. Conventional treatments for such malformations have a 
very poor outcome and the ESGN study confirms that long term outcomes from 
neosphincter surgery for such patients is rarely successful. The prospect of 
neuromodulation assisting is such cases is therefore attractive. Previously, a 
hyposensate megarectum had been demonstrated which was responsible for a  
continuous passive seepage of stool. This had been treated with a Vertical 
Reduction Rectoplasty (VRR)118 some years earlier which corrected both the 
megarectum and rectal sensory thresholds, however rendered this patient 
completely incontinent. In the absence of the rectal evacuatory disorder, the 
severely disrupted, non functioning sphincter complex was completely exposed.  
SNS provided better discrimination of the call to stool, a perceived ability to 
defer defecation and improved defecatory dynamics. Importantly, however once 
again there was no change in the morphology or functional ability of the 
sphincter complex. Thus continence has been improved by enhancing 
(colo)rectal function without demonstrating an improvement in sphincter 
function; this implies that the mechanism(s) of SNS may be due principally to 
alterations in supra sphincteric or central neurological factors. Given that FI and 
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RED frequently coexist, improvement in symptoms of FI may indeed result from 
an enhancement in the mechanisms governing defecation; SNS is now 
paradoxically being used for treatment of constipation119, and has recently been 
shown to modulate colonic propulsive function120, however it is unknown what 
would have happened if SNS had been tried prior to the VRR. Considering that 
the rectum, anal canal and sphincter complex were severely abnormal, this may 
also hint that SNS works via central modulation. There was little normal native 
tissue to benefit from efferent stimulation but the afferent fibres lead to healthy 
normal neuronal tissue which may have been amenable to modulation to 
produce the perceived improvement in function. 
 
8.2.4 Peripheral Modulation of the Sacral Plexus 
If the efficacy of neuromodulation is central and altered via the afferent fibres, 
then it should make no difference where the stimulation is applied.  As with 
SNS, the mechanism of action of PTNS is unknown, though it is possible that 
PTNS effects electrical stimulation of the sacral plexus adapting bowel and 
bladder function via a mechanism similar to SNS. The tibial nerve contains 
afferent and efferent fibres and originates from the 4th and 5th lumbar and 1st, 
2nd and 3rd sacral nerves, the same spinal nerves that innervate the bladder and 
rectum. However, it has recently been demonstrated that PTNS modulates long 
latency somatosensory evoked potentials in patients with overactive bladder 
syndrome whereas sham stimulation has no effect, suggesting central 
modification may be involved.121  
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The ideal treatment for FI, or indeed any condition, is one that has high efficacy, 
is inexpensive, acceptable to patients and with a low morbidity.  PTNS is a 
simple procedure that is well tolerated, minimally invasive and can be offered in 
an outpatient setting to the majority of patients with UFI. In the presence of a 
trained nurse specialist, the set up costs for PTNS are under £1000 for the 
stimulator (which can be used on multiple patients) and at a cost of £385 per 
patient for the disposable equipment for the treatment course. It is more cost 
effective than SNS, ESGN or even an end colostomy81,122. Although it is 
perceivable that patient inconvenience and personnel costs may limit the 
widespread application of PTNS, the minimally invasive nature of the process 
and lack of permanent implant may be desirable to some patients and also 
enabling treatment to be provided to patients deemed unsuitable for more 
complex procedures. 
 
8.2.5 Efficacy of Percutaneous Tibial Nerve Stimulation 
From this small preliminary study, it would appear that PTNS is effective 
treatment for UFI with or without anatomical or physiological anal sphincter 
dysfunction. Though statistically insignificant, it would appear that those with an 
intact anal sphincter complex were more likely to respond to PTNS, however, a 
larger cohort of patients will be required to clarify this. Overall, nearly three 
quarters of patients had a 50% reduction in incontinence episodes and 12 
(32%) patients, became fully continent, while the ability to defer defecation 
improved from a median of 1 minute to 5 minutes post treatment. These results 
compare favourably with the other treatment modalities29,44,87.  The actual 
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reduction in incontinence scores are however modest. This is also a feature in 
SNS studies for FI87 and may merely reflect the limitation of the standard 
current scoring systems, whereby the true clinical picture is not accurately 
represented.  
 
The data analysis was performed with intention to treat, nevertheless the 
response rate in this study compares favourably with that published for 
SNS44,87. There has been one single previous large study investigating the 
management of FI with PTNS, however all patients had intact sphincters and 
normal anal manometry and this was of poor methodology and design with no 
analysis of incontinence episodes pre and post stimulation57. More recently, 
another study of patients with an intact or repaired external anal sphincter has 
shown that PTNS may be effective treatment of “severe” FI for a minority of 
patients123. Two other studies published have extremely small sample size56 or 
have included patients with FI secondary to organic bowel disease55.  
 
PTNS has been shown to be effective in up to 80% of patients from a number of 
studies deploying it for urological symptoms of frequency, overactive bladder 
and incontinence124. Although results in this study do not achieve such a high 
response rate, the optimal stimulation protocol for UFI remains unclear. It is 
likely that the efficacy and indication of PTNS for FI will increase with further 
research and developments.  From this study, it would appear that PTNS is 
highly effective in the treatment of UFI, and very acceptable for the patients.  
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8.2.6 Hypothesised Mechanisms of Action 
Both PTNS and SNS appear to be effective in the treatment of FI in a 
percentage of patients, however prior to this thesis, they have never been 
compared.  In two similar groups of patients with UFI, there was a trend for 
PTNS to produce more patients who achieved a 50% reduction in symptoms 
and a resolution of symptoms of UFI when compared to SNS. PTNS patients 
experienced significantly fewer episodes of UFI when compared to SNS 
patients after treatment. There are three main differences between the two 
techniques, namely: i) the site of stimulation, ii) the duration of stimulation and 
iii) the permanency of the stimulus. As previously discussed, the mechanism of 
action for both is unknown and care is required when analysing possible 
reasons why one may perform better than the other, however, PTNS involves 
stimulation at a distal site and targets the 4th and 5th lumbar and 1st, 2nd and 3rd 
sacral nerves via afferent fibres while SNS stimulates both efferent and afferent 
fibres at S3. It is possible that the wider array of nerves encompassed by PTNS 
may be beneficial and site of stimulation may be important. However, if the two 
techniques worked in a similar fashion, it is unlikely that the mechanism is via 
efferent fibres as these lead to the foot and not the anus in PTNS and again 
point to modulation of more central neuronal responses via afferent fibres. The 
second difference is the duration of stimulation. SNS is continuous sub sensory 
stimulation while PTNS is half hourly sessions once per week. The superior 
effect of PTNS compared to SNS becomes difficult to explain as it would be 
intuitive that more stimulation should produce enhanced results. The ideal 
stimulation parameters for both techniques are unknown and whether 
continuous SNS stimulation is sub optimal has never been explored. Certainly, 
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if 30 minutes weekly stimulation by SNS was effective, then that would certainly 
prolong the life of the battery and reduce the running costs of SNS 
considerably. The duration of effect of stimulation has not been addressed in 
these studies, however it was clear clinically that on withdrawal of the 
stimulation, the SNS patients would experience a resumption of symptoms 
within 48-96 hours and this was apparent post PNE and also from histories with 
patients who had inadvertently turned off the implant. PTNS patients however, 
experienced a prolonged effect which lasted months after withdrawal of any 
stimulus. It may be postulated that intermittent stimulation invokes a different, 
better, more lasting neuromodulation when compared to the chronic stimulation 
from SNS. Although trying to explain potential better efficacy of PTNS over SNS 
via site and duration involves speculation and hypothesis, the third main 
difference, namely permanency of stimulus could be important. When the PNE 
or tined lead are placed, care is taken to position them in the site with the 
strongest motor responses, but both are at risk of migration resulting in 
deterioration and lack of long term effect. Admittedly the 4 electrodes on the 
tined lead allow for some adaptation once in situ, however adjustment of the 
lead is not possible.  PTNS placement is reassessed weekly to ensure repeated 
correct placement. There is little risk of repeated lead migration in multiple 30 
minute sessions and hence repeated inadequate stimulation is unlikely. It is 
therefore possible, if not probable, that optimal targeting of site of stimulation is 
better for PTNS in the longer term. 
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8.2.7 Morbidity and Economic Considerations 
In the comparative study, alterations in CCFI scores and ability to defer were 
similar for both groups. However, SNS is associated with more morbidity than 
PTNS reflecting the relative invasive nature of SNS when compared to PTNS 
and this would be expected. There were no reported alterations in motor or 
sensory function, infection or pain in the stimulated legs from PTNS. The PTNS 
study shows that some patients experience a resumption of symptoms and as 
yet this “washout” period is unknown. Repeated treatments are likely to 
increase the costs and inconvenience associated with PTNS. However the 
comparative study shows that PTNS is considerably cheaper than SNS and 
would require over 17 years of constant treatment to be as expensive as the 
first 7 years of SNS. Clearly continuous treatment is not required and it is likely 
that formal long term costing of PTNS will show this to be a far more 
economical treatment for FI. Given the restricted funding of the NHS, the benign 
nature of pelvic floor dysfunction and the matching, if not superior efficacy of 
PTNS, economic factors alone may outweigh other considerations when 
choosing one technique over the other in the longer term. This limited study 
shows PTNS to be a more effective treatment, that has high efficacy, is 
inexpensive, acceptable to patients and with a low morbidity. However, a 
randomised, sham controlled trial alongside SNS will be required to eliminate 
placebo effect, elucidate the true efficacy and determine which treatment 
modality is superior. Nevertheless, it would appear PTNS is a valuable addition 
to the current available treatments for UFI.  
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8.3 Electrically Stimulated Gracilis Neosphincter 
Despite the promising results from PTNS and SNS, a cohort of patients remain 
who will have failed therapy. They may already have, or indeed go on to fail 
other treatment modalities such as sphincter repair. Such individuals could be 
classified as having end stage FI and be faced with a stark choice: end 
colostomy or persist with their symptoms of FI. This can be a devastating 
situation which results in psychological morbidity and considerable social 
stigma. Those with severe symptoms who are highly motivated to avoid an end 
colostomy may be candidates for ESGN.  Variable results, morbidity, and lack 
of long-term efficacy associated with standard surgical treatment options led to 
the development of the ESGN1,125,126.  
 
ESGN construction has been performed in this tertiary centre since 1988 to 
restore anal canal function and improve symptoms of FI in patients with well-
defined anatomical and physiological abnormalities33.  The use of this 
procedure in those who have failed standard surgical treatments has been 
supported by the publication of short and mid-term outcome data by several 
investigators35-37,127,128, in addition to favorable reviews by both the National 
Institute for Clinical Excellence (NICE) in the UK129, and the Australian Safety 
and Efficacy Register of New Interventional Procedures-Surgical (ASERNIP-
S)130. Despite these assessments, the place of ESGN construction in the 
hierarchy of interventions for the treatment of FI remains contentious as the 
long term efficacy and indications for this procedure remain unclear. 
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For the first time, this study presents long-term outcome data following ESGN 
construction for patients with end stage FI. ESGN formation was found to 
improve continence to an acceptable level, with only occasional loss of liquid 
stool, for 60% of patients in the medium-term and 43% in the long-term. 
However, the success of long-term functional outcome varied by indication. 
Seventy eight percent of patients undergoing ESGN formation for surgical 
sphincter injuries were found to report occasional incontinence to liquid stool at 
midterm evaluation, while 70% described a similar outcome at 12-year follow-
up. Medium-term assessment of patients with obstetric injuries revealed 85% 
describing this level of continence, which was maintained in only 41% of 
patients long- term. However, the differing outcomes for the surgical trauma and 
obstetric injury subgroups are perhaps predictable. If we consider that within the 
surgical trauma subgroup, the sphincter has been injured but the 
suprasphinteric continence apparatus remains intact. Therefore, replacing the 
sphincter should produce a reasonable outcome as you have replaced the 
damaged tissue. However, following pregnancy and childbirth, it is possible that 
suprasphincteric mechanisms as well as the sphincter complex may be 
affected. In this situation, replacement of the sphincter with ESGN will only 
partly compensate for this insult and perhaps produce a less favourable 
outcome.  
 
Although poorer outcomes were noted with other surgical indications, with the 
exception of ileoanal pouch incontinence, these did not necessarily result in 
permanent stoma construction, as indicated by Table 7.1 (page 106). 
Consequently, while these data suggest that ESGN formation is more likely to 
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fail in these groups, trial of this procedure may still be warranted in appropriately 
counseled and motivated patients.   
 
ESGN formation has previously been associated with considerable complication 
rates35-37. Morbidity was reported by approximately half of all subjects in this 
study with a considerable number developing more than one complication; 
however these data are largely historical as recent technical developments 
have dramatically reduced morbidity rates associated with this procedure131. In 
contrast, new onset postoperative rectal evacuatory disorder continues to be a 
common difficulty33-35 and is associated with poor functional outcome, as this 
study has demonstrated. The cause for this association is unclear, but in part 
may be due to the relative insensitivity of the Williams score, which is unable to 
discriminate between passive and overflow incontinence following neosphincter 
construction.  Surprisingly, given the association between ESGN and rectal 
evacuatory disorder (RED), preoperative constipation was not found to correlate 
with poor postoperative functional outcome. Similarly, postoperative RED does 
not seem to be associated with preoperative rectal sensory function, since 
demonstrable rectal hyposensitivity was not found to correlate with increased 
rates of RED. However, reduced toleration to distention was associated with 
decreased rates of postoperative RED, although no clinically useful threshold 
was identified for patient selection.  
 
Despite promising long-term functional outcome after ESGN construction in 
highly selected patients, it must be remembered that this is a demanding 
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multistage procedure for both patient and surgeon. There is likely to be a 
significant surgical learning curve, yet this study failed to show any 
improvement in outcomes for those operated on in the latter half of the study, 
despite shorter follow up. This finding is independent of indication for surgery, 
although whether patient selection in the latter group is a confounding factor is 
unclear, and should be a matter addressed by future studies. 
 
This study demonstrates that ESGN construction permits the majority of 
patients who suffer refractory FI following surgical or obstetric sphincter injury to 
avoid permanent stoma construction with acceptable long-term continence. 
Nevertheless, ESGN formation is a considerable undertaking necessitating 
several operations without an absolute guarantee of success, and the possibility 
of additional surgery should complications occur. However, it must be 
considered in the context of the severe disruption to life, and psychological 
morbidity, caused by intractable faecal incontinence or stoma formation. 
Therefore, this procedure may be offered to such patients who are suitably 
motivated, who have failed both maximal conservative management and less 
invasive surgery. 
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8.4 Future Directions 
Prevention is better than cure. The studies described in this thesis have shown 
a deterioration in the function of the sphincter complex associated with aging 
which may in turn, be directly related to the onset of symptoms of FI. If the 
mechanism of action driving this deterioration was identified, then it may be 
possible to arrest or reverse these effects, thereby preventing symptoms. In the 
interim, further work will be required to maximise the performance of 
neuromodulation techniques. Primarily, elucidation of what exactly is being 
“modulated” would be an obvious first step. Only then will the optimal placement 
of SNS electrodes, optimal stimulation parameters for both SNS and PTNS, 
CNS responses to both, identifying and maximizing modes of action and 
identifying predictive factors which may guide patient selection for each 
modality be found.  
 
A definition of successful treatment is required. Complete continence and return 
to the premorbid state is likely to be unrealistic in the short term, and as such, 
adopting this measure may harshly reflect on very promising techniques which 
limit symptoms. However, it is clear that with a 50% reduction in symptoms as 
the threshold, patients who continue with daily episodes of incontinence are 
unlikely to consider their treatment a success even if frequency is reduced by 
half. Quality of life studies will be required to assist with this aspect, comparing 
pre and post treatment, and also comparing an asymptomatic, comorbidity 
matched population.   
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8.5 Conclusions 
The numerous aetiologies, expectations and desires amongst patients almost 
guarantees that a panacea for FI is unlikely to be found. Psychosocial variation 
between patients ensures that to date, this remains an unrealistic goal. 
Symptom control is the primary end point when treating FI and this thesis has 
assessed three ‘rungs of the treatment ladder’ showing positives and negatives 
for each. Cure would appear too unrealistic for the majority of patients with the 
current techniques available. This study has not assessed quality of life (QOL) 
measures pre and post treatment which limits firm conclusions over which 
treatment modality is superior for the patient cohort.  
 
The management of FI is complex and requires a detailed assessment of 
psychology and expectations of the patient, aetiology of their symptoms and 
their symptom profile. It requires a multidisciplinary team approach with 
anorectal physiologists, nurse specialists and specialist tertiary referral centre 
surgeons. It is rare to “cure” patients with FI, as even those who achieve 
apparent continence often do not have a return to “normality”. In order to 
achieve high levels of patient satisfaction, it is important that limitations of 
current treatment modalities is clear from the outset. Managing expectations 
remains as important as managing symptoms as there is a significant failure 
rate from the available treatments. A clear definition of successful treatment is 
required. This should probably aim towards the cessation of the symptoms of 
FI, combined with an ability to measure improvement in those with ongoing 
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symptoms. A 50% reduction in symptoms is unhelpful and has the potential to 
mislead patients when asking about success rates from various treatments.  
 
This thesis has shown that PTNS, SNS and ESGN can all be effective 
treatments for FI in a proportion of patients. It is unclear how either PTNS and 
SNS precisely work and therefore maximising the potential of these 
interventions remains a challenge. It is also unclear which patients will 
ultimately derive most benefit and careful counselling is required prior to 
embarking on these interventions. 
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The Effects of Age and Childbirth on Anal Sphincter
Function andMorphology in 999 Symptomatic
Female Patients With Colorectal Dysfunction
D. J. Boyle, M.R.C.S. • C. H. Knowles, Ph.D. • J. Murphy, M.R.C.S.
C. Bhan, M.R.C.S. • N. S. Williams, M.S. • S. M. Scott, Ph.D. • P. J. Lunniss, M.S.
Academic Surgical Unit (GI Physiology Unit), Barts and The London School of Medicine and Dentistry, Queen Mary
University, London, United Kingdom
BACKGROUND AND OBJECTIVES: Conflicting data exist
on the contributions of advancing age and childbirth on
the structure and function of the anal sphincter. This
study aimed to examine the relative contributions of age
and childbirth in a large cohort of women referred for
investigation of symptoms of colorectal dysfunction
(fecal incontinence and constipation).
SETTING: This study was conducted at a specialist
surgical colorectal investigation unit in a university
teaching hospital.
PATIENTS: Retrospective analysis was performed on
prospectively collected demographic, symptom profile,
and physiologic data from 3686 female patients. Strict
exclusion criteria were applied, leaving 999 patients for
univariate, multivariate, and logistic statistical modeling.
MAIN OUTCOME MEASURES: The effects of independent
variables alone and in combination on anal sphincter
pressures (resting and squeeze increment) and the
presence of sphincter defects (internal and external) were
expressed as regression coefficients and odds ratios.
RESULTS: Median age was 42 years (range, 16–88), and
parity was 2 (range, 0–11); 16% were nulliparous. Three
hundred sixty patients had fecal incontinence, 352 had
constipation, and 287 had combined symptoms. Anal
resting tone decreased with age by 0.66 cm H2O per year,
and by 4.3 cm H2O per birth, and was associated with
both internal and external anal sphincter defects (p
0.0001 for both). Squeeze increment pressures decreased
by 0.3 cm H2O per year, and by 3.8 cm H2O per birth;
decreased pressures were, however, only significantly
associated with external anal sphincter defects (p
0.0001) as a result of childbirth. Cesarean delivery was
protective against both reduced anal pressures and
sphincter defects. Pudendal nerve terminal motor
latencies increased bilaterally with age and with vaginal
delivery; the impact of both was greater on the left nerve.
Rectal sensation was unaffected by age or parity.
CONCLUSIONS: Aging predominantly affects anal resting
pressures; childbirth, particularly instrumental delivery,
is detrimental to the structure and function of the
external sphincter.
KEY WORDS: Anorectal physiology; Fecal incontinence;
Constipation; Age; Childbirth; Anal spincter.
A
norectal physiologic assessment is now generally
considered an important adjunct to history taking
and clinical examination in the management of pa-
tients with functional colorectal disorders refractory to
conservative management. Several studies attest to the
clinical impact of such investigations in patients with fecal
incontinence or constipation, demonstrating that informa-
tion provided improves diagnostic yield1,2 and can directly
influence or alter the management plan in a significant pro-
portion of cases.1,3 The major caveat is that there is no uni-
form standardization of tests, and thus results between cen-
ters are often difficult to compare. In addition, there is a lack
of normative data for all measures of function, particularly
with regard to age and sex stratification.4 The most widely
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accepted tools for investigation of anorectal function and
structure are manometry, assessment of rectal sensation, en-
doanal ultrasonography, and, perhaps more controversially,
determination of pudendal nerve conduction.4
In women, it is acknowledged that vaginal childbirth
may be associated with compromise in anorectal function
andmorphology, irrespective of the presence or absence of
symptoms.5 In addition, several studies assessing cohorts
of predominantly asymptomatic women have shown that
measures of anorectal function may change with age.
However, results have been conflicting. In some studies,
for example, it has been demonstrated that anal resting
tone reduces with age, increasing parity, and obstetric-re-
lated factors5–9; yet, in others, such relationships have not
been established.7,9–13 Similarly, although age, parity, and
obstetric factors have been shown to be associated with
decreased anal squeeze increment pressures,6–9,14 other
studies have failed to show these associations.7,9,10,12,13,15
Aging has also been shown to both increase and decrease
rectal sensory thresholds,7,13,16 whereas both age and par-
ity have been implicated in the prolongation of pudendal
nerve terminal motor latencies.5,17,18 Interpretation of the
results of tests of anorectal function and morphology is
confounded by the interdependent effects of aging and ob-
stetric history. The aim of this study was to examine the
relative contributions of these factors in a large cohort of
patients with hindgut dysfunction (fecal incontinence and
constipation) of sufficient severity to warrant referral for
specialist physiologic investigation.
PATIENTS ANDMETHODS
Patients
Three thousand six hundred eighty-six consecutive female
patients referred to a single surgical tertiary referral center
underwent anorectal physiologic assessment. To reduce con-
founding factors, only those reporting chronic constipation,
fecal incontinence, or both were considered; further rigorous
exclusion criteria were applied, including a history of any
form of gastrointestinal, pelvic, or anal surgery; anorectal pa-
thology; metabolic and neurologic conditions (eg, diabetes,
hypo/hyperthyroidism, multiple sclerosis); ongoing medica-
tion with known effects on anorectal function; a history of
psychotic illness or eatingdisorders; and finally,where the full
complement of physiologic investigations had not been per-
formed.
Methods: Anorectal Physiology
Standard anorectal physiologic assessment included the
measurement of anal sphincter resting and squeeze incre-
ment pressures using water-perfused anal canal pull-through
manometry, determination of rectal sensory thresholds to
air-filled balloon distension, pudendal nerve terminal mo-
tor latency (PNTML) measurements using the St Mark’s
electrode (Dantec Ltd, Bristol, UK), and structural sphinc-
ter assessment by endoanal ultrasound (7 or 10 MHz, B-K
Medical, Berkshire, UK). All patients also underwent evac-
uation proctography, and in some, a test of colonic transit
when indicated (results pertaining to these investigations
are not included in this study). Detailed methods have
been published previously.19,20
Statistical Analysis
Prospective collection of clinical and physiologic data was
standardized between different investigatorswithin the de-
partment by the use of questionnaires and reporting forms,
and these data were entered onto a bespoke database. Ex-
planatory variables were systematically recorded including
age, parity, and obstetric factors (mode of delivery). Main
presenting symptoms were treated as individual binary co-
variates (constipation and fecal incontinence). Parity was
stratified as nulliparous (0), 1, 2, 3, and 4 or more deliver-
ies; parity was analyzed as a continuous variable taking
values of 0 to 4. In parous women, the influence of delivery
type was initially analyzed on the basis of binary covariates
(1 vaginal delivery, 1 cesarean deliveries, and 1 in-
strumental delivery). A summary variable (analyzed as an
indicator variable) was also derived for the mode of deliv-
ery: 0  no delivery (nulliparous), 1  cesarean delivery
only, 2 any vaginal delivery, and 3 instrumented vag-
inal delivery.
Both univariate and multivariate regression analyses
were performed to examine the effects of age, presenting
symptom, parity, and obstetric factors on anorectal phys-
iologic measures. Linear regression models were used in
the case of continuous variables such as anal resting and
squeeze incremental pressures, whereas logistic regression
models were used in the case of the binary outcomes of
internal and external anal sphincter defects. All analyses
were performed with the use of proprietary software (Stata
v10.0, College Station, TX). Main results are presented
with linear regression coefficients or odds ratios and con-
fidence intervals; p 0.05 was taken to indicate statistical
significance.
RESULTS
Patient Demographics
Two thousand six hundred and eighty-seven patients were
excluded. Of these, 598 patients had undergone gyneco-
logic surgery, 560 had anal surgery/pathology, 61 had un-
dergone colonic surgery, 85 had undergone other abdom-
inal surgery, and 18 had undergone pelvic radiotherapy.
Medical criteria for exclusion included diabetes (n 123),
neurologic causes (n  55), metabolic causes (n  18),
IBD (n  26), and psychiatric disorders (n  76). Many
patients had more than one exclusion criteria, and the re-
mainder were excluded on the basis of incomplete results
of physiologic tests.
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Nine hundred and ninety-nine women satisfied the
inclusion criteria.Median agewas 46 years (range, 16–88),
andmedian parity was 2 (range, 0–11). One hundred sixty
women were nulliparous, with a median age of 31 years
(range, 16–87).Overall, 360 patients (median age, 52 years
(range, 19–87); parity 2 (range, 0–11)) reported symp-
toms of fecal incontinence, 352 (age, 41 years (range, 16–
84); parity 2 (range, 0–10)) presented with symptoms
of intractable constipation, and 287 (age, 46 years (range,
17–88); parity 2 (range, 0–10)) had combined symptoms.
Age at presentationwas associatedwith incremental parity,
with patients predicted to be 4.6 years older with each
birth, (p 0.0001, r2 0.137, coefficient (coef): 4.6, CI
3.89–5.32; Fig. 1).
Anorectal Physiology
Summary data for the whole cohort are presented in Table 1.
Effects of Age
Anal resting tone decreased significantly with advancing
age, equivalent to 0.66 cmH2O per year (linear regression,
p 0.0001, r2 0.10, coef:0.66, CI0.8 to 0.53), eg,
a 70-year-old patient would be expected to have a resting
tone 26 cm H2O lower than that of a 30-year-old patient
(Fig. 2). Anal squeeze increment pressures also decreased
significantly, but by only 0.3 cm H2O per year (linear re-
gression, p  0.001, r2  0.01, coef: 0.30, CI  0.4 to
0.11). The relationship with resting pressure was main-
tained in the nulliparous cohort, with a 0.6 cm H2O per
year reduction in resting tone (p 0.0001, r2 0.09, coef:
0.60, CI0.8 to0.28); however, no statistical effect
of age was observed for squeeze increment pressures in the
nulliparous cohort (p 0.38, r2 0.005, coef:0.13, CI
0.46 to 0.18).
Age had no significant association with the finding of
an internal anal sphincter defect and a small (albeit statis-
tically significant) association with external anal sphincter
defects (OR 1.01, p 0.002; CI 1.0–1.02). With regard
to pudendal nerve function, left PNTML increased signif-
icantly with age (0.01 ms/y; p  0.0001, r2  0.05, coef:
0.008, CI 0.006–0.010), eg, a 70-year-old patient would
be expected to have a left PNTML 0.4 milliseconds longer
than that of a 30-year-old. Results were similar for right
PNTML, although the magnitude of change was halved
(0.005 milliseconds/year). There was no relationship be-
tween age and rectal sensory thresholds.
Effects of Parity
Anal resting tone decreased significantly with parity, and
was associated with a reduction of 4.3 cm H2O per incre-
mental birth (p 0.0001, r2 0.03, coef:4.3, CI5.9
to 2.7). There was a similar significant decrease in
squeeze increment pressures of 3.8 cmH2O per birth (p
0.0001, r2  0.02, coef: 3.8, CI  5.5 to 1.9). There
Parity
0 1 2 3 4+
Age at presentation
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FIGURE 1. Comparison of parity and age at presentation. A roughly
linear relationship is seen between increasing parity and increasing
age (n 999, ie, including cesarean deliveries).
TABLE 1. Results of anorectal physiology tests in 999 women
studied
Variable Mean SD
Anal resting tone, cmH2O 72 34
Anal squeeze increment, cmH2O 56 37
IAS defect, % 16
EAS defect, % 47
Both IAS and EAS defects, % 13
Left PNTML, ms 2.37 0.54
Right PNTML, ms 2.34 0.43
Rectal sensation, mL
FCS 51 43
DDV 118 71
MTV 177 82
IAS internal anal sphincter; EAS external anal sphincter; PNTML pudendal
nerve terminal motor latency; FCS first constant sensation; DDV defecatory
desire volume; MTVmaximum tolerable volume.
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FIGURE 2. Relationship between anal resting tone and age. Anal
resting tone is seen to decrease significantly with advancing age
(n 999). Linear regression line is shown.
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was no relationship between increasing parity and rectal
sensory thresholds. With each vaginal delivery, PNTMLs
significantly increased by 0.06milliseconds on the left (p
0.0001, r2  0.02, coef: 0.060, CI  0.032–0.087), and by
0.04 milliseconds on the right.
Overall, increasing parity was also associated with the
finding of both an internal (p 0.006, OR 1.2, CI 1.1–
1.4) and external anal sphincter defect (p 0.0001,OR1.4,
CI1.3–1.6). Figure 3 shows that this relationship is borne
out almost exclusively by the first delivery (external anal
sphincter: p 0.0001, OR 7.6, CI 4.3–13.2; internal anal
sphincter: p  0.002, OR 3.3, CI  1.5–7.2). Anal resting
pressure was reduced in association with both an internal
and external anal sphincter defect (intact internal anal
sphincter (IAS): median, 77 cm H2O (range, 6–213) vs
defective IAS: 42 cm H2O (range, 3–184), p  0.0001; in-
tact external anal sphincter (EAS): median, 80 cm H2O
(range, 6–207) vs defective EAS: 60 cm H2O (range,
3–213), p  0.0001). Anal squeeze increment pressures
were only reduced in association with an EAS defect (in-
tact: median, 59 cm H2O (range, 0–249) vs defective: 40
cm H2O (range, 0–205), p 0.0001; Fig. 4).
Obstetric Factors
Of the 839 parous women, 354 (42%) had delivery assisted
with instrumentation (forceps, Ventouse, or episiotomy)
on at least 1 occasion. One hundred twelve patients had
undergone at least 1 cesarean delivery (elective and/or
emergency) with 45 women having only undergone cesar-
ean deliveries (range, 1–4).
Patients who had only had cesarean sections had
higher anal resting tone in comparisonwith those who had
delivered vaginally, with or without instrumentation (ce-
sarean: median, 95 cm H2O (range, 10–160) vs normal
vaginal delivery: 67 cm H2O (range, 3–213) vs instrumen-
tal vaginal delivery: 68 cm H2O (range, 10–185); p 
0.0013)). Anal squeeze increment pressures were greater in
both the cesarean group (median, 70 cm H2O (range, 40–
225)) and nonassisted vaginal deliveries (median, 50 cm
H2O (range, 0–249)) than those having instrumental de-
liveries (median, 40 cm H2O (range, 0–160), p  0.0001;
Fig. 5). Univariate analysis using the single derived mode
of delivery indicator variable for resting pressure revealed
no significant effect of cesarean delivery, but roughly equal
effects of vaginal (P000.1, coef: 13.5, CI  19.5 to
15.4) and instrumental (p  0.0001, coef: 11.6, CI 
17.7 to5.4) delivery. For the external sphincter, instru-
mental delivery was associatedwith a greater fall in squeeze
pressure than vaginal delivery (p  0.0001, coef: 18.4,
CI  25.1 to 11.7) vs (p  0.0001, coef: 8.1, CI 
14.6 to1.6).
In keeping with these observations (with the use of the
same indicator variable), the risk of an IAS defect was sig-
nificantly higher but roughly equal after both unassisted
(p 0.0001, OR 4.0, CI 0.9–7.6), and instrumental (p
0.0001, OR 3.6, CI  1.7–7.4) deliveries, but not with
cesarean delivery (no difference from nulliparous).
However, all 3 methods of delivery were associated with
increased risk of EAS injury (cesarean: p  0.0001, OR
5.7, CI 2.7–12.3; unassisted: p 0.0001, OR 8.6, CI
5.1–14.5; instrumental: p 0.0001, OR 10.2, CI 6.0 –
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FIGURE 3. Histogram showing prevalence of (A) internal and (B)
external anal sphincter defects with increasing parity. IAS internal
anal sphincter; EAS external anal sphincter.
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17.4) with the additive risk of instrumental delivery
clearly demonstrated.
Effect of Presenting Symptom
Patients presenting with constipation had higher mean
resting and squeeze pressures than those with inconti-
nence: resting pressures, constipation mean 77 cmH2O
(CI  75–80) vs incontinent mean  65 cm H2O (CI 
62–68), difference 12 cmH2O, p 0.0001; squeeze pres-
sures, constipation mean  63 cm H2O (CI  60–66) vs
incontinent mean  49 cm H2O (CI  46–52), differ-
ence 12 cmH2O, p 0.0001. One hundred of 360 (28%)
patients with fecal incontinence only had IAS defects in
comparison with 12 of 352 (3%; p 0.0001) patients with
constipation only and 51 of 287 (18%) with both fecal
incontinence and constipation. Two hundred and twenty-
four of 360 (62%) patients with fecal incontinence only
had EAS defects in comparison with 103 of 352 (29%; p
0.0001) patients with constipation only and 141 of 287
(49%) with both fecal incontinence and constipation.
Multivariate Analysis
Multivariate models were developed for anal pressures
(Table 2) and anal sphincter defects (Table 3). These mod-
els took an iterative approach from information derived
from univariate analyses by using stepwise omission of
200
100
A
Resting pressure (cm H
2
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Instrument delivery
Instrument delivery
Cesarean section
Cesarean section
Vaginal delivery
Vaginal delivery
100
200
B
Squeeze pressure (cm H
2
O)
FIGURE 5. Relationship between obstetric factors and anal
function. A, Mode of delivery and resting tone. B, Mode of delivery
and squeeze increment pressures.
TABLE 2. Multivariate models of anal resting tone and squeeze
increment pressures (cmH2O)
Coef. p t 95% CI
Resting
Fecal incontinence 10.9 0.0001  14.9 to6.9
Agea 0.5 0.0001  0.6 to0.4
IAS defect 21.4 0.0001  26.8 to16.1
EAS defect 4.7 0.021  8.7 to0.7
Constant 105.8 0.0001 99.8 to 111.8
Model: Prob F 0.0000,
adjusted R2 0.20
Squeeze
Fecal incontinence 16.1 0.0001  20.5 to11.7
Instrumental delivery 9.4 0.0001  13.9 to4.9
EAS defect 12.9 0.0001  17.3 to8.5
Constant 72.8 0.0001 64.8 to 80.8
Model: Prob F 0.0000,
adjusted R2 0.13
IAS internal anal sphincter; EAS external anal sphincter; coef coefficient.
aBased on 1 year of advancing age.
Intact Defect
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FIGURE 4. Relationship between anal sphincter defects and anal
function. A, Internal anal sphincter and resting tone. B, External anal
sphincter and squeeze increment pressures. IAS internal anal
sphincter ; EAS external anal sphincter.
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covariates to improve the models. Table 2 shows that, for
anal resting pressure, the main determinants were age,
presence of sphincter defects (particularly IAS defects),
and a presentation with fecal incontinence. Of these, the
strongest association was with IAS defects, which on aver-
age conferred a 21 cm H2O reduction in sphincter pres-
sure. Reduced incremental squeeze pressures were also as-
sociated with presentation (fecal incontinence), but the
other main independent determinants were a defective
EAS and instrumental delivery. Table 3 shows that IAS
defects are only associated with a presenting complaint of
fecal incontinence, this being roughly reciprocal (as would
be expected) with that of constipation. In contrast, EAS
defects are also independently associated with parity and
type of delivery.
DISCUSSION
This study has addressed the impact of age, parity, and
obstetric factors on anorectal function in a large cohort of
women, all investigated with the use of contemporary
physiologic assessment for significant symptoms of hind-
gut dysfunction (fecal incontinence and constipation), but
in whom potentially confounding factors have been ex-
cluded. It is important to stress that, because subjects were
all symptomatic, results cannot be extrapolated to asymp-
tomatic populations. Nevertheless, discussion of the re-
sults from this study group (n 999), a number unfeasible
in healthy volunteers, is justified. Although previous stud-
ies have examined the effect of aging, main presenting
symptoms, parity, and mode of delivery in isolation and
together,5,7–9,11–16 because of the likely interdependence of
these covariates (eg. age and parity), an attempt at model-
ing data together is required. We have addressed this issue
with a series of univariate and multivariate models accept-
ing that, in statistical terms, some of these models poorly
explain the overall distribution and interdependence of
data.
With regard to anal sphincter function, univariate
analysis revealed that nulliparous women showed a reduc-
tion in resting tone with advancing years almost identical
to the parous group, with the decrease in resting pressure
associated with successive vaginal deliveries to be equiva-
lent to 6.5 years of aging per birth. However, when child-
birth resulted in an internal, external, or combined sphinc-
ter defect (exclusion criteria allowing the assumption that
any defect arose as a consequence of childbirth), the effect
on anal resting tone was much more profound. The effect
of aging on squeeze increments, although statistically sig-
nificant, was, in functional terms, minor and similar to the
effect of parity in the absence of sphincter defects. The
impact of an external sphincter defect on squeeze incre-
ment pressures was far greater. The study has demon-
strated, as have others,5,8,21 that sphincteric disruption is
almost exclusively related to the first vaginal delivery, with
the incidence of external sphincter defects (and thus im-
pact on anal function) greatest in those who had under-
gone instrumentation-assisted delivery. Delivery by cesar-
ean was protective against external sphincter defects and
against reduction of resting and squeeze increment pres-
sures. Univariate analysis revealed rectal sensation to be
unaltered by age, parity, or mode of delivery. There was,
however, correlation between age and parity with increas-
ing PNTML, with a greater impact of each on the left pu-
dendal nerve.
Multivariate analysis using models to investigate anal
function (resting tone and squeeze increment) demon-
strated that age and an IAS defect22 were the strongest de-
terminants of reduced tone. As might be expected, an ex-
ternal sphincter defect was the greatest determinant of
reduced squeeze, with parity per se an insignificant cova-
riate. However, the assumption that IAS dysfunction alone
is responsible for reduced resting tone and symptoms22,23
must be challenged, because EAS integrity is also signifi-
cantly associated with anal resting pressure.
The innervation of the sphincter complex has also
been shown to be affected by both age and parity,5,7,17
which our data confirm. However, despite an apparent
small increase in PNTML with age but a greater increase
with successive births, multivariate analysis shows that the
effect is almost entirely secondary to aging, as a result of the
colinearity between age and parity. The correlation be-
tween age and increasing PNTMLmust therefore be taken
into account when interpreting results of this test in the
context of defining a neuropathy. The greater impact of
parity on the left pudendal nerve is in accord with the re-
sults of the prospective study by Sultan et al24 investigating
pudendal nerve conduction in relation to childbirth.
TABLE 3. Multivariate models for prediction of anal sphincter
defects
OR p t 95% CI
IAS defect
Age 0.99 0.218 0.98–1.00
Parity 1.14 0.083 0.98–1.33
Type of deliverya 1.10 0.259 0.93–1.31
Constipation 0.38 0.0001 0.25 to0.57
Fecal incontinence 2.90 0.0001 1.86–4.51
Model: Prob 2 0.0000,
pseudo R2 0.10
EAS defect
Age 0.99 0.642 0.99–1.00
Parity 1.16 0.022 1.02–1.33
Type of deliverya 1.63 0.0001 1.37–1.93
Constipation 0.415 0.0001 0.31–0.55
Fecal incontinence 1.51 0.007 1.12–2.02
Model: Prob 2 0.0000,
pseudo R2 0.09
IAS internal anal sphincter; EAS external anal sphincter.
aAll types of delivery vs cesarean only.
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These data suggest that not only is cesarean delivery
protective of the sphincter complex, but that manometri-
cally recorded pressures are preserved, in accord with re-
sults from other studies.5,11 Furthermore, we confirm the
result of several other studies,5,8,25 which show that a his-
tory of instrumentation results in increased frequency of
sphincter defects. Although we also confirm studies show-
ing that instrumentation adversely affects anal pressures,8
this relationship is related to squeeze increment but not
resting pressures. Some of the cesarean-only group however,
did have sphincter defects. Given the exclusion criteria and
stratification of parity applied, this is likely to represent
trauma occurring before emergency cesarean delivery.
The study does have several limitations, including its
retrospective design, and although physiology testing was
performed bymultiple investigators, all were trained in the
same way by one senior physiologist (M.S.) and all fol-
lowed the Unit’s guidelines. Ultrasound evidence of de-
generation, rather than true structural defects, was not
sought, and it may be that degeneration may have a rela-
tion to age, perhaps through prolongation of pudendal
motor nerve conduction. Of course, half the cohort stud-
ied experienced fecal incontinence, which may have
skewed the data in terms of prevalence of sphincter defects,
although, interestingly, parity and age were similar be-
tween those with incontinence and those with constipa-
tion. Unfortunately, data relating to time of menopause
were not sought; it is known that there are independent
effects of changes in the hormonal milieu on certain as-
pects of pelvic26 and anorectal function.27
It must be remembered that this is not a study of
asymptomatic subjects, and the concepts of normality and
abnormality have been avoided. Defining normality, strat-
ified according to age and parity, thus remains a challenge.
This study adds to the literature confirming some, yet re-
futing other results of previous reports. The vigorous ex-
clusion criteria used limit as far as possible the effect of any
other confounding causative factor, other than increasing
age and parity, on the female anorectum. The statistical
models presented reveal that the individual changes with
each advancing year of age are small but cumulatively sig-
nificant in statistical terms. Whether such small effects are
of clinical or practical importance, however, is acknowl-
edged to be more difficult to judge. There are predictable
associations between increasing age and increasing parity
and also parity and EAS defects. It is thus clear why other
studies have attributed statistically significant associations
thatmay now appear tenuous. Despite someweaknesses in
statistical modeling, it remains clear, however, that aging
affects resting pressures (presumably by effects on inner-
vation of the sphincter complex, or myopathy), whereas
parity is detrimental to the structure and thence function
of the external sphincter. The effect of parity is exacerbated
by a history of instrumentation, whereas cesarean delivery
is protective. Neither age nor parity have any association
with rectal sensory thresholds.
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BACKGROUND: Sacral nerve stimulation has been shown
to be an effective treatment for fecal incontinence and
early studies reported success rates of 67% to 100%.
However, “success” has been arbitrarily set at a 50%
reduction in symptoms, and data are rarely reported with
“intention to treat.”
OBJECTIVE: This study aimed to assess the true efficacy
of sacral nerve stimulation for fecal incontinence
compared with the published literature.
DESIGN: This prospective 5-year study was conducted to
assess 50 patients with fecal incontinence treated with
sacral nerve stimulation. All analyses were performed on
an intention-to-treat basis.
SETTINGS: This study took place in a single tertiary
referral colorectal department.
PATIENTS: Fifty consecutive patients with fecal
incontinence refractory to conservative management
were included in the study.
INTERVENTIONS: The interventions performed were
temporary evaluation with or without permanent sacral
nerve stimulation.
MAIN OUTCOME MEASURES: Primary outcomemeasures
were 1) attainment of continence, 2) reduction in fecal
incontinence episodes, 3) improvement in Cleveland
Clinic Fecal Incontinence scores, and 4) improvement in
the ability to defer defecation.
RESULTS: Thirteen patients (26%) did not respond at the
temporary evaluation stage or were dissatisfied with the
result. Ten further patients (20%) did not achieve a 50%
reduction in symptoms following permanent
implantation. The median follow-up was 17 months
(range, 2–55), at which time 27 patients (54%)
experienced a 50% or more reduction in symptoms,
including 13 (26%) who achieved apparent continence.
Median fecal incontinence episodes per fortnight reduced
from 14 (range, 0–53) to 2 (range, 0–20; P .0001).
Median Cleveland Clinic Fecal Incontinence scores
reduced from 15 (range, 3–20) to 8 (range, 0–17; P
.0001). The ability to defer defecation improved
significantly (P .0001). These results compare
favorably with the published literature.
LIMITATIONS: Quality of life was not assessed.
CONCLUSIONS: This study demonstrates that sacral nerve
stimulation can be an effective treatment for patients
with fecal incontinence; however, when analyzed by
intention to treat, the symptoms of fecal incontinence
continue in the majority (74%) of patients.
KEY WORDS: SNS; Sacral nerve stimulation; Fecal
incontinence.
F
ecal incontinence (FI) is a common condition and
represents a major public health issue.1,2 Patients
with symptoms that were refractory to conservative
therapies may be considered for surgical intervention.3
The management of FI has evolved with the advent of
sacral nerve stimulation (SNS). SNS was initially devel-
oped for the treatment of patients with detrusor instability,
urinary frequency, and urge urinary incontinence with
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59% to 83% of patients experiencing a 50% or greater
reduction in symptoms.4,5 More recently, this technique
has been applied to patients with FI, with early reports
revealing the success rate to be between 67% and
100%.6–15
Since 2003, patients referred to Barts and The Lon-
don NHS Trust with FI unresponsive to conservative
management were considered for SNS as first-line sur-
gical therapy. During the study period, it became appar-
ent that the level of success reported elsewhere6–15 was
not being replicated within this tertiary referral center.
The aim of this study was to establish the true efficacy of
SNS within a single center and to compare this with
previous studies.
METHODS
The study protocol was approved by the East London and
City Health Authority Research Ethics Committee (P1/04/
025), and all patients provided written informed consent.
Where appropriate for a cohort study, this trial adhered to
the CONSORT guidelines.16 Fifty consecutive patients (47
female) undergoing SNS for FI unresponsive to conserva-
tive management were recruited over a 5-year period. The
overall median age was 55 (range, 30–84) years, with a
median parity of 2 (range, 0–5) deliveries for female pa-
tients. All patients had symptoms that were refractory to
maximal conservative treatment (including biofeedback),
and had undergone a detailed clinical history and investi-
gation to exclude any obvious organic cause for their in-
continence; clinical history included assessment of the
Cleveland Clinic Fecal Incontinence (CCFI) score.17 Be-
fore commencing the study 4 primary outcome mea-
sures were identified: 1) the percentage of patients who
were free of FI throughout a 2-week monitoring period
following permanent implantation; 2) the reduction in
episodes of FI; 3) the change in CCFI scores; and 4) the
perceived increase in the ability to defer defecation in
minutes. Two secondary outcome measures were also
identified: 1) the percentage of patients achieving a 50%
reduction in episodes of FI during peripheral nerve eval-
uation (PNE) and 2) the percentage of patients achiev-
ing a 50% reduction in episodes of FI during permanent
implantation. Clinical outcome measures were assessed
at all time points by requesting patients to prospectively
record the above data points in a 2-week nonvalidated
bowel diary. Quality-of-life data were not recorded for
study participants, because this was not identified as a
primary or secondary outcome measure during the de-
sign of this study.
Standard anorectal physiology testing was performed
before treatment and consisted of anorectal manometry
assessment of anal sphincter function by a pull-back tech-
nique, rectal sensation to volumetric distension, endoanal
ultrasonography, evaluation of pudendal nerve terminal
motor latency, and defecating proctography.18
Sacral Nerve Stimulation
Peripheral Nerve Evaluation. Patients underwent unilat-
eral PNE with the percutaneous insertion of a stimulating
electrode (3065USC; Medtronic, Minneapolis, MN) into
the sacral foramen under general (n 41) or local (n 9)
anesthesia. Optimal positioning of the electrode was con-
firmed by fluoroscopy and observation of the appropriate
motor contraction responses, which consisted of a bellow-
ing of the pelvic floor and plantar flexion of the ipsilateral
great toe. Testing was undertaken in the S3 foramina and
performed bilaterally. The side that demonstrated the best
motor response was chosen. The stimulating wire was
secured with dressings and connected to an external
pulse generator (3625; Medtronic). Patients were ad-
vised against driving, bathing, engaging in energetic ac-
tivities, and lifting heavy objects during the test period
to avoid wire displacement.
Stimulation parameters were set at 210s pulse width,
15 Hz frequency, and subsensory amplitude ranging be-
tween 0.5 and 10 V that continued for 14 days. The ampli-
tude was patient controlled, and perineal sensation was
documented throughout the test period. A clinical result
was deemed “successful” when, on review of the bowel
diary, patients demonstrated a 50% decrease in episodes
of FI.9 A permanent implant was offered if continence
improved in combination with a patient’s desire to pur-
sue permanent stimulation. Ten patients were nonre-
sponders to PNE, and 3 patients achieved a 50% reduc-
tion in episodes of FI but chose not to proceed to
permanent implant secondary to dissatisfaction with the
response to stimulation. At the end of the test phase, the
electrode was removed with the patient conscious, in an
outpatient setting.
Permanent Stimulation.Thirty-seven patients (74%of to-
tal patients; median age, 48 (range, 31–84) y; 35 females)
who experienced significantly reduced FI with temporary
SNS subsequently underwent permanent stimulation with
a unilateral tined lead (3093-28; Medtronic) and pulse
generator (3023; Medtronic), implanted under general
(n  34) or local (n  3) anesthesia. The electrode was
sited in the same sacral foramen as that used for temporary
stimulation, with the exception of 2 patients in whom the
original foramen could not be accessed; hence, the con-
tralateral foramen was used. The pulse generator was
placed in a subcutaneous pocket in the ipsilateral but-
tock of the implanted electrode. Stimulation com-
menced the following day with the use of stimulation
parameters similar to those detailed above, again at a
subsensory threshold.
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Clinical Assessment
Patients completed a CCFI assessment and a 2-week
bowel diary before and during temporary stimulation.
Diaries recorded both controlled and uncontrolled
(urge- and passive-related) bowel movements. In the
responders, a further CCFI assessment and bowel diary
were completed by day 90 and at a median of 17 months
(range, 2–55) after permanent stimulation.
Analysis of Previous Studies
Because the success rates following SNS for FI reported
elsewhere were not replicated within our center,6–15 a
systematic review was conducted to establish the pub-
lished efficacy of this treatment. A literature search was
performed using PubMed and the Cochrane Databases
for cohort studies between January 1995 (first descrip-
tion of the use of SNS for FI) and March 2010 reporting
patients undergoing this treatment for FI. The literature
was reviewed independently by 2 surgeons (D.J.B. and
J.M.), and data extraction was performed. Data were
formally tabulated by preset data criteria (Table 1). Only
studies in English were considered. The search terms
used, either in isolation or various combinations, were
SNS, sacral nerve stimulation, sacral neuromodulation,
and fecal (and faecal) incontinence. A manual search of
all references in the reviewed literature was performed
to complete the search.
Articles were included when patients awaiting per-
manent implant were specified and could be subtracted
from the data at the PNE stage (Table 1). Where multi-
ple time points were reported by individual studies, the
follow-up period with the greatest number of patients
was used and the others excluded. Articles were ex-
cluded if they were an analysis physiological data, cost,
and technique, but not functional outcome, and if pa-
tient outcomes were reported as a cohort without spec-
ification of absolute patient numbers at each phase of
treatment. Studies were not included if from the same
institution, unless data were clearly mutually exclusive;
otherwise, the study containing the greatest number of
recruited patients was used, and the others excluded.
When intention-to-treat (ITT) outcome measure anal-
yses were not presented by studies, these were calculated
by the authors (D.J.B., J.M.).
This literature review adheres to the Quality of Re-
porting of Meta-Analyses protocol. Despite these rec-
ommendations being initially designed for meta-analy-
ses, where appropriate for a systematic review, its
guidelines have been implemented. In keeping with this,
the validity of each included study was determined. As-
sessment of methodology, as described by the Delphi
criteria for quality assessment of randomized controlled
trials where appropriate for cohort studies, was per-
formed and a rating of 1 to 9 assigned to each study
(Table 1).19
Statistical Analysis
Data are expressed as the median and range. Statistical
analysis was performed for nonparametric data (episodes
of FI, deferment of defecation, CCFI scores) by the Fried-
man test and the Dunn Multiple Comparison Test using a
commercially available statistical software package (Prism
TABLE 1. Efficacy of SNS from literature
Author Year
No. of
temporary
Success
n (%)
No. of
permanent
Success
n (%)
Continent
n (%)
ITT
success
n (%)
Follow-up
median
(months)
ITT
continent
n (%)
Delphi
score
Ripetti et al14 2002 21 4 (19) 4 4 (100) 0 (0) 4 (19)a 15 0 (0) 2
Rasmussen et al20 2004 45 37 (82) 37 32 (86) n/a 32 (71)a 6 n/a 1
Conaghan et al21 2005 5 3 (60) 3 3 (100) 2 (67%) 3 (67)a n/a 2 (40) 0
Faucheron et al22 2006 40 29 (73) 29 24 (83) n/a 24 (60)a 6 n/a 0
Gourcerol et al23 2007 61 35 (57) 33 20 (61) 6 (18) 20 (33)a 12 6 (10) 2
Melenhorst et al24 2007 134 100 (75) 100 79 (79) n/a 79 (59)a 26 n/a 2
Hetzer et al25 2007 44 37 (84) 37 34 (92) n/a 34 (77) 13 n/a 3
Holzer et al26 2007 36 29 (81) 29 28 (97) n/a 28 (78)a 35 n/a 2
Dudding et al27 2008 70 61 (87) 51 41 (80) 19 (37) 41 (58)a 24 19 (27) 0
Gstaltner et al28 2008 11 5 (45) 5 5 (100) 4 (80) 5 (45)a n/a 4 (36) 2
Muñoz-Duyos et al29 2008 43 29 (67) 29 25 (86) 14 (48) 25 (58)a 35 14 (32) 2
Tjandra et al30 2008 60 54 (90) 53 38 (72) 22 (42) 38 (63) 12 22 (37) 2
Vitton et al31 2008 5 5 (100) 5 5 (100) n/a 5 (100) 14 n/a 3
Roman et al32 2008 18 18 (100) 18 14 (78) n/a 14 (78)a 3 n/a 1
Boyle et al33 2009 15 13 (87) 13 10 (77) 6 (40) 10 (66) n/a 6 (40) 3
Altomare et al34 2009 94 60 (64) 60 37 (61) 9 (15) 37 (39)a 74 9 (10) 0
Vallet et al35 2010 45 32 (71) 32 23 (72) 9 (28) 23 (51) 44 9 (20) 3
Michelsen et al36 2010 167 132 (79) 126 91 (72) n/a 91 (54) 24 n/a 1
Wexner et al37 2010 133 120 (90) 106 88 (83) 43 (41) 88 (66) 12 43 (32) 3
SNS sacral nerve stimulation; ITT intention to treat; n/a not available.
aDenotes studies where ITT was calculated from presented data.
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4.0; GraphPad Software, San Diego, CA). P values repre-
sent the statistical difference between preoperative and
postoperative values, with a value of .05 considered to
show statistical significance.
RESULTS
Preoperative Assessment
Primary risk factors for FI were identified for individual
patients3: obstetric injury, 26; anal surgery, 8; idiopathic, 6;
mixed anal surgery/obstetric trauma, 8; and pelvic surgery,
2. Patients reported a median of 14 (range, 0–53) episodes
of FI per fortnight, with a median maximal deferment of 1
(range, 0–15) minute(s). Median preprocedure CCFI
scores were 15 (range, 3–20). Thirty-six patients were
found to have a disrupted external anal sphincter. Twenty-
two patients also had a concomitant abnormality of the
internal anal sphincter; 1 patient was found to have an
isolated internal anal sphincter defect. For all patients pre-
operatively, median maximum anal resting pressure was
54mmH2O (range, 16–132)with amedianmaximumanal
squeeze increment of 27 (range, 0–90). Median first con-
stant sensory threshold volume during rectal balloon dis-
tension was 45 mL (range, 10–285), median defecatory
desire volume was 98 mL (range, 20–300), and median
maximal tolerable volume was 145 mL (range, 35–380).
Eleven patients demonstrated rectal hypersensitivity, de-
fined as a maximum tolerated volume of less than 90 mL,
and 5 were hyposensate, defined as a maximum tolerated
volume of more than 300 mL. Preoperative evacuation
proctography identified a functional rectocele4 cm in 9
patients. Volume of neostool instilled was 200 mL (range,
80–600) with an expulsion value of 75% (range, 0–100)
over 70 seconds (range, 10–300).
Postoperative Assessment
Peripheral Nerve Evaluation. At the end of the test pe-
riod, 13 (26%) patients reported no episodes of incon-
tinence with median episodes of incontinence reduced
to 2 (range, 0 –21) per fortnight (P .001) (Fig. 1). Over-
allmedian continence score reduced to 9 (range, 0–18;P
.001) during PNE (Fig. 2). The ability to defer increased to
5 minutes (range, 0–20; P  .001). At the end of the test
period, the lead was found to be radiologically displaced in
5 patients, 2 of whom underwent repeat evaluation before
progressing to permanent implantation. The remaining 3
patients did not wish to undergo repeat PNE. Forty pa-
tients (80%)met the criteria to progress to permanent im-
plantation; however, only 37 (74%) elected to do so, with 3
further patients dissatisfied with the effect of the treatment
(Fig. 3).
Short-term Follow-up: 3 Months. At 90 days after perma-
nent implantation, median episodes of incontinence were
2 (range, 0–19) per fortnight (P  .001). The ability to
defer defecation increased to 5 minutes (range, 0–15; P
.001). The overall median continence score reduced to 9
(range, 0–18;P  .001). One patient required a further
period of PNE at the S3 level, because permanent implan-
tation at S4 did not improve symptoms. Twenty-seven pa-
tients (54%) reported a significant decrease in episodes of
FIGURE 1. Episodes of FI during a 2-week evaluation period.
Presented data are median and range. *Friedman (Dunn
postanalysis) test: P .0001. FI fecal incontinence; PNE
peripheral nerve evaluation.
FIGURE 2. Alteration in Cleveland Clinic scores following treatment
with SNS. Presented data are median and range. *Friedman (Dunn
postanalysis) test: P .0001. SNS sacral nerve stimulation; PNE
peripheral nerve evaluation.
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incontinence (50% or greater) following permanent im-
plantation; however, 10 patients did not obtain a satisfac-
tory outcome at 90 days follow-up. One patient received
oral antibiotics for a superficial wound infection.
MidtermFollow-up: 17Months.At amedian follow-up of
17 months (range, 2–55), 33 of the 37 patients who pro-
gressed to permanent implantation could be assessed,
with 4 unavailable for the following reasons: lost to
follow-up; treatment failure, electrically stimulated gra-
cilis neosphincter; treatment failure, end ileostomy;
death unrelated to treatment. Overall, the 33 assessed pa-
tients reported a median of 2 (range, 0–20) episodes of FI
per fortnight with a maximum deferment of 5 minutes
(range, 0–20). Median CCFI score was 8 (range, 0–17) at
this time point. When assessing the 10 patients who had
disappointing 90-day outcomes, 2 patients reported a sig-
nificant improvement in continence following adjustment
of stimulation parameters. Of the 27 patients who had re-
ported a successful 90-day outcome, 2 patients experi-
enced a deterioration in symptoms at midterm follow-up.
Therefore, at the midterm assessment period, 27 patients
(54% of total subjects) reported greater than 50% reduc-
tion in episodes of FI when assessed in accordance with an
ITT basis, with 13 (26%) reporting no episodes of FI dur-
ing the 2-week monitoring period. Tined lead migration
occurred in 4 cases; reimplantation on the contralateral
side was required in one case. Two patients experienced
discomfort from superficial implantation of the stimulator
that required repositioning in both cases.
Comparisonwith Previous Studies
Nineteen studies that satisfied the eligibility criteria were
identified14,20–37 (Table 1). Two randomized controlled
trials were excluded from the systematic review because
they reported outcomes from patient cohorts that had
previously been described in the published literature by
other authors from the same institutions.38,39 All studies
included in the analysis reported patient cohorts with
27 (54%) “success” with
permanent SNS
10 (20%) failed to regain
benefit of PNE (1 lost to
follow-up)
37 (74%) proceeded to
permanent SNS
10 failed to achieve a
50% reduction in
symptoms
3 achieved 50%
reduction in symptoms,
but were dissatisfied
50 patients (3 male) with
fecal incontinence
underwent PNE
13 (26%) with no
symptoms of FI
14 (28%) with ongoing
FI but 50% better or
more
FIGURE 3. Flowchart of patient outcomes from SNS. SNS sacral nerve stimulation; PNE peripheral nerve evaluation; FI fecal
incontinence.
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heterogeneous etiologies of FI. Seven of the 19 studies pre-
sented ITT analyses with the remaining 12 (63%) calcu-
lated by the authors (D.J.B., J.M.). Fourteen of the studies
analyzed involvedmore than 20 patients and had provided
data that showed an ITT success between 19%and 78%.Of
these 14 studies, only 8 highlighted patients free from FI
during the monitoring period following permanent im-
plantation. These 8 studies reported continence rates of
between 0% and 37% during a 2-week monitoring period
following treatment with SNS. The results from our own
study demonstrate an ITT success of 54% and ITT conti-
nence of 26%, comparing favorably with the published lit-
erature.
DISCUSSION
This study reports the experience of a single tertiary colo-
rectal referral center over a 5-year period with results ex-
pressed as intention to treat. With 54% of patients describ-
ing an improvement in symptoms, the above data
demonstrate that SNS can be an effective treatment for FI.
However, these results appear at variance with early re-
ports of SNS which suggest that themajority of individuals
who undergo this procedure derive significant benefit.
Therefore, although multiple studies have investigated
SNS as a treatment for FI, the efficacy of this procedure
remains contentious.
Reports describing functional outcome following SNS
for FI have previously specified success rates of between
67% and 100% following implantation of the permanent
stimulator.6–15 If functional outcome data reported by this
study were presented in a similar fashion to themajority of
the published literature, a response rate of 73%would have
been achieved, because 27 of 37 patients who progressed to
permanent stimulation experienced a 50% or greater re-
duction in episodes of FI. This is comparable with previous
reports and confirms that these results are not secondary to
surgical technique, or biased by experience or patient se-
lection. However, when assessed with an ITT analysis, the
overall “success” rate for SNSwas reduced to 54%, because
PNE failed in 13 (26%)patients, whereas 10 (20%)patients
did not experience an improvement in symptoms com-
pared with those during PNE. Furthermore, only 26% of
patients experienced complete resolution of symptoms.
Studies included in the systematic review that have pre-
sented data on those not responding to PNE have response
rates similar to those described in this study.
Establishing the true efficacy of SNS is further com-
pounded by the definition of what is deemed an acceptable
outcome. Although a 50% reduction in episodes of FI is
widely held as the threshold of success, the significance of
such a limited improvement should be explored. Seventy-
four percent of the patients enrolled in this study contin-
ued to experience at least fortnightly episodes of FI,
whereas 68% had weekly episodes. Consequently, al-
though SNS may have resulted in a degree of improve-
ment, the majority of patients would satisfy the criteria for
considering further surgical intervention. SNS was origi-
nally used to treat detrusor instability and urinary fre-
quency4,5 and, although a 50% reduction in symptoms
may be acceptable for these conditions, it is questionable
whether the same arbitrary measure of success should be
applied to FI. It is generally accepted that, for a medical
treatment to be considered a “success,” patients would ei-
ther have to experience a resolution in symptoms or the
physiological parameter being assessed would have to re-
turn to an acceptable level. Our results show that, despite
having a similar outcome to other units, 68% of patients
who enter into treatment with SNS for FI continue to ex-
perience weekly episodes of incontinence. Such a level of
incontinence is unlikely to represent a satisfactory resolu-
tion of symptoms and this is highlighted by midterm me-
dian CCFI score of 8. Similarly, the effect of SNS on per-
ceived ability to defer defecation is uncertain; although
most study participants reported an improvement, theme-
dian deferment of 5 minutes falls short of a return to nor-
mality. Therefore, the lifestyle of the majority of patients is
likely to remain affected by urgency and the need to be near
toileting facilities, even in those who achieve apparent
“continence.” However, although this study evaluated the
effect of SNS on symptoms of FI, it does not address alter-
ations in the quality-of-life (QOL) scores of these patients.
Further studies will be required to assess improvements in
QOL following SNS and, specifically, the threshold reduc-
tion in symptoms required to consistently produce an im-
provement in QOL scores to deem the treatment a success.
Irrespective of the definition of a successful outcome
following SNS, a proportion of patients report resolution
of FI symptoms following this intervention, but the preop-
erative identification of this subgroup remains problem-
atic. PNE has been used as means to identify these individ-
uals; however, in addition to the 26% of study participants
who derived no improvement in symptoms following test
stimulation, PNE failed to exclude a further 20% forwhom
SNS was ultimately unsuccessful. The reason for this ap-
parent failure to regain the effect of temporary stimulation
is unclear. It is possible that lifestyle restrictions while un-
dergoing temporary stimulation may contribute to fewer
episodes of FI, or that patient concerns over being refused
permanent treatment for their symptoms could influence
the completion of bowel diaries at PNE. Nevertheless, the
reported data do suggest that, for most patients, the short-
term benefits of permanent implantation are sustained at
midterm follow-up, in keeping with previous reports.
The treatment of FI with SNS is expensive,27 and
this study suggests that the actual cost involved to
achieve resolution of symptoms may be considerable.
The efficacy of PNE to select patients appears uncertain
despite the greater control afforded by the 4 electrodes
on the tined lead. From our data following PNE, we are
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unable to predict whowould achieve continence at perma-
nent stimulation; therefore, the cost of deploying PNE and
permanent implant as it is designed is questionable. From
these data, 1 in 4 patients achieved “continence,” at a cost
of 4 patients undergoing PNE and 3 having permanent
implantation. Therefore, if cost were analyzed with an in-
tention to achieve continence, SNS may be significantly
more expensive than previously reported. As yet, we are
unable to determine either preoperatively, or following
PNE, which patients will achieve maximal benefit.
CONCLUSION
It would appear that SNS is an effective therapy for some
patients with FI, but this study would suggest that careful
counseling of patients regarding outcomes is required be-
fore embarking on this treatment. In particular, suggesting
that SNS is effective in the treatment of FI for 67% to 100%
of patients may be misleading and result in false expecta-
tions. This is compounded by the fact that predictive cri-
teria identifying those who will obtain the most benefit
from SNS remain elusive. Ultimately, further studies will
be required to determine the extent of improvement re-
quired from the preoperative symptom level that consti-
tutes an acceptable outcome, and whether the efficacy,
cost, and low rate of progression to permanent implanta-
tion associated with SNS will allow its use as a practical
therapeutic intervention for the majority of patients.
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Efficacy of Sacral Nerve Stimulation for
Fecal Incontinence in Patients with Anal
Sphincter Defects
Derek J. Boyle, M.B., Ch.B. • Charles H. Knowles, Ph.D. • Peter J. Lunniss, M.S.
S. Mark Scott, Ph.D. • Norman S. Williams, M.S. • Kathryn A. Gill, M.D.
Centre for Academic Surgery (Gastrointestinal Physiology Unit), Barts and The London School of Medicine and Dentistry,
London, United Kingdom
PURPOSE: Sacral nerve stimulation has traditionally been
used to treat patients with fecal incontinence with intact
anal sphincters. This rationale has been challenged, but it
remains unknown if its efficacy is related to the extent of
the sphincter injury.
METHODS: This was a prospective study of 15 patients
with sphincter defects (9 combined, 2 external only, and
4 internal only) undergoing sacral nerve stimulation for
fecal incontinence. Endoanal ultrasound scans were
reviewed and defects scored (0–16) with use of a system
published by two independent observers. These were
correlated with the following outcomes: 1) reduction in
fecal incontinence episodes, 2) reduction in soiling, 3)
improvement in Cleveland Clinic scores, and 4)
improvement in ability to defer defecation. All patients
were studied after temporary stimulation and again at
three to six months after permanent implantation.
RESULTS: Thirteen patients (87%) progressed to
permanent stimulation. Median fecal incontinence
episodes per two weeks decreased from 15 (range, 1–53)
to 3 (range, 0–16; P 0.01). Median soiling episodes
were reduced from 10 (range, 1–14) to 6 (range, 0–14;
P 0.009). Median Cleveland Clinic scores decreased
from 12 (range, 9–18) to 9 (range, 4–14; P 0.0005).
The ability to defer defecation was improved significantly
(P 0.05). There were no relationships between
sphincter defect scores and outcome measures after sacral
nerve stimulation (r2 0.001–0.10; P 0.28–0.94).
CONCLUSION: Sacral nerve stimulation is an effective
treatment in patients with fecal incontinence who have
anal sphincter defects, and outcome is not associated
with severity of sphincter disruption.
KEY WORDS: Sacral nerve stimulation; Fecal
incontinence; Anal sphincter defects.
T
he reported community prevalence of fecal inconti-
nence (FI) varies between 0.4% and 18%; in those
studies thatminimize significant sources of bias, the
estimate is 11% to 15%.1 This represents a major public
health problem,2 which is likely to intensify with a propor-
tionally older population.3,4 Patients with intractable
symptoms and impaired quality of life, in whom failed
conservative management has failed,4 may be offered a
surgical treatment. Because the primary etiologic factor in
FI is a most commonly compromised anal sphincter func-
tion,5 surgery has traditionally been directed to restoration
of anatomy. However, direct repair of isolated sphincter
defects is reported to have a less than 50% success rate over
the long term.6
More recently, sacral nerve stimulation (SNS) has pro-
vided an alternative surgical therapeutic option.7 SNS has
been shown to effectively improve symptoms of FI and
quality of life, over themedium term, in patients withweak
but structurally intact sphincters.8,9 Indeed, this was the
principal indication for SNS when the first U.K. National
Institute of Clinical Excellence guidelines were published
in 2004.10 Recently, however, it has been reported that
SNS may also be effective in patients with limited internal
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(IAS) or external anal sphincter (EAS) defects.8,11,12 Con-
sequently, we sought to determine, by prospective study,
the efficacy of SNS in patients with FI and sphincter defects
and to assess the relationship between extent of sphincter
disruption and clinical outcome.
MATERIALS ANDMETHODS
Patients
Between 2003 and 2007, 32 patients with FI were treated
with SNS at the Royal London Hospital. In 15 (all female;
median age, 53 (range, 26–82) years), anal sphincter de-
fects were demonstrated on endoanal ultrasound (EAUS).
The likely etiology of sphincter disruption was obstetric
injury in 12 and anal surgery in 3 patients. No patient had
previously undergone secondary sphincter repair. Preop-
erative evaluation also included a detailed history, exami-
nation, recording of standardized continence diaries over a
two-week period,13 determination of Cleveland Clinic
continence score,14 and comprehensive physiologic ano-
rectal assessment (anal manometry, rectal sensation, mea-
surement of pudendal nerve terminal motor latencies, and
evacuation proctography). Clinical symptoms were de-
rived from the bowel diary and patient history and were
classified according to severity of FI, soiling, and urgency,
with soiling defined as the number of days with stained
undergarments during the 14-day evaluation period with-
out frank incontinence. Fecal urgency was defined as the
ability to defer defecation and was classified as follows: less
than one minute, one to five minutes, and more than five
minutes. Patients were considered for SNS ifmaximal con-
servativemanagement had failed, if they had a frequency of
incontinent episodes of one or more per two weeks, and if,
after counseling, they wished to proceed.
Structural Assessment of Anal Sphincters
Sphincter integrity was assessed by EAUS (Type 1846
probe with 10-MHz transducer, B-K Medical, Berkshire,
UK) and graded by use of a previously published scoring
system,15 inwhich both the IAS andEAS are independently
assessed. Hard-copy two-dimensional axial images were
acquired at five levels from the puborectalis to the anal
verge. Defects were graded from these images according to
length, depth, and circumference to produce a score of 0 to
8 for both the IAS and EAS and a combined sphincter
complex score of 0 to 16 (Table 1). Sphincter defects were
scored by two independent observers to calculate inter-
observer variation. This was repeated after three months
by one of the observers (blinded) to assess intraobserver
variation.
Sacral Nerve Stimulation
Temporary and permanent stimulation were performed as
previously described in detail.16 Stimulation parameters
were set at 210 s pulse width, 15 Hz frequency, and a
subsensory amplitude ranging between 0.5 and 10 V. The
subsensory amplitude was patient-controlled. Patients
were evaluated after two weeks of temporary stimulation,
and permanent implantation was offered if temporary
stimulation resulted in a 50% improvement in symp-
toms, as evidenced by bowel diary records. The patient’s
enthusiasm to progress to permanent stimulation was also
required.
Outcome Variables and Analysis
Bowel diaries were collated prospectively to determine
changes in symptoms. For this study, four outcome vari-
ables were defined a priori: 1) episodes of FI per week, 2)
episodes of soiling per week, 3) Cleveland Clinic conti-
nence scores (all ordinal continuous), and 4) ability to de-
fer defecation (categorical). Differences before and after
stimulation were compared by use of paired t-tests (ordi-
nal) on the basis of normality testing of data (Shapiro-
Wilk’s test) or by use of chi-squared tests (categorical).
The relationship between EAUS severity scores and FI ep-
isodes was examined by use of linear regression. Intraob-
server and interobserver agreement were determined and
expressed by use of theWilcoxon rank-sum test. A P value
0.05 was considered to indicate significance. All analyses
were performed by use of Stata® 7.0 (Stata Corporation,
College Station, TX).
RESULTS
Structural Assessment
Severity scores for sphincter defects as determined on
EAUS are shown in Table 2 (median, 10; range, 3–16).
Overall, six patients had an isolated sphincter defect (four
EAS, two IAS), and the remaining nine patients had
combined defects. There was minimal intraobserver error
(difference (range,1 to5,P 0.0001; Spearman’s
rho  0.85)) and interobserver error (difference  1
(range,4 to6,P 0.0002; Spearman’s rho 0.80)). At
baseline, there were no correlations between defect scores
and clinical measures of FI severity.
TABLE 1. Sphincter defect scoring system15
Score
0 1 2 3
EAS
Length None Half Half Whole
Depth None Partial Total
Size None 90° 91–180° 180°
IAS
Length None Half Half Whole
Depth None Partial Total
Size None 90° 91–180° 180°
EAS external anal sphincter; IAS internal anal sphincter.
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Clinical Outcome of SNS
No operative morbidity relating to the placement of either
temporary or permanent electrodes occurred. One patient
had a poor response to temporary stimulation and was
dissatisfied with the treatment, and one derived good ben-
efit from temporary stimulation but declined permanent
implantation for personal reasons. Two patients who had
very few episodes of FI before treatment did not achieve a
50% reduction in episodes of FI with temporary stimula-
tion, but their overall symptom improvement and enthu-
siasm were such that they proceeded to permanent stimu-
lation.
Episodes of FI
Thirteen of the 15 patients (87%) progressed to permanent
stimulation, with episodes of incontinence decreasing
from a median of 15 (range, 1–53) per two weeks before
stimulation to 3 (range, 0–16) per 2 weeks after stimula-
tion (P  0.01; Table 2, Fig. 1). Ten of the 13 patients
(77%) derived a 50% reduction in episodes of FI with
permanent implantation, including 2 with isolated EAS
defects, 2 with isolated IAS defects, and 6 with combined
defects (Table 1). Three patients (one with EAS and two
with combined defects) had a reduced response to perma-
nent stimulation as comparedwith temporary stimulation.
One is awaiting re-siting of the permanent electrode (Pa-
tient 5), one remains satisfied that symptoms are improved
as comparedwith baseline (Patient 6), and one (Patient 10)
eventually regained benefits to a level comparablewith that
achieved with temporary stimulation after adjustment of
stimulation parameters. The presence of a pudendal neu-
ropathy was unrelated to success or failure of the proce-
dure in this study.
Episodes of Soiling
All 15 patients described symptoms of soiling before SNS.
Of the 13 patients who progressed to permanent stimula-
tion, 7 described a 50% improvement in soiling, with a
median frequency of soiling of six (range, 0–14) days per
two weeks, compared with a median of 10 (range, 1–14)
days per two weeks at baseline (P 0.009).
Cleveland Clinic Incontinence Score
Scores improved in 11 of the 13 patients who had a perma-
nent SNS device implanted (baseline: median, 12; range,
9–18; permanent: median, 9; range, 4–14; P  0.0005).
The median reduction in incontinence scores, however,
was only 3 (range, 0–10).
FIGURE 1. Episodes of fecal incontinence after SNS.
TABLE 2. Sphincter defect score and outcome after sacral nerve stimulation
Patient
no.
EAS defect
score
IAS defect
score
Total
score Baseline
Episodes of FIa
After temporary
stimulation
After permanent
stimulation
1 4 0 4 28 10 10
2 3 0 3 8 1 Declined
3 3 0 3 9 3 3
4 0 3 3 53 26 5
5 6 7 13 6 1 9
6 6 0 6 21 10 13
7 6 4 10 25 20 Failed
8 0 4 4 1 2 0
9 4 4 8 21 10 6
10 5 7 12 15 2 16
11 6 7 13 1 1 0
12 7 5 12 7 0 0
13 7 3 10 21 1 0
14 5 8 13 35 1 0
15 8 8 16 4 0 0
EAS external anal sphincter; FI fecal incontinence; IAS internal anal sphincter.
aNumber of episodes per two weeks.
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Ability to Defer Defecation
Urgency was improved after temporary stimulation in 12
patients, and this was sustained in 10 of the 13 who pro-
gressed to permanent stimulation. Overall, for the 15 pa-
tients, contingencies of different degrees of urgency were
significantly improved (P 0.05; Fig. 2).
Outcome vs. Sphincter Defect Severity Score
There was no correlation between the sphincter defect
score and the reduction in the number of FI episodes or
soiling episodes after permanent stimulation (r2  0.10,
P  0.29 (Fig. 3), and r2  0.001, P  0.94, respectively).
Similarly, the reduction in incontinence scores after per-
manent stimulation was unrelated to defect scores (r2 
0.10, P 0.28).
DISCUSSION
This study of a small series of patients with FI and a range
of sphincter defects (detected by preoperative EAUS) dem-
onstrated that the efficacy of SNS is not related to, or lim-
ited by, the extent of sphincter injury. Within this limited
series, there was no correlation between the extent of
sphincter disruption and episodes of FI, episodes of soil-
ing, incontinence scores, or the ability to defer defecation.
Defect score reproducibility, examined by both intraob-
server and interobserver evaluation, was good.
Recently, studies examining SNS in patients with lim-
ited IAS8 and EAS11 defects have shown that patients with
sphincter defects can benefit from SNS. In these studies,
sphincter damage was described in terms of the percentage
of the circumference involved, with maximum defects of
25%17 to 33%,12 but neither the length nor depth of the
defect was considered. The scoring system used in the
present study considered the circumference, depth, and
length of the defect.15 The same scoring systemwas applied
in one previous study of SNS,18 which suggested that pa-
tients with an intact sphincter may have a better outcome,
but this study did not explore the relationship between the
extent of defect and outcome after SNS.
The threshold for offering permanent stimulation has
historically been based on a50% reduction in episodes of
FI. In the present study, however, patient satisfaction was
also considered to be important, and two patients in this
trial went on to permanent stimulation despite not achiev-
ing the 50% improvement threshold. Such improvements
are difficult to quantify and are not reflected in standard
continence scoring systems. Indeed, the reduction in
ClevelandClinic scores after permanent stimulation in this
study was modest at best (median, 3; range, 0–10). These
results compare with mean improvements of 2 to 14 in
previous studies of SNS.19 In addition, although 85%of the
patients who underwent permanent stimulation reported
an increase in the ability to defer defecation, this was often
for only one minute or more (with only four patients hav-
ing an improvement to more than five minutes). Whether
such an increase represents a significant clinical improve-
ment is probably debatable depending on social context.
Nevertheless, 6 of 15 patients were completely rid of FI
episodes.
The anal sphincter complex is the final continence
barrier. Themechanism of SNS is unclear, but it seems not
to relate directly to augmentation of sphincteric function
as assessed manometrically.20,21 In addition, the influence
of neuropathy has not been fully explored. The results of
this study indicate that SNS may result in positive out-
comes irrespective of the degree of sphincter disruption
and should not be denied on this basis. This study was
limited by the small number of patients and by the absence
of a comparison group with a different or no intervention.
Thus, whether the patients would have benefited more
from direct sphincter repair or repair in combination with
SNS could not be determined. This remains an area of
great interest, not least because of the high cost of SNS in
comparison with sphincter repair. However, this issue can
be adequately addressed only by a randomized, controlled
trial design and formal economic analysis. Such a study
would answer the question of appropriate (after optimal
conservative therapy) second-line management for severeFIGURE 2. Change in ability to defer defecation after SNS.
FIGURE 3. Correlation between severity of sphincter defect and
change in episodes of FI from baseline.
DISEASES OF THE COLON & RECTUM VOLUME 52: 7 (2009) 1237
FI. Further study is also required to elucidate the compo-
nents of the continence mechanism that are augmented or
altered by SNS. Certainly these findings support contem-
porary thinking that factors other than sphincter integrity,
such as colonic or rectal sensorimotor function, are central
to continence.5
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Abstract Functional outcomes following surgery for
anorectal malformation are variable, with many children
experiencing persisting anorectal dysfunction. We describe
a 34-year-old female with previous vestibular fistula who
experienced lifelong rectal evacuatory dysfunction and
faecal incontinence; she was treated in a two stage process
producing efficient defecation and almost total continence.
Keywords Anorectal malformation 
Faecal incontinence  Megarectum 
Sacral nerve stimulation
Introduction
Long-term functional outcome following reconstructive
surgery for anorectal malformation (ARM) is dependent on
the type of ARM and the surgery performed [1]. Even after
treatment in a specialist centre, 61% of patients with a
vestibular fistula will have ongoing constipation and 45%
will experience faecal incontinence into adult life [1]. If
coexistent, these two (seemingly opposing) problems need
to be addressed to restore normal excretion of stool and
bowel continence. In this case, a megarectum was treated
with vertical reduction rectoplasty (VRR; Fig. 1) [2], fol-
lowed by sacral nerve stimulation (SNS) [3] for faecal
incontinence.
Case report
The patient was born at 36 weeks and was diagnosed with an
imperforate anus, vestibular fistula and a patent ductus
arteriosus. Following a rectoplasty at 3 weeks and an anal
dilatation at 8 months, there was continual seepage of faeces
without the passage of formed stool. After 3 years, the colon
was defunctioned and a revision rectoplasty performed.
While defunctioned, the anal canal was dilated on 26 occa-
sions (Hegar 8–22) due to stricturing. Upon reversal of the
colostomy at 4 years of age, the previous pattern of continual
faecal seepage resumed immediately, and the patient started
school in nappies. In adult life, social continence was
established using laxatives (docusate sodium and bisacodyl)
to purge the colon every 48 hours. After taking laxatives,
frank faecal incontinence (FI) occurred until the colon was
empty. The patient was subsequently referred to this tertiary
centre for assessment and treatment.
Initial examination revealed a gaping anal canal and a
capacious loaded rectum. On endoanal ultrasound, the
internal anal sphincter had anterior and posterior defects.
Some striated muscle was identified posteriorly; however,
the external anal sphincter was grossly deficient. Anal
manometry validated the ultrasound findings with signifi-
cantly attenuated resting and squeeze pressures (Table 1).
A hyposensate megarectum was identified on radiology,
balloon distension and barostat studies (elevated sensory
thresholds). Two problems therefore needed to be addres-
sed: a rectal evacuatory disorder (RED) residing in a
insensate megarectum and lack of call to stool, and FI with
a significantly deficient sphincter complex. Nevertheless,
these disorders are almost certainly inter-related, with the
incontinence secondary to faecal loading, rectal stasis and
overflow, compounded by a poorly functioning sphincteric
barrier.
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A vertical reduction rectoplasty [2] was first performed
in an attempt to address the RED. VRR was designed to
reduce rectal capacity in a megarectum thus improving
rectal sensation and bowel function. Following VRR, fae-
cal retention and passive seepage were replaced by
increased frequency of stool with spontaneous uncontrolled
bowel motions and faecal urgency. The sensation of a need
to defecate had been restored but it coincided with instant
urge incontinence. Anorectal physiology studies following
this procedure showed that the function of the sphincter
complex was unchanged, but rectal sensation to distension
had normalized (Table 1). Some degree of rectal evacu-
atory dysfunction persisted, however, both clinically and
proctographically. Laxatives were again used in an attempt
to overcome these symptoms.
Two years after VRR, with symptoms unchanged, a trial
of (temporary) sacral nerve stimulation was performed.
SNS is now a well-recognized part of the armamentarium
available in the management of FI [3]. Recently, it has
been shown to be a viable option in the management of
bladder and bowel dysfunction in children [4]. SNS
involves inserting an electrode into the S3 (usually) fora-
men and stimulating the sacral roots with a low voltage.
This is initially performed transcutaneously on a trial basis
for 2 weeks of continual stimulation and if there is a 50%
improvement in symptoms, then a permanent stimulator is
implanted into the buttock with the lead burrowed subcu-
taneously to the S3 foramen. Sphincter defects are now not
considered a contraindication to efficacy of SNS, but intact
sphincters have been shown to respond more reliably [5].
Temporary SNS resulted in a marked reduction in
urgency and FI, and an ability to defer defecation. This
produced a call to stool and a normal defecation habit.
Permanent SNS was thus performed with persistence of
symptomatic improvement and a further increase in the
ability to delay defecation (Table 2). Post SNS, anorectal
physiology showed no increase in resting or squeeze
pressures on anal manometry, but a further reduction in
maximum tolerated volume and also an improvement in the
ability to expel barium neostool on proctography.
Discussion
The establishment of a bowel pattern approaching nor-
mality in our patient required the identification and
Table 1 Anorectal physiology
Base line Post rectoplasty Post SNS
MRP (cmH20) 54 59 30
MSP (cmH20) 20 16 11
FCS (mls) 100 50 45
DD (mls) 180 110 150
MTV (mls) 300 240 180
Neostool expelled 80% in 150 s 50% in 180 s 90% in 60 s
Neostool expelled corresponds to ability to expel barium contrast
during proctography
MRP maximum resting pressure; MSP maximum squeeze pressure,
represents readings from anal canal manometry; FCS first constant
sensation; DD desire to defecate; MTV maximal tolerated volume,
represents results from distension of an air filled latex balloon in the
rectum inflated at 1 ml/s
Table 2 Alteration in bowel diary: (figures represent episodes over a
2-week monitoring period)
Post
rectal
reduction
Temporary
SNS
Permanent
SNS
Ability to defer defecation (min) 0 1 15
Controlled bowel motions 0 20 26
Episodes of urgency 28 3 5
Episodes of urge faecal
incontinence
3 0 0a
Episodes of passive faecal
incontinence
1 0 0
a Post permanent stimulation, there has been one episode of urge FI
following a meal of chilli, but this was out with the monitoring period
Fig. 1 Vertical reduction rectoplasty. A sigmoid colectomy is
performed, rectum is mobilized and capacity reduced by a linear
stapler along the antimesenteric border with anterior portion excised.
An endoluminal circular stapler deployed to fashion the colorectal
anastomosis
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treatment of both the RED and the FI components of her
bowel dysfunction which appeared to originate in both
supra-sphincteric and sphincteric anomalies. A dilated
hyposensate rectum is associated with delayed transit,
stasis and impaction, leading to incomplete evacuation and
soiling (overflow) [6]. It has been previously shown in
certain patients with intractable faecal incontinence and a
history of ARM that excision of a megarectum can result in
continence [7]. By performing the more conservative VRR,
we have demonstrated a normalization of the sensate
ability of the rectum with conscious perception of intra-
rectal stool, compatible with reduced rectal capacity fol-
lowing surgery [8]. Subsequently, SNS provided better
discrimination of the call to stool, an ability to defer def-
ecation and improved defecatory dynamics. Importantly,
however, there was no change in the morphology of the
sphincter complex nor its functional ability. Thus, conti-
nence has been improved by enhancing (colo)rectal func-
tion without demonstrating an improvement in sphincter
function; this implies that the mechanism(s) of SNS may be
due principally to alterations in supra-sphincteric factors.
Given that FI and RED frequently coexist, improvement in
symptoms of FI may indeed result from an enhancement in
the mechanisms governing defecation; SNS is now para-
doxically being used for treatment of constipation [9] and
has recently been shown to modulate colonic propulsive
function [10]. Taken together, these findings support the
concept that the sphincteric barrier may be less important
than previously thought.
In conclusion, we have treated a patient with a signifi-
cant anatomical deformity and a complex reconstruction
history in a two stage process, resulting in a near normal
bowel habit and her taking up, for the first time in her life,
normal social activities.
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Percutaneous Tibial Nerve Stimulation for the
Treatment of Urge Fecal Incontinence
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PURPOSE: Percutaneous tibial nerve stimulation has
been shown to be an effective treatment in patients with
urinary disorders, but its benefit in fecal incontinence is
uncertain. This study aimed to assess the efficacy of
percutaneous tibial nerve stimulation in the treatment of
urge fecal incontinence.
METHODS: This prospective study, conducted over a 14-
month period, assessed 31 patients with urge fecal
incontinence treated with percutaneous tibial nerve
stimulation. The outcomes measured were: 1) reduction
in fecal incontinence episodes, 2) improvement in
Cleveland Clinic incontinence scores, and 3)
improvement in ability to defer defecation. All analysis
was performed on an intention-to-treat basis.
RESULTS: The median follow-up was 9 months (range,
3–14). Twenty-one (68%) patients improved following
percutaneous tibial nerve stimulation and remain
satisfied with the clinical response. Median fecal
incontinence episodes per week declined from 4 (range,
0 –30) to 0 (range, 0 –27) (P .0001). Median Cleveland
Clinic incontinence scores declined from 13 (range,
5–20) to 7 (range, 0 –20) (P .0001). Ability to defer
defecation was improved significantly (P .0001). No
morbidity was encountered for any patient.
CONCLUSION: This preliminary study demonstrates that
percutaneous tibial nerve stimulation is an effective and
very well tolerated treatment for patients with urge fecal
incontinence with particular improvement in reducing
fecal urgency.
KEY WORDS: Percutaneous tibial nerve stimulation; Fecal
incontinence.
F
ecal incontinence (FI) is a common condition affect-
ing between 0.4% and 18% of the population1 and
represents a major public health issue.2 Patients with
intractable symptoms for whom conservative therapies fail
may be considered for surgical management.3 Because the
primary etiology of FI in the majority of patients is thought
to be anal sphincter disruption secondary to obstetric trau-
ma,4 surgeons have concentrated almost solely on restora-
tion of normal anatomy. It is now well recognized that
extrasphincteric mechanisms also play an important role
in the control of continence.4 – 6 More recently, less inva-
sive techniques such as sacral nerve stimulation (SNS) have
been shown to be beneficial in the treatment of FI.7,8 The
mechanism of action of SNS in FI is unclear, but it may
involve neuromodulation via the S3 level with the effect
of increasing the ability to defer defecation and reduce
episodes of FI regardless of sphincteric integrity.8 SNS is
expensive, however, with limited adaptability once in situ
and has well described associated morbidity.9
Neuromodulation of the sacral nerve plexus is possible
via percutaneous tibial nerve stimulation (PTNS).10 This is
a remote, minimally invasive technique, with reported
similar efficacy to SNS in patients with urinary dysfunc-
tion.11,12 Despite limited data, PTNS has been approved
as an acceptable potential treatment for urge FI13–16 (the
appreciation of impending defecation with an inability to
defer, UFI). The aim of this study was therefore to prospec-
tively study the efficacy of PTNS in the treatment of pa-
tients with UFI.
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MATERIALS ANDMETHODS
Patients
Between January 2008 and January 2009, 31 patients (1
male) satisfied the study criteria and received PTNS for
symptoms of UFI (age range, 34 –77 y; median age, 58 y).
Pretreatment evaluation included detailed history, exami-
nation, and comprehensive anorectal physiological assess-
ment (endoanal ultrasound (type 1846 probe with
10-MHz transducer; B-K Medical, Berkshire, UK), water-
perfused anal canal pull-through manometry, rectal sensa-
tion, measurement of pudendal nerve terminal motor la-
tencies, and evacuation proctography). The etiology of FI
in the females was obstetric trauma in 24 (77%) patients,
pelvic surgery in 2 (6%) patients, and unknown (labeled
idiopathic) in 4 (13%) patients. Parity ranged from 0 to 5
(median, 2). The single male patient had undergone a
hemorrhoidectomy 6 years previously with iatrogenic
sphincter injury.
Intractable symptoms (failure of conservative man-
agement) remain a prerequisite before invasive surgery for
FI within our unit. During the study period, conservative
management was requested for 39 potential surgical can-
didates with symptoms of UFI. Inclusion criteria for this
study were all patients referred for conservative manage-
ment of UFI. Exclusion criteria included pregnancy or in-
tended pregnancy, implanted pacemaker or defibrillator, a
history of ischemic heart disease, peripheral neuropathy,
or any medication affecting coagulation. Patients with
mixed symptoms (eg, concomitant passive incontinence,
constipation, and rectal evacuatory disorder) were ex-
cluded from this preliminary study. Urinary symptoms
were not considered for this present study. Patients were
counseled for PTNS, and those who wished to proceed
were offered PTNS as first-line therapy after obtaining in-
formed consent. The procedure was performed by clinical
nurse specialists within a specialist colorectal surgery unit.
No patient involved received any other conservative man-
agement techniques along with PTNS.
All patients were reassessed regarding outcome in
March 2009 at a median follow-up of 9 months (range,
3–14) from the end of treatment. All patients who em-
barked on treatment with PTNS are included in the anal-
ysis, regardless of length of treatment and outcome, with
results expressed as intention to treat. Success of the pro-
cedure was considered a 50% or more reduction in epi-
sodes of UFI as measured by bowel diary combined with
patient enthusiasm to continue.
Percutaneous Tibial Nerve Stimulation
PTNS was performed by using the Urgent PC neuromodu-
lation system (Uroplasty Ltd, Manchester, UK) on an out-
patient basis as described in detail previously.17 This sys-
tem is licensed in the United Kingdom for treatment of
urinary and fecal incontinence.13 A needle is inserted
through the skin posterior to the medial malleolus and
advanced toward the posterior tibial nerve. Stimulation
was gradually increased until sensation was perceived in
the foot, or motor flexor response was seen at the great toe.
Stimulation parameters were set at 200-s pulse width,
20-Hz frequency, and at an amplitude ranging between 0.5
and 9 mA. The amplitude was then maintained at a toler-
able, sensory level. To assess efficacy for individual pa-
tients, an initial course of treatment involved 12 weekly
sessions of 30 minutes duration, followed by 2 sessions at
2-week intervals, and one a month later as described pre-
viously.17,18 Patient commitment to the whole course of
treatment was essential. Patients were encouraged to self-
refer back for further treatment if/when symptoms deteri-
orated, at which point they were offered further 3 weekly
sessions as a “top up.”17,18
Outcome Variables and Analysis
Incontinence records and scores were collated prospec-
tively to determine changes in symptoms. For this study, 3
outcome measures were defined a priori: 1) episodes of FI
per week, 2) Cleveland Clinic continence scores,19 and 3)
degree of fecal urgency. Fecal urgency was defined as the
patient’s perceived ability to defer defecation, and classi-
fied as maximal deferment of defecation in minutes fol-
lowing the call to stool. Differences before and after stim-
ulation were compared by use of paired t tests or Wilcoxon
signed-rank test depending on normality testing of data
(D’Agostino and Pearson omnibus normality test). Anal-
ysis of variance was performed on nonparametric data us-
ing Mann-Whitney U tests. A P value of 0.05 was taken
to indicate significance. All analyses were performed by
use of GraphPad Version 4.02 (GraphPad Software Inc, La
Jolla, CA).
RESULTS
Anorectal Physiological Assessment
The internal anal sphincter was disrupted in 10 patients,
and the external anal sphincter was disrupted in 17 pa-
tients. Nine patients had a combined external anal sphinc-
ter defect/internal anal sphincter defect, and 13 patients
had an intact sphincter complex. The resting manometry
pressures were attenuated in 14 patients (range, 10 –105;
median, 50 cm H2O). Maximal squeeze increment was at-
tenuated in 25 patients (range, 4 –150; median, 40 cm
H2O). Rectal sensory thresholds to balloon inflation re-
vealed that 8 patients had relative rectal hypersensitivity
(maximal tolerated volume, 90 ml), and none were hy-
posensate (maximal tolerated volume,300 mL). Normal
ranges were calculated from 92 healthy volunteers exam-
ined in this unit.
PTNS: Clinical Outcome
The procedure was very well tolerated by all patients with
no morbidity observed in the placement of the electrode
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and during or after stimulation. Two patients withdrew
from the study after only the second treatment session; one
cited lack of commitment to continue the treatment and
the other became pregnant. A further 2 patients withdrew
after the 6th session, 2 withdrew after the 7th session, and 3
withdrew after the 12th session having shown no improve-
ment when assessed by the outcome measures above. One
patient, who demonstrated a marked improvement in all
outcome measures and achieved apparent continence, de-
cided to embark on alternative treatment. Thus, from the
initial 31 patients, 21 were satisfied with the response and
continued within the treatment protocol. This conferred
an overall treatment response rate (50% reduction in epi-
sodes of UFI combined with patient satisfaction) of 68%
when analyzed with intention to treat (Fig. 1).
Episodes of Fecal Incontinence
Twenty-two of the 31 patients (71%) improved by 50% or
more, with episodes of incontinence decreasing from a me-
dian of 4 per week (range, 0 –30) prestimulation to 0 per
week (range, 0 –27) poststimulation (P  .0001) (Fig. 2).
Twelve patients (32%) were “continent” (complete cessa-
tion of episodes of UFI) after treatment. The median re-
duction in incontinence episodes was 3 per week (range,
2 to 24). The 9 patients who failed to record a 50%
improvement included 4 patients who did not experience
weekly episodes in incontinence. Of these four, 3 had in-
continence on a monthly basis, whereas one had episodes,
on average, every 2 months.
Incontinence Scores
Cleveland Clinic Score improved in 20 of the 31 patients
(65%) and deteriorated in one following PTNS (baseline:
median, 13; range, 5–20; poststimulation: median, 7;
range, 0 –20, P .0001) (Fig. 3). The median reduction in
incontinence scores, however, was only 2 (range, 1 to
13).
Ability to Defer Defecation
Urgency was improved following PTNS in 20 patients
(65%) (baseline: median, 1 min; range, 0 –15; posttreat-
ment: median, 5 min; range, 0 –25, P .0001) (Fig. 4). The
median increase in ability to defer was 3 minutes (range,
0 –25).
Duration of Effect
Currently, 4 patients have requested “top up” therapy, 2
with a return of symptoms and 2 for prophylaxis. Of the 2
patients who had recurrent incontinence, one received 2
blocks of 3 weekly 30-minute sessions of “top up” therapy
after symptom-free periods of 4 and 3 months, whereas the
other patient has received a single block after 7 symptom-
free months. The other 2 patients requested and received a
single block of treatment after 3 and 7 months without the
resumption of incontinence.
FIGURE 1. Flowchart of patient outcomes. PTNS percutaneous
tibial nerve stimulation.
FIGURE 2. Weekly episodes of fecal incontinence prestimulation
and poststimulation (medians marked with bar).
FIGURE 3. Cleveland Clinic incontinence scores prestimulation and
poststimulation (medians marked with bar).
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Outcome vs Physiological Parameters
There was no correlation between improvement (or dete-
rioration) in outcome measures and any physiological pa-
rameters assessed: age, resting anal tone, squeeze incre-
ment, internal or external sphincter defects, rectal
sensation thresholds (desire to defecate, maximal tolerated
volume). An intact anal sphincter complex appeared to
confer an increased probability of improvement when this
group was compared with patients with any anal sphincter
defect, but the result was not statistically significant (P 
.077) (Fig. 5).
DISCUSSION
The prevalence of FI increases with age, and represents a
major public health issue in an ageing population, with
significant financial and social implications.20 The ideal
treatment is one that has high efficacy, is inexpensive, is
acceptable to patients, and has a low morbidity.
As yet, a panacea for FI remains elusive, in part, be-
cause of the diverse spectrum of pathologies and etiologies.
Current therapies are limited by lack of long-term efficacy,
morbidity, and expense9,21–24 Anterior sphincter repair
aims to restore the anatomy of the sphincter complex, yet
the long-term results are disappointing and it has no role in
patients without sphincter disruption.21 SNS may be less
invasive, but it is expensive, associated with considerable
morbidity and limited adaptability once in situ.9 More in-
vasive treatments such as the electrically stimulated gracilis
neosphincter and the artificial bowel sphincter have been
shown to be effective; however, they are very complex, in-
vasive, and extremely expensive, often requiring more than
one operation.22,25 PTNS, in contrast, is a simple proce-
dure that is well tolerated and minimally invasive, and it
can be offered in an out-patient setting to the majority of
patients with UFI. In the presence of a trained nurse spe-
cialist, the setup costs for PTNS are less than £1000 for
the stimulator (which can be used on multiple patients)
and a cost of £500 per patient for the disposable equipment
for the treatment course. It is therefore likely to be more
cost effective than SNS, electrically stimulated gracilis
neosphincter, or even an end colostomy,23,24 but this re-
mains the subject of future study. Although it is perceivable
that patient inconvenience and personnel costs may limit
the widespread application of PTNS, the minimally inva-
sive nature of the process and lack of permanent implant
may be desirable to some patients and enable treatment to
be provided to patients deemed unsuitable for more com-
plex procedures.
From this small preliminary study, it would appear
that PTNS is an effective treatment for UFI with or without
anatomical or physiological anal sphincter dysfunction.
Although statistically insignificant, it would appear that
those with an intact anal sphincter complex were more
likely to respond to PTNS; however, a larger cohort of pa-
tients will be required to clarify this. Overall, nearly three-
fourths of patients had a 50% reduction in incontinence
episodes and 12 (32%) patients became fully continent,
and the ability to defer defecation improved from a median
of 1 minute to 5 minutes after treatment. These results
compare favorably with the other treatment modali-
ties.7,8,21 The actual reduction in incontinence scores are
modest, however. This is also a feature in SNS studies for
FI8 and may merely reflect the limitation of the standard
current scoring systems, whereby the true clinical picture is
not accurately represented.
The data analysis was performed with intention to
treat; nevertheless, the response rate in this study compares
favorably with that published for SNS.7,8 One single large
study previously investigated the management of FI with
PTNS, but all patients had intact sphincters and normal
FIGURE 4. The ability to defer in minutes prestimulation and
poststimulation (medians marked with bar).
FIGURE 5. Effect of sphincter defect on outcome in PTNS. IAS
internal anal sphincter defect; EAS external anal sphincter defect;
ASD anal sphincter defect (IAS and/or EAS); CSD combined
sphincter defect (IAS and EAS); PTNS percutaneous tibial nerve
stimulation.
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anal manometry; this study had poor methodology and
design with no analysis of incontinence episodes prestimu-
lation and poststimulation.16 More recently, another study
of patients with an intact or repaired external anal sphinc-
ter has shown that PTNS may be effective treatment of
“severe” FI for a minority of patients.26 Two other studies
published have extremely small sample size15 or have in-
cluded patients with FI secondary to organic bowel dis-
ease.14 As with SNS, the mechanism of action of PTNS is
unknown, although it is possible that PTNS effects electri-
cal stimulation of the sacral plexus, adapting bowel and
bladder function via a mechanism similar to SNS. The pos-
terior tibial nerve contains afferent and efferent fibers and
originates from the 4th and 5th lumbar and 1st, 2nd, and
3rd sacral nerves, the same spinal nerves that innervate the
bladder and rectum. However, it has recently been demon-
strated that PTNS modulates long latency somatosensory-
evoked potentials in patients with overactive bladder syn-
drome, whereas sham stimulation has no effect, suggesting
central modification may be involved.27
PTNS has been shown to be effective in up to 80% of
patients from a number of studies deploying it for urolog-
ical symptoms of frequency, overactive bladder, and in-
continence.28 Although results in this study do not achieve
such a high response rate, the optimal stimulation protocol
for UFI remains unclear. It is likely that the efficacy and
indication of PTNS for FI will increase with further re-
search and developments. From this study, it would appear
that PTNS is highly effective in the treatment of UFI, and
very acceptable for the patients. However, a randomized,
sham-controlled trial alongside SNS will be required to
eliminate placebo effect, elucidate the true efficacy of this
treatment, and determine which treatment modality is su-
perior. Nevertheless, we believe PTNS is a valuable addi-
tion to the current available treatments for UFI.
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Abstract
Aim Percutaneous tibial nerve stimulation (PTNS) is
increasingly being used as a treatment for faecal incon-
tinence (FI). The evidence for its efficacy is limited to a
few studies involving small numbers of patients. The aim
of the study was to assess the efficacy of PTNS in patients
with urge, passive and mixed FI.
Method A prospective cohort of 100 patients with FI
was studied. Continence scores were determined before
treatment and following 12 sessions of PTNS using a
validated questionnaire [Cleveland Clinic Florida (CCF)-
FI score]. The deferment time and average number of
weekly incontinence episodes before and after 12 sessions
of treatment were estimated from a bowel dairy kept by
the patient. Quality of life was assessed prior to and on
completion of 12 sessions of PTNS using a validated
questionnaire [Rockwood Faecal Incontinence Quality of
Life (QoL)].
Results One hundred patients (88 women) of median
age of 57 years were included. Patients with urge FI
(n = 25) and mixed FI (n = 60) demonstrated a statisti-
cally significant improvement in the mean CCF-FI score
(11.0 ± 4.1 to 8.3 ± 4.8 and 12.8 ± 3.7 to 9.1 ± 4.4)
with an associated improvement in the QoL score. This
effect was not observed in patients with purely passive FI
(n = 15).
Conclusion The study demonstrates that PTNS benefits
patients with urge and mixed FI, at least in the short
term.
Keywords Faecal incontinence, PTNS, neuromodulation
What is new in this paper?
Percutaneous tibial nerve stimulation is increasingly used
to treat faecal incontinence. In this prospective study,
the largest to date, patients were classified for the first
time according to the type of incontinence (passive,
urge and mixed). The results are given for these clinical
categories.
Introduction
Faecal incontinence (FI) affects up to 18% of adults,
predominantly women, with a significant deterioration in
quality of life (QoL) [1,2]. Injury of the anal sphincter,
most commonly obstetric, altered rectal sensation and
colonic dysmotility may all impair continence [3,4].
Initial management includes constipating medication,
dietary manipulation, pelvic floor exercises and biofeed-
back [5,6]. Failure of conservative treatment may require
surgery. Surgical options include sphincteroplasty,
sphincter augmentation and an artificial bowel sphincter
to more major procedures such graciloplasty, which is
now only rarely performed, and stoma formation [7–9].
These have variable outcome and significant morbidity.
Sacral nerve stimulation (SNS) has a reported success
rate of 75–80% but it is expensive and requires a general
or regional anaesthetic. There is also a small risk of
complications including infection, pain at the implant
site, migration of the electrode and failure of the
equipment [10,11]. The exact mechanism of neuromod-
ulation is unknown [11]. Unlike SNS, percutaneous tibial
nerve stimulation (PTNS) is less invasive. It induces
neuromodulation without the need for anaesthesia and
may be more cost-effective [6]. The posterior tibial nerve
carries motor and sensory fibres that originate from the
lumbar and sacral plexuses, and it has been suggested that
PTNS causes retrograde stimulation of the sacral nerve
plexus [11,12]. We have reported that PTNS improves
urge FI, reducing the weekly number of incontinence
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episodes and improving the ability to defer defaecation
[12]. In this study we aimed to evaluate the efficacy of
PTNS in patients with passive, urge and mixed FI.
Method
Percutaneous tibial nerve stimulation was performed on an
outpatient basis using the Urgent PC neuromodulation
system (Uroplasty Ltd, Manchester, UK). A needle elec-
trode was inserted through the skin at a 60 angle, 5 cm
(three fingerbreadths) above the medial malleolus and
2 cm (one finger breadth) posterior to the tibia without
any anaesthetic. The current was gradually increased until
sensation was elicited in the foot or amotor flexor response
was seen in the great toe. Stimulation parameters were set
at 200 ls pulse width, 20 Hz frequency and the amplitude
ranged between 0.5 and 9 mA. The amplitude was
maintained at a level that induced a response but was
comfortable for the patient. Following this test phase, a 30-
min therapy session commenced. The PTNS treatment
protocol is shown in Fig. 1.
A prospective cohort of patients was studied over a
3-year period (January 2008–January 2011). Continence
scores were measured prior to the initiation of treatment
and following 12 sessions of neuromodulation using a
validated questionnaire [Cleveland Clinic Florida-Faecal
Incontinence (CCF-FI) score]. The average number of
weekly incontinence episodes was determined from the
patient’s bowel diary. The maximum time for deferral of
defecation was established from the incontinence ques-
tionnaire and the bowel diary. Data on QoL were
collected before treatment and on completion of 12
sessions of PTNS using a validated questionnaire (Rock-
wood FI QoL [13]).
Statistical analysis
Data analysis was performed using GraphPad Version 5
(GraphPad Software Inc, La Jolla, California, USA).
Normal distribution of the data was determined using
the De Agostino–Pearson omnibus normality test. Nor-
mally distributeddatawere presented asmean and standard
deviation and nonparametric data were given as median
and range. Normally distributed data were compared at
baseline and following neuromodulation using the paired
t-test. Nonparametric data were compared using the
Mann–Whitney U-test. A P-value < 0.05 was considered
significant.
Results
In all, 100 patients (88 women) with FI underwent PTNS
(Table 1). The mean age was 57.5 ± 13.8 years. FI was
classified as true passive, urge and mixed. Underlying
aetiological associations included trauma to the anal
sphincter in 85 (obstetric trauma 67, post-anal surgical
trauma 14, accidental trauma 4) patients and previous
radiotherapy (two patients). There was no apparent pre-
disposing factor in the remaining 13 patients. An intact
internal sphincter was observed in 49 patients and an intact
external sphincter in 36 on transanal ultrasound (Table 1).
The baseline median maximum resting pressure was
45.5 cm H2O (10.0–126.0) and the median maximum
squeeze pressure was 35.5 cm H2O (4.0–160.0).
All patients tolerated the treatment without any
serious adverse events. In 10 patients slight bleeding at
the site of needle insertion was controlled by direct
digital pressure and in one patient the transient tingling
sensation in the foot after the first session completely
resolved spontaneously within a few hours.
Passive FI
Fifteen (15%) patients reported true passive FI without
any urgency. Table 1 shows the characteristics of this
subgroup of patients. In all 15 the underlying association
Pre-treatment evaluation with history, examination, colonoscopic 
evaluation and detailed anorectal physiological assessment. 
Maximum conservative measures and  subsequent referral to clinical 
nurse specialists for consideration of PTNS if symptoms persist.  
Telephone contact to discuss PTNS. Information leaflet about 
treatment and questionnaires and bowel diary sent by post and 
completed prior to first appointment.
 First PTNS treatment session.  
Patient returns questionnaire and bowel diaries sent prior to treatment 
commencement. 
12 treatment sessions once or twice weekly over a 6–12 week period. 
Completion of bowel diaries and QoL questionnaires following 12th 
session. If treatment successful two further treatments 2 weeks apart and 
one a month later.
Patients return at 6 months following final treatment for two "top up 
sessions" or earlier if symptoms deteriorate.
Figure 1 Percutaneous tibial nerve stimulation (PTNS) study
flow chart.
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was either previous anorectal surgery (haemorrhoidecto-
my, Delorme’s procedure) or obstetric trauma. Only
three patients had an intact internal sphincter on ultra-
sound and four patients had an intact external sphincter.
The baseline median maximum resting pressure for the
group was 50.0 (15.0–105.0) cmH2O and the median
maximum squeeze pressure was 41.0 (21.0–105.0)
cmH2O. The mean CCF-FI score improved from
11.5 ± 4.1 to 9.41 ± 4.3 and was accompanied by similar
improvements in the median defaecation deferment time
(5.0 to 12.5 min) and median number of weekly incon-
tinence episodes (from four to three per week). None of
the differences, however, was statistically significant
(Table 1). The disease-specific QoL assessment with the
Rockwood FI QoL questionnaire showed improvements
in all four domains but none was statistically significant
with the exception of improvement in the depression and
lifestyle elements of the questionnaire (Table 2).
Urge FI
Twenty-five patients were grouped as having pure urge
FI. Seventeen (68%) of these had a previous obstetric
injury following a prolonged or difficult labour (Ta-
ble 1). Patients with urge FI had marginally higher
maximum resting pressures [median 51.0 (26.0–126.0)
cmH2O] than those with passive FI and a significantly
lower squeeze pressure [median 35.0 (4.0–160.0)
cmH2O]. Following treatment, there were statistically
significant improvements in the CCF-FI score (from
11.0 ± 4.1 to 8.3 ± 4.8), the time to postpone defae-
cation (from 1.0 to 5.0 min) and the average number of
weekly incontinence episodes(from four to zero per
week) (Table 1). These changes were accompanied by
statistically significant improvements in the coping and
depression domains of the Rockwood FI QoL ques-
tionnaire (Table 2).
Table 1 Characteristics and outcome in patients with passive, urge and mixed faecal incontinence (FI).
Passive FI (n = 15) Urge FI (n = 25) Mixed FI (n = 60)
Demographics
Age years median ± SD 57.9 ± 13.1 56.0 ± 15.6 57.9 ± 13.4
Women:men 11:4 21:4 56:4
Aetiology of FI
Obstetric 8 17 42
Anal surgery 6 3 5
Trauma 1 1 2
Idiopathic – 4 9
Radiotherapy – – 2
Anorectal manometry
Median maximum resting
pressure (cm H2O)
50.0
(15.0–105.0)
51.0
(26.0–126.0)
44.5
(10.0–105.0)
Median maximum squeeze
pressure (cm H2O)
41.0
(21.0–105.0)
35.0
(4.0–160.0)
35.0
(4.0–150.0)
Anorectal ultrasound
Intact internal sphincter 3 16 30
Intact external sphincter 4 15 17
CCF-FI score
Pre-PTNS 11.5 ± 4.1 11.0 ± 4.1 12.8 ± 3.7
Post-PTNS 9.41 ± 4.3 8.3 ± 4.8 9.1 ± 4.4
P = 0.3293 P = 0.0188 P < 0.0001
Deferment time (min)
Pre-PTNS 5.0 (0.0–45.0) 1.0 (0.0–5.0) 1.0 (0.0–15.0)
Post-PTNS 12.5 (1.0–60.0) 5.0 (0.0–30.0) 5.0 (0.0–25.0)
P = 0.2684 P = 0.0010 P < 0.0001
FI episodes ⁄ week
Pre-PTNS 4.0 (0.0–21.0) 4.0 (0.0–30.0) 5.0 (0.0–35.0)
Post-PTNS 3.0 (0.0–21.0) 0.0 (0.0–10.0) 1.0 (0.0–27.0)
P = 0.2839 P = 0.0047 P < 0.0001
CCF-FI, Cleveland Clinic Florida FI; PTNS, percutaneous tibial nerve stimulation.
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Mixed FI
In 60 patients the FI was of mixed type. The median
maximum resting pressure 44.5 (10.0–105.0) cmH2O
and the median maximum squeeze pressure was 35.0
(4.0–150.0) cmH2O. Patients with mixed FI demon-
strated statistically significant improvement in the mean
CCF-FI score (12.8 ± 3.7 to 9.1 ± 4.4,), median defer-
ment time (from 1.0 to 5.0 min) and median number of
weekly incontinence episodes (from five to one per week)
(Table 1). All domains of the Rockwood FI QoL
questionnaire showed statistically significant improve-
ment (Table 2).
Discussion
The evidence regarding the efficacy of PTNS in FI is
limited to a few methodologically heterogeneous studies
with small numbers of participants [12,14–18]. It is
therefore difficult to establish the ideal treatment proto-
col and the true efficacy of PTNS in treating FI. Our
study, the largest to date, aimed to distinguish between
passive, urge and mixed FI and to quantify the short-term
response to PTNS in each of these patient groups.
Anorectal manometry demonstrated that patients with
urge FI had lower maximum squeeze pressure than
patients with passive FI. Similarly, patients with mixed FI
had lower resting and squeeze pressures reflecting the
heterogeneity of their symptoms. PTNS appears to be
beneficial in the treatment of patients with urge and
mixed FI, resulting in improved FI and QoL scores. No
such effect was observed in patients with passive FI,
although they showed statistically significant improve-
ments in the depression and lifestyle components of the
QoL questionnaire. This negative finding may be related
to the small sample size (n = 15). As the cohort of
patients with passive FI increases, benefits may become
apparent. Furthermore, it may be possible to identify
patient characteristics, such as the resting and squeeze
pressures that predict a better response of selected
patients with passive FI to neuromodulation.
Whilst PTNS offers short-term benefits, very little is
known about the duration of these effects and longer-
term evaluation is necessary. Govaert et al. [14]
reported an improved clinical outcome and QoL scores
within a follow-up period of 1 year in patients who
underwent a 12-treatment regime followed by mainte-
nance sessions. In another study, an improved outcome
following PTNS was sustained after 6 months without
further treatment [15]. However, both studies con-
tained small numbers (n = 22 and n = 16) and included
a heterogeneous group of patients. It is therefore
difficult to draw meaningful conclusions. Clinical expe-
rience in our unit suggests that the effect of PTNS is
likely to diminish with time necessitating regular ‘top-
up’ sessions to achieve a continuing effect. Evaluation of
the efficacy of ‘top-up’ sessions is currently under way
and is likely to reveal important information regarding
the longer-term outcome of PTNS and whether the
initial short-term results can be sustained with time as
suggested by previous studies [14,15]. In any case,
PTNS may have an important role to play in avoiding
surgical intervention, particularly in high risk patients or
as a short-term control measure in those awaiting more
definitive treatment [19].
In conclusion, PTNS is a safe, well-tolerated,
minimally invasive procedure that appears to be effec-
tive in treating patients with urge and mixed FI. Larger
randomized controlled trials will further determine its
true efficacy, the mechanism of action and its relative
merit regarding other forms of neuromodulation such
as SNS or transcutaneous tibial nerve modulation.
Table 2 Quality of life data pre- and post-percutaneous tibial nerve stimulation.
Domain FIQoL score (passive FI) FIQoL score (urge FI) FIQoL score (mixed FI)
Lifestyle – pre 2.96 ± 1.1 1.94 ± 0.77 2.4 ± 0.95
Lifestyle – post 3.14 ± 1.06 2.35 ± 0.91 2.9 ± 0.93
P > 0.005 P = 0.163 P = 0.0002
Coping – pre 2.31 ± 0.98 1.43 ± 0.36 1.74 ± 0.61
Coping – post 2.56 ± 1.00 1.92 ± 0.73 2.36 ± 0.77
P = 0.067 P = 0.026 P < 0.0001
Depression – pre 2.85 ± 0.79 2.36 ± 0.63 2.89 ± 0.91
Depression – post 3.23 ± 0.87 2.88 ± 0.79 3.27 ± 0.77
P = 0.0156 P = 0.0089 P = 0.0023
Embarrassment – pre 2.19 ± 0.85 2.19 ± 0.85 2.03 ± 0.89
Embarrassment – post 2.29 ± 0.90 2.29 ± 0.90 2.6 ± 0.89
P = 0.65 P = 0.066 P < 0.0001
FIQoL, Rockwood Fi Quality of Life score.
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Editor’s choice doi:10.1111/j.1463-1318.2012.03193.x
In this prospective series the short-term results of
percutaneous tibial nerve stimulation (PTNS) are promis-
ing. In 85 patients with urge or mixed type fecal inconti-
nence the Cleveland score improved significantly by about
30%, and 15 patients with passive incontinence did not
benefit from PTNS. Improved control, although it may
appear to be only modest, did lead to a better quality of life
in this series. Long-term results are eagerly awaited and
PTNS should be pitched against other invasive procedures
in randomised studies. PTNS is a rather straighforward
minimal-invasive procedure that, after exhausting conser-
vative options, may become a procedure of choice in
patients with urge and mixed type fecal incontinence.
Alexander Engel
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